PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
21632718-1	2011	Rare CD1d-alpha-galactosylceramide-specific T cells that do not express the invariant Valpha24 chain of human NKT cells were recently identified after expansion in vitro with the lipid Ag, but their phenotype and frequency in vivo and lineage relationship with NKT cells could not be elucidated.	Galactosylceramides	16-34	CD1d molecule	Homo sapiens	5-9
21552205-0	2011	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.	Galactose	0-9	CD1d molecule	Homo sapiens	70-74
21552205-5	2011	These findings highlight the previously unexploited flexibility of CD1d in accommodating galactose-modified glycolipids and broaden the range of glycolipids that can stimulate iNKT cells.	Galactose	89-98	CD1d molecule	Homo sapiens	67-71
21552205-5	2011	These findings highlight the previously unexploited flexibility of CD1d in accommodating galactose-modified glycolipids and broaden the range of glycolipids that can stimulate iNKT cells.	Glycolipids	108-119	CD1d molecule	Homo sapiens	67-71
21552205-5	2011	These findings highlight the previously unexploited flexibility of CD1d in accommodating galactose-modified glycolipids and broaden the range of glycolipids that can stimulate iNKT cells.	Glycolipids	145-156	CD1d molecule	Homo sapiens	67-71
21454514-0	2011	Binding strength and dynamics of invariant natural killer cell T cell receptor/CD1d-glycosphingolipid interaction on living cells by single molecule force spectroscopy.	Glycosphingolipids	84-101	CD1d molecule	Homo sapiens	79-83
21394364-1	2011	Associated with the CD1d protein, KRN 7000, a potent synthetic alpha-galactosylceramide, is known to activate the invariant NKT immune cells.	alpha-galactosylceramide	63-87	CD1d molecule	Homo sapiens	20-24
21454514-2	2011	Using soluble iNKT T cell receptor (TCR) molecules, we applied single molecule force spectroscopy for the investigation of the iNKT TCR affinity for human CD1d molecules loaded with glycolipids differing in the length of the phytosphingosine chain using either recombinant CD1d molecules or lipid-pulsed THP1 cells.	Glycolipids	182-193	CD1d molecule	Homo sapiens	155-159
21454514-3	2011	In both settings, the dissociation of the iNKT TCR from human CD1d molecules loaded with the lipid containing the longer phytosphingosine chain required higher unbinding forces compared with the shorter phytosphingosine lipid.	phytosphingosine	121-137	CD1d molecule	Homo sapiens	62-66
21454514-5	2011	We present new insights into the energy landscape and the kinetic rate constants of the iNKT TCR/human CD1d-glycosphingolipid interaction and emphasize the unique potential of single molecule force spectroscopy on living cells.	Glycosphingolipids	108-125	CD1d molecule	Homo sapiens	103-107
21061446-6	2010	Confocal microscopy detected iNKT cells in plaques, and plaque-derived iNKT cell lines promptly produced proinflammatory cytokines when stimulated by CD1d-expressing APC-presenting alpha-galactosylceramide lipid antigen.	alpha-galactosylceramide lipid	181-211	CD1d molecule	Homo sapiens	150-154
21439833-3	2011	Recently, the detailed illustration of the CD1d/alpha-GalCer/NKT TCR complex crystal structural, together with other latest structural and biological understanding on glycolipid ligands and NKT cells, provided a new platform for developing novel glycolipid ligands with optimized therapeutic effects.	Glycolipids	167-177	CD1d molecule	Homo sapiens	43-47
21439833-3	2011	Recently, the detailed illustration of the CD1d/alpha-GalCer/NKT TCR complex crystal structural, together with other latest structural and biological understanding on glycolipid ligands and NKT cells, provided a new platform for developing novel glycolipid ligands with optimized therapeutic effects.	Glycolipids	246-256	CD1d molecule	Homo sapiens	43-47
21444811-3	2011	Their positive selection is mediated by double-positive (DP) thymocytes, which present glycolipid self-antigens through the noncanonical MHC class I-like molecule CD1d.	Glycolipids	87-97	CD1d molecule	Homo sapiens	163-167
21483778-4	2011	CD1d expressed on HeLa cells contained significantly increasing amounts of alphaGalCer with increasing concentrations of alcohol, suggesting that alcohol facilitated the passive loading of alphaGalCer to CD1d.	Alcohols	121-128	CD1d molecule	Homo sapiens	0-4
21483778-4	2011	CD1d expressed on HeLa cells contained significantly increasing amounts of alphaGalCer with increasing concentrations of alcohol, suggesting that alcohol facilitated the passive loading of alphaGalCer to CD1d.	Alcohols	146-153	CD1d molecule	Homo sapiens	0-4
21483778-4	2011	CD1d expressed on HeLa cells contained significantly increasing amounts of alphaGalCer with increasing concentrations of alcohol, suggesting that alcohol facilitated the passive loading of alphaGalCer to CD1d.	Alcohols	146-153	CD1d molecule	Homo sapiens	204-208
21376640-2	2011	Here, we have characterized NKT TCR recognition of CD1d molecules loaded with natural self-antigens (Ags) and report the 2.3 A resolution structure of an autoreactive NKT TCR-phosphatidylinositol-CD1d complex.	Phosphatidylinositols	175-195	CD1d molecule	Homo sapiens	51-55
21376640-2	2011	Here, we have characterized NKT TCR recognition of CD1d molecules loaded with natural self-antigens (Ags) and report the 2.3 A resolution structure of an autoreactive NKT TCR-phosphatidylinositol-CD1d complex.	Phosphatidylinositols	175-195	CD1d molecule	Homo sapiens	196-200
20851496-13	2011	Furthermore, this occurs at the transcriptional level as NaB led to a decrease in mRNA levels of CD1a and upregulation of CD1d.	nab	57-60	CD1d molecule	Homo sapiens	122-126
21196373-2	2011	Most NKT cells express a semi-invariant T cell receptor that reacts with glycolipid antigens presented by the major histocompatibility complex class I-related protein CD1d on the surface of antigen-presenting cells.	Glycolipids	73-83	CD1d molecule	Homo sapiens	167-171
21174558-1	2011	Invariant NK T (iNKT) cells are a subset of T lymphocytes that recognize glycolipid antigens bound with the antigen-presenting molecule CD1d.	Glycolipids	73-83	CD1d molecule	Homo sapiens	136-140
21179412-1	2010	CD1d-restricted natural killer T cells with invariant T cell receptor alpha chains (iNKT cells) are a unique lymphocyte subset that responds to recognition of specific lipid and glycolipid antigens.	Glycolipids	178-188	CD1d molecule	Homo sapiens	0-4
20022305-1	2010	Invariant natural killer T (iNKT) cells are a subset of T cells that recognize glycolipid antigens presented by the CD1d molecule.	Glycolipids	79-89	CD1d molecule	Homo sapiens	116-129
20810727-10	2010	CD1d protein levels were rescued by the proteasome inhibitor, MG132, indicating a role for proteasome-mediated degradation in HPV-associated CD1d downregulation.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	62-67	CD1d molecule	Homo sapiens	0-4
20810727-10	2010	CD1d protein levels were rescued by the proteasome inhibitor, MG132, indicating a role for proteasome-mediated degradation in HPV-associated CD1d downregulation.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	62-67	CD1d molecule	Homo sapiens	141-145
20589634-2	2010	Similarly to homologous CD1d, EPCR binds a phospholipid [phosphatidylethanolamine (PTY)] in a groove corresponding to the antigen-presenting site, although it is not clear if lipid exchange can occur in EPCR as in CD1d.	Phospholipids	43-55	CD1d molecule	Homo sapiens	24-28
20591421-1	2010	Alpha-Galactosylceramide (alphaGalCer, KRN7000) has been identified as a modulator of immunological processes through its capacity to bind iNKT cells mediated by CD1d molecules.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	162-166
20185414-2	2010	Dietary fatty acids also alter hepatic NKT cells that are activated by antigens presented by CD1d.	dietary fatty acids	0-19	CD1d molecule	Homo sapiens	93-97
20585371-8	2010	These functionally different iNKT subsets segregate in their ability to bind CD1d-tetramers loaded with the partial agonist alpha-linked glycolipid antigen OCH and structurally different endogenous beta-glycosylceramides.	alpha-linked glycolipid	124-147	CD1d molecule	Homo sapiens	77-81
20585371-8	2010	These functionally different iNKT subsets segregate in their ability to bind CD1d-tetramers loaded with the partial agonist alpha-linked glycolipid antigen OCH and structurally different endogenous beta-glycosylceramides.	beta-glycosylceramides	198-220	CD1d molecule	Homo sapiens	77-81
19651460-0	2010	Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness.	Tretinoin	48-61	CD1d molecule	Homo sapiens	19-23
19651460-0	2010	Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness.	conduritol epoxide	66-86	CD1d molecule	Homo sapiens	19-23
19651460-4	2010	We also show that retinoic acid (RA) and the beta-glucocerebrosidase inhibitor conduritol-B-epoxide (CBE) lead to upregulation of CD1d expression by THP-1 cells, which correlated with an increase in mRNA expression.	Tretinoin	18-31	CD1d molecule	Homo sapiens	130-134
19651460-4	2010	We also show that retinoic acid (RA) and the beta-glucocerebrosidase inhibitor conduritol-B-epoxide (CBE) lead to upregulation of CD1d expression by THP-1 cells, which correlated with an increase in mRNA expression.	Tretinoin	33-35	CD1d molecule	Homo sapiens	130-134
19651460-4	2010	We also show that retinoic acid (RA) and the beta-glucocerebrosidase inhibitor conduritol-B-epoxide (CBE) lead to upregulation of CD1d expression by THP-1 cells, which correlated with an increase in mRNA expression.	conduritol epoxide	79-99	CD1d molecule	Homo sapiens	130-134
19651460-6	2010	Interestingly, even though addition of exogenous isoglobotrihexosylceramide (iGb3), a physiological CD1d ligand, augmented the percentage of dividing CD4(+) T cells, we could not detect a significant expansion of CD4(+)Valpha24(+) invariant Natural Killer T (iNKT) cells.	isoglobotrihexosylceramide	49-75	CD1d molecule	Homo sapiens	100-104
19651460-7	2010	In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers.	alpha-galactosylceramide	25-49	CD1d molecule	Homo sapiens	150-154
19651460-7	2010	In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers.	alpha-galactosylceramide	51-59	CD1d molecule	Homo sapiens	150-154
19651460-7	2010	In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers.	alpha-galactosylceramide	128-136	CD1d molecule	Homo sapiens	150-154
19824039-6	2010	We also found that a ligand for CD1d-reactive natural killer T (NKT) cells, alpha-glucuronosylceramide (GSL1), enhanced MvP728-induced interleukin-12 production in human dendritic cells and that in vivo coadministration of a NKT ligand with MvP728-Llo or MvP728-survivin enhanced effector-memory cytotoxic T lymphocyte (CTL) responses.	alpha-glucuronosylceramide	76-102	CD1d molecule	Homo sapiens	32-36
20173232-5	2010	Combined fluorescence and TREC imaging was applied to detect density, distribution and localization of YFP-labeled CD1d molecules on alpha-galactosylceramide (alphaGalCer)-loaded THP1 cells.	alpha-galactosylceramide	133-157	CD1d molecule	Homo sapiens	115-119
21853044-1	2011	CD1d is a MHC I like molecule which presents glycolipid to natural killer T (NKT) cells, a group of cells with diverse but critical immune regulatory functions in the immune system.	Glycolipids	45-55	CD1d molecule	Homo sapiens	0-4
20616071-1	2010	The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines.	Glycolipids	4-14	CD1d molecule	Homo sapiens	78-82
20616071-1	2010	The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines.	alpha-galactosylceramide	15-39	CD1d molecule	Homo sapiens	78-82
20616071-1	2010	The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines.	alpha-galactosylceramide	41-53	CD1d molecule	Homo sapiens	78-82
20185414-6	2010	In vitro treatment of normal hepatocytes with fatty acids also demonstrates impaired ability of CD1d to present endogenous antigen by dietary fatty acids.	Fatty Acids	46-57	CD1d molecule	Homo sapiens	96-100
20185414-6	2010	In vitro treatment of normal hepatocytes with fatty acids also demonstrates impaired ability of CD1d to present endogenous antigen by dietary fatty acids.	Fatty Acids	142-153	CD1d molecule	Homo sapiens	96-100
20368272-0	2010	A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression.	Threonine	2-11	CD1d molecule	Homo sapiens	48-52
20368272-2	2010	The cytoplasmic tail of human CD1d possesses a tyrosine-based endosomal targeting motif (YXXZ).	Tyrosine	47-55	CD1d molecule	Homo sapiens	30-34
20368272-4	2010	In the current study, it was found that the T322 residue in the human CD1d tail is a major signal controlling transport to the cell surface and thus its functional expression.	Rosaniline Dyes	44-48	CD1d molecule	Homo sapiens	70-74
19945296-0	2010	Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.	Glycolipids	10-20	CD1d molecule	Homo sapiens	33-37
19945296-1	2010	In spite of their relatively limited antigen receptor repertoire, CD1d-restricted NKT cells recognize a surprisingly diverse range of lipid and glycolipid antigens.	Glycolipids	144-154	CD1d molecule	Homo sapiens	66-70
19945296-2	2010	Recent studies of natural and synthetic CD1d-presented antigens provide an increasingly detailed picture of how the specific structural features of these lipids and glycolipids influence their ability to be presented to NKT cells and stimulate their diverse immunologic functions.	Glycolipids	165-176	CD1d molecule	Homo sapiens	40-44
20352088-7	2010	On stimulation with alpha-galactosylceramide loaded on human CD1d molecules, sooty mangabey NKT lymphocytes underwent degranulation and secreted IFN-gamma, TNF-alpha, IL-2, IL-13, and IL-10, indicating the presence of both effector and immunoregulatory functional capabilities.	alpha-galactosylceramide	20-44	CD1d molecule	Homo sapiens	61-65
20083656-6	2010	Furthermore, we demonstrate that DPPE-PEG acts as antagonist to alpha-GalCer and competes with alpha-GalCer for binding to CD1d.	DPPE-PEG2000	33-41	CD1d molecule	Homo sapiens	123-127
20861926-3	2010	CD1d-restricted type I NKT cells express an invariant TCR and can recognize alphaGalCer, whereas a major subset of type II NKT expressing diverse TCR can recognize a self-glycolipid, sulfatide.	Glycolipids	171-181	CD1d molecule	Homo sapiens	0-4
19879910-5	2010	iNKT cells were stained with 6B11 mAb, anti-TCRvalpha24 mAb, or alpha-galactosylceramide (GalCer)-loaded CD1d- tetramer and analyzed with flow-cytometric assays.	alpha-galactosylceramide	64-88	CD1d molecule	Homo sapiens	105-109
19879910-5	2010	iNKT cells were stained with 6B11 mAb, anti-TCRvalpha24 mAb, or alpha-galactosylceramide (GalCer)-loaded CD1d- tetramer and analyzed with flow-cytometric assays.	alpha-galactosylceramide	90-96	CD1d molecule	Homo sapiens	105-109
19949076-4	2010	Th1-biasing C-glycoside/CD1d has even weaker TCR interactions than OCH/CD1d.	C-glycoside	12-23	CD1d molecule	Homo sapiens	24-28
19949076-6	2010	We found that this difference correlated with the finding that C-glycoside/CD1d complexes survive much longer in vivo.	C-glycoside	63-74	CD1d molecule	Homo sapiens	75-79
20861926-6	2010	Our earlier studies have shown that activation of CD1d-restricted type II NKT cells by sulfatide and their interactions with plasmacytoid dendritic (pDC) and myeloid dendritic (mDC) cells result in anergy induction in type I NKT cells in several models.	Sulfoglycosphingolipids	87-96	CD1d molecule	Homo sapiens	50-54
20080535-3	2010	Here we show that the mouse and human CD1d present glycolipids having different fatty acids, based in part upon a difference at a single amino acid position that is involved in positioning the sugar epitope.	Glycolipids	51-62	CD1d molecule	Homo sapiens	38-42
20080535-3	2010	Here we show that the mouse and human CD1d present glycolipids having different fatty acids, based in part upon a difference at a single amino acid position that is involved in positioning the sugar epitope.	Fatty Acids	80-91	CD1d molecule	Homo sapiens	38-42
20080535-3	2010	Here we show that the mouse and human CD1d present glycolipids having different fatty acids, based in part upon a difference at a single amino acid position that is involved in positioning the sugar epitope.	Sugars	193-198	CD1d molecule	Homo sapiens	38-42
20861926-13	2010	Since the CD1d-mediated immune pathway is highly conserved between rodents and humans, sulfatide treatment may represent a novel HLA-independent approach for intervention of HIV-1 pathogenesis.	Sulfoglycosphingolipids	87-96	CD1d molecule	Homo sapiens	10-14
20034230-2	2009	NKT cells are a subset of innate lymphocytes that recognize endogenous or exogenous glycolipids in the context of CD1d molecules.	Glycolipids	84-95	CD1d molecule	Homo sapiens	114-118
19859526-8	2009	These results demonstrate that human NKT cells recognize cholinated lyso-phospholipids as antigens presented by CD1d.	Lysophospholipids	68-86	CD1d molecule	Homo sapiens	112-116
19734232-0	2009	Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.	C-glycoside	69-80	CD1d molecule	Homo sapiens	26-30
19842132-7	2009	The L-arabino diols 7 and 15 stimulate invariant natural killer T (iNKT) cells when presented by living antigen-presenting cells (APC) and also by plate-bound human CD1d, whereas the L-ribo diols 8 and 16, the L-arabino amino alcohols 17-18, and the dimethylamines 21-22 did not activate iNKT cells.	l-arabino diols	4-19	CD1d molecule	Homo sapiens	165-169
19842132-8	2009	The L-gluco ceramide analogues 43, 46a, and 47 had strongly stimulatory effects on iNKT cells when presented by living APC and also by plate-bound human CD1d, whereas the L-altro ceramide analogue 52 activated only weakly.	l-gluco ceramide	4-20	CD1d molecule	Homo sapiens	153-157
19734232-4	2009	Overall, the structural difference of invTCR appears to supersede those of CD1d molecule in shaping the strength of the biological activity of C-glycoside analogues.	C-glycoside	143-154	CD1d molecule	Homo sapiens	75-88
19590406-9	2009	CONCLUSION: The ex-vivo Th1 responses of circulating NKT cells to CD1d-glycolipid complexes are impaired in HIV-infected patients.	Glycolipids	71-81	CD1d molecule	Homo sapiens	66-70
19590406-5	2009	We measured cytokines from NKT cells after stimulation with either alpha-galactosyl ceramide-loaded CD1d dimers (DimerX-alphaGalCer) or phorbol myristate acetate and ionomycin.	alpha-galactosylceramide	67-92	CD1d molecule	Homo sapiens	100-104
19620401-4	2009	ApoE dramatically enhances B-cell presentation of alpha-galactosylceramide (alphaGalCer), an exogenous CD1d presented antigen, inducing activation of NKT cells and the subsequent activation of B cells.	alpha-galactosylceramide	50-74	CD1d molecule	Homo sapiens	103-107
19769737-6	2009	Recently, we demonstrated the presence of CD1d-restricted T cells specific for an inflammation-associated lipid, lysophosphatidylcholine, in patients with advanced myeloma.	Lysophosphatidylcholines	113-136	CD1d molecule	Homo sapiens	42-46
19592275-0	2009	Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.	alpha-galactosylceramide	33-58	CD1d molecule	Homo sapiens	28-32
19592275-3	2009	We report the structures of V alpha 14-V beta 8.2 and V alpha 14-V beta 7 NKT TCRs in complex with CD1d-alpha-galactosylceramide (alpha-GalCer) and the 2.5 A structure of the human NKT TCR-CD1d-alpha-GalCer complex.	Galactosylceramides	110-128	CD1d molecule	Homo sapiens	99-103
19594637-5	2009	NKT cells recognize antigens presented by CD1d with hexose sugars in alpha-linkage to lipids, although other, related antigens are known.	hexose sugars	52-65	CD1d molecule	Homo sapiens	42-46
19594637-6	2009	The hydrophobic alkyl chains are buried in the CD1d groove, with the carbohydrate exposed for TCR recognition, together with the surface of the CD1d molecule.	Carbohydrates	69-81	CD1d molecule	Homo sapiens	47-51
19594637-7	2009	Therefore, understanding the biochemical basis for antigen recognition by NKT cells requires an understanding of how the trimolecular complex of CD1d, glycolipid, and the TCR is formed, which is in part a problem of carbohydrate recognition by the TCR.	Carbohydrates	216-228	CD1d molecule	Homo sapiens	145-149
19506241-1	2009	Short or polyunsaturated lipid variants of the NKT cell antigen alpha-galactosylceramide (alphaGC) exhibit decreased potency and a Th2 bias in vivo despite conserved TCR contact residues and stable binding to CD1d at neutral and acidic pH.	alpha-galactosylceramide	64-88	CD1d molecule	Homo sapiens	209-213
19538930-3	2009	Using a monoclonal antibody specific for alphaGalCer-CD1d complexes to visualize and quantitate glycolipid presentation, we found that Th2 cell-type cytokine-biasing ligands were characterized by rapid and direct loading of cell-surface CD1d proteins.	Glycolipids	96-106	CD1d molecule	Homo sapiens	53-57
19538930-4	2009	Complexes formed by association of these Th2 cell-type cytokine-biasing alphaGalCer analogs with CD1d showed a distinctive exclusion from ganglioside-enriched, detergent-resistant plasma membrane microdomains of antigen-presenting cells.	Gangliosides	138-149	CD1d molecule	Homo sapiens	97-101
19646850-2	2009	These glycolipid antigens have hexose sugars in alpha-linkage to two types of lipids that can bind to CD1d.	Hexoses	31-37	CD1d molecule	Homo sapiens	102-106
19646850-2	2009	These glycolipid antigens have hexose sugars in alpha-linkage to two types of lipids that can bind to CD1d.	Sugars	38-44	CD1d molecule	Homo sapiens	102-106
19369232-2	2009	iNKT cells are activated through their T-cell receptors by glycolipid moieties (typically the alpha-galactosylceramide [alpha-GalCer] derivative KRN7000) presented within CD1d.	Glycolipids	59-69	CD1d molecule	Homo sapiens	171-175
19369232-2	2009	iNKT cells are activated through their T-cell receptors by glycolipid moieties (typically the alpha-galactosylceramide [alpha-GalCer] derivative KRN7000) presented within CD1d.	alpha-galactosylceramide	94-118	CD1d molecule	Homo sapiens	171-175
19392798-1	2009	Invariant natural killer T (iNKT) cells are a subset of T lymphocytes that react with glycolipid antigens presented by the major histocompatibility complex class I-related glycoprotein CD1d.	Glycolipids	86-96	CD1d molecule	Homo sapiens	185-189
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Phospholipids	130-142	CD1d molecule	Homo sapiens	59-63
19414797-2	2009	alpha-Galactosylceramide (alpha-GalCer) is presented by CD1d molecule on APCs to invariant Valpha14(+) NKT (iNKT) cells, which upon activation rapidly produce large amounts of immunomodulatory cytokines, leading to activation of a variety of innate and adaptive immune cells.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	56-69
19479838-5	2009	Only 7 and 24 associated with plate-bound recombinant CD1d prevented stimulation of iNKT cells by alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	98-122	CD1d molecule	Homo sapiens	54-58
19479849-5	2009	Triazoles 14 and 15 prevent binding of alpha-galactosylceramide (alpha-GalCer) to plate-bound human CD1d and subsequent T-cell response to alpha-GalCer.	Triazoles	0-9	CD1d molecule	Homo sapiens	100-104
19479849-5	2009	Triazoles 14 and 15 prevent binding of alpha-galactosylceramide (alpha-GalCer) to plate-bound human CD1d and subsequent T-cell response to alpha-GalCer.	alpha-galactosylceramide	39-63	CD1d molecule	Homo sapiens	100-104
19479849-5	2009	Triazoles 14 and 15 prevent binding of alpha-galactosylceramide (alpha-GalCer) to plate-bound human CD1d and subsequent T-cell response to alpha-GalCer.	alpha-galactosylceramide	65-77	CD1d molecule	Homo sapiens	100-104
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Phosphatidylcholines	156-176	CD1d molecule	Homo sapiens	59-63
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Sphingomyelins	238-251	CD1d molecule	Homo sapiens	59-63
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Sphingomyelins	238-251	CD1d molecule	Homo sapiens	218-222
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Lysophospholipids	256-273	CD1d molecule	Homo sapiens	59-63
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Lysophospholipids	256-273	CD1d molecule	Homo sapiens	218-222
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Phosphatidylcholines	289-309	CD1d molecule	Homo sapiens	59-63
19342656-5	2009	By using multiple mass spectrometry methods, we found that CD1d retained in the ER is predominantly loaded with the most abundant phospholipid in the cell, phosphatidyl choline, while the protease cleavable version of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.	Phosphatidylcholines	289-309	CD1d molecule	Homo sapiens	218-222
19342656-6	2009	The secreted soluble version of CD1d, in contrast, lacks detectable phosphatidyl choline and the only detectable associated lipid is sphingomyelin.	Phosphatidylcholines	68-88	CD1d molecule	Homo sapiens	32-36
19342656-6	2009	The secreted soluble version of CD1d, in contrast, lacks detectable phosphatidyl choline and the only detectable associated lipid is sphingomyelin.	Sphingomyelins	133-146	CD1d molecule	Homo sapiens	32-36
18930085-1	2009	Natural killer T (NKT) cells recognize lipid antigens, such as glycosphingolipids (GSLs), via CD1d and contribute to host defense against various pathogens.	Glycosphingolipids	63-81	CD1d molecule	Homo sapiens	94-98
19056691-2	2009	Whether CD1d, a nonconventional, glycolipid-presenting HLA class I-like molecule instructing the function of the immunoregulatory invariant NKT cells can affect tumor cell survival is not known.	Glycolipids	33-43	CD1d molecule	Homo sapiens	8-12
19056691-5	2009	Cell death induced by monoclonal antibody engagement of CD1d is associated with overexpression of proapoptotic Bax and mitochondrial membrane potential loss but it is caspase-activation independent; in addition, it requires the cytoplasmic tail but not the Tyr residue critical for lysosomal sorting of CD1d.	Tyrosine	257-260	CD1d molecule	Homo sapiens	56-60
19137519-2	2009	In vivo evaluation demonstrates that this fluorinated glycolipid induces CD1d-dependent TCR activation of NKT cells, with a bias towards Th2 cytokine production.	Glycolipids	54-64	CD1d molecule	Homo sapiens	73-77
19236234-2	2009	The most widely studied NKT cell subset is the invariant (i)NKT cells that recognize glycolipids in the context of the CD1d molecule.	Glycolipids	85-96	CD1d molecule	Homo sapiens	119-132
18930085-1	2009	Natural killer T (NKT) cells recognize lipid antigens, such as glycosphingolipids (GSLs), via CD1d and contribute to host defense against various pathogens.	Glycosphingolipids	83-87	CD1d molecule	Homo sapiens	94-98
19273100-1	2009	Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer.	Glycolipids	0-10	CD1d molecule	Homo sapiens	20-24
19860680-4	2009	Structural and biochemical insights into presentation of glycolipids by CD1d have led to the discovery of novel lipid antigens and to a broader understanding of the underlying structural and mechanistic principles of NKT cell stimulation.	Glycolipids	57-68	CD1d molecule	Homo sapiens	72-76
19057011-1	2008	Invariant natural killer T (iNKT) cells constitute a subpopulation of T cells that recognize glycolipids presented by CD1d molecules.	Glycolipids	93-104	CD1d molecule	Homo sapiens	118-122
18957879-5	2008	The importance of the phospholipid transfer activity of MTP in the lipidation of apolipoprotein B and CD1d has been indicated.	Phospholipids	22-34	CD1d molecule	Homo sapiens	102-106
18706662-4	2008	In contrast NKT-cells that express the invariant Valpha24-Jalpha18(+) T-cell receptor identified here by specific receptor antibody and CD1d-tetrameric PBS57-loaded complexes, were increased in MS patients compared with HS.	PBS 57	152-157	CD1d molecule	Homo sapiens	136-140
19047090-9	2008	Ascites treatment also partially blocked the ability of alpha-galactosylceramide-loaded CD1d-immunoglobulin-based aAPC to activate NKT cells.	alpha-galactosylceramide	56-80	CD1d molecule	Homo sapiens	88-92
18783990-1	2008	Invariant CD1d restricted natural killer T (iNKT) cells are regulatory cells that express a canonical TCR-Valpha-chain (Valpha24.Jalpha18 in humans and Valpha14.Jalpha18 in mice) which recognizes glycolipid antigens presented by the monomorphic CD1d molecule.	Glycolipids	196-206	CD1d molecule	Homo sapiens	10-14
19434842-4	2009	The following research focuses on computationally analyzing the recently crystallized CD1d/alpha-GalCer/TCR tertiary complex by molecular dynamics simulations using AMBER along with studying the structure activity relationship of the sugar headgroup also by simulation and docking using Autodock for a variety of alpha-GalCer analogs.	Sugars	234-239	CD1d molecule	Homo sapiens	86-90
19434842-5	2009	The results show that the crystal structure is stable under simulation making it an accurate representation of the CD1d/alpha-GalCer/TCR complex and that modifications to the C2" and C3" positions of the sugar are not tolerated by the tertiary complex, whereas modifications to the C4" position are tolerated.	Sugars	204-209	CD1d molecule	Homo sapiens	115-119
18783990-1	2008	Invariant CD1d restricted natural killer T (iNKT) cells are regulatory cells that express a canonical TCR-Valpha-chain (Valpha24.Jalpha18 in humans and Valpha14.Jalpha18 in mice) which recognizes glycolipid antigens presented by the monomorphic CD1d molecule.	Glycolipids	196-206	CD1d molecule	Homo sapiens	245-249
18542099-0	2008	CD1d presentation of glycolipids.	Glycolipids	21-32	CD1d molecule	Homo sapiens	0-4
18671950-6	2008	This effect was not induced by increased IFN-gamma release by APC, and it was functionally correlated with increased L-kynurenine (L-KYN) release by alpha-GalCer-treated CD1d-transfected THP-1 cells.	Kynurenine	117-129	CD1d molecule	Homo sapiens	170-174
18712867-2	2008	In this study, a variety of glycolipid ligands were attached to a microarray surface and their binding with dimeric CD1d was investigated.	Glycolipids	28-38	CD1d molecule	Homo sapiens	116-120
18712867-3	2008	An alpha-galactosyl ceramide (alpha-GalCer) bearing a carbamate group at the 6"-OH position was tethered to the surface, and the dissociation constant on surface with CD1d was determined to reflect the multivalent interaction.	alpha-galactosylceramide	3-28	CD1d molecule	Homo sapiens	167-171
18712867-3	2008	An alpha-galactosyl ceramide (alpha-GalCer) bearing a carbamate group at the 6"-OH position was tethered to the surface, and the dissociation constant on surface with CD1d was determined to reflect the multivalent interaction.	Galactosylceramides	35-42	CD1d molecule	Homo sapiens	167-171
18712867-3	2008	An alpha-galactosyl ceramide (alpha-GalCer) bearing a carbamate group at the 6"-OH position was tethered to the surface, and the dissociation constant on surface with CD1d was determined to reflect the multivalent interaction.	Carbamates	54-63	CD1d molecule	Homo sapiens	167-171
18712867-5	2008	The 4-fluorophenyloctanoyl-modified alpha-GalCer (18) was found to bind most strongly with CD1d (Ki 0.21 microM), 2 orders of magnitude stronger than alpha-GalCer and more than three times more selective than alpha-GalCer for IFN-gamma release from NKT cells.	-fluorophenyloctanoyl	5-26	CD1d molecule	Homo sapiens	91-95
18712867-6	2008	Various alpha-GalCer analogues were analyzed, and the results showed that the binding affinity of glycolipids to CD1d correlates well with IFN-gamma production but poorly with IL-4 secretion by NKT cells, suggesting that tighter binding ligands could bias cytokine release through the T(H)1 pathway.	Glycolipids	98-109	CD1d molecule	Homo sapiens	113-117
18671950-6	2008	This effect was not induced by increased IFN-gamma release by APC, and it was functionally correlated with increased L-kynurenine (L-KYN) release by alpha-GalCer-treated CD1d-transfected THP-1 cells.	Kynurenine	131-136	CD1d molecule	Homo sapiens	170-174
18346153-2	2008	In the current study, we report that the induction of apoptosis by topoisomerase I inhibition or elevation of intracellular ceramide levels substantially impairs CD1d-mediated antigen presentation.	Ceramides	124-132	CD1d molecule	Homo sapiens	162-166
20641577-9	2004	However, because of its immunogenicity, the (99m)Tc-labeled ior egf/r3 MAb has limited clinical utility, particularly if repeated imaging investigations are necessary (5).	Technetium	49-51	CD1d molecule	Homo sapiens	68-70
20641577-12	2004	The hR3 was subsequently labeled with (99m)Tc and investigated for its tissue distribution and imaging properties (5, 8).	Technetium	43-45	CD1d molecule	Homo sapiens	4-7
18346153-4	2008	Confocal microscopic analysis showed an altered intracellular distribution of CD1d following the inhibition topoisomerase I or by an increase in intracellular ceramide levels, that was prevented by p38 and caspase inhibitors.	Ceramides	159-167	CD1d molecule	Homo sapiens	78-82
18552205-9	2008	CD1d expression was also induced by ATRA in HL-60 cells and ligation with anti-CD1d antibody-induced apoptosis.	Tretinoin	36-40	CD1d molecule	Homo sapiens	0-4
18478523-0	2008	Alpha-lactosylceramide as a novel "sugar-capped" CD1d ligand for natural killer T cells: biased cytokine profile and therapeutic activities.	alpha-lactosylceramide	0-22	CD1d molecule	Homo sapiens	49-53
18713998-2	2008	Central to their function is the interaction of the invariant TCR with glycosphingolipid (GSL) ligands presented by the nonpolymorphic MHC class I molecule CD1d and their ability to secrete rapidly large amounts of immunomodulatory cytokines when activated.	Glycosphingolipids	71-88	CD1d molecule	Homo sapiens	156-160
18713998-2	2008	Central to their function is the interaction of the invariant TCR with glycosphingolipid (GSL) ligands presented by the nonpolymorphic MHC class I molecule CD1d and their ability to secrete rapidly large amounts of immunomodulatory cytokines when activated.	Glycosphingolipids	90-93	CD1d molecule	Homo sapiens	156-160
18535199-0	2008	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.	Lysophospholipids	24-41	CD1d molecule	Homo sapiens	57-61
18535199-7	2008	These data identify a distinct population of human CD1d-restricted T cells specific for inflammation-associated lysolipids and suggest a novel mechanism for inflammation mediated immune regulation in human cancer.	lysolipids	112-122	CD1d molecule	Homo sapiens	51-55
18601810-1	2008	Invariant natural killer T (iNKT) cells are innate lymphocytes whose functions are regulated by self and foreign glycolipid antigens presented by the antigen-presenting molecule CD1d.	Glycolipids	113-123	CD1d molecule	Homo sapiens	178-182
18478523-2	2008	They can be activated by glycolipids that bind to CD1d.	Glycolipids	25-36	CD1d molecule	Homo sapiens	50-54
18453560-3	2008	Threitolceramide-pulsed DCs are more resistant to iNKT cell-dependent lysis than alpha-galactosylceramide-pulsed DCs due to the weaker affinity of the human iNKT TCR for CD1d/ threitolceramide than CD1d/alpha-galactosylceramide complexes.	Threitolceramide	0-16	CD1d molecule	Homo sapiens	170-174
18460919-4	2008	Microsomal triglyceride transfer protein also transfers phospholipids to the glycolipid antigen presentation molecule CD1d.	Phospholipids	56-69	CD1d molecule	Homo sapiens	118-122
18460919-4	2008	Microsomal triglyceride transfer protein also transfers phospholipids to the glycolipid antigen presentation molecule CD1d.	Glycolipids	77-87	CD1d molecule	Homo sapiens	118-122
18206371-2	2008	Furthermore, antigen processing and CD1d loading in lysosomes play central roles in controlling the stimulatory properties of glycolipid antigens.	Glycolipids	126-136	CD1d molecule	Homo sapiens	36-40
18453560-1	2008	Invariant NKT cells (iNKT cells) recognize CD1d/glycolipid complexes.	Glycolipids	48-58	CD1d molecule	Homo sapiens	43-47
18453560-3	2008	Threitolceramide-pulsed DCs are more resistant to iNKT cell-dependent lysis than alpha-galactosylceramide-pulsed DCs due to the weaker affinity of the human iNKT TCR for CD1d/ threitolceramide than CD1d/alpha-galactosylceramide complexes.	Threitolceramide	0-16	CD1d molecule	Homo sapiens	198-202
18378792-2	2008	Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d.	alpha-galactosylceramide	60-84	CD1d molecule	Homo sapiens	55-59
18378792-2	2008	Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d.	alpha-galactosylceramide	86-98	CD1d molecule	Homo sapiens	55-59
18378792-2	2008	Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d.	alpha-galactosylceramide	86-98	CD1d molecule	Homo sapiens	248-252
18378792-2	2008	Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d.	Alanine	136-143	CD1d molecule	Homo sapiens	55-59
18328185-3	2008	The recombinant protein hCD1d-alpha3 was purified with Ni(2+)-NTA agarose column and used as immunogen to immunize the rabbit.	nickel nitrilotriacetic acid	55-65	CD1d molecule	Homo sapiens	24-29
18275142-4	2008	Removing Phe(-) from Delta-1 and Lambda-1 using perchloric acid gave two enantiomers of [Ni(alpha-SS-L)](ClO4)2 (S-3) and [Ni(alpha-RR-L)](ClO4)2 (R-3).	Phenylalanine	9-12	CD1d molecule	Homo sapiens	147-150
18275142-4	2008	Removing Phe(-) from Delta-1 and Lambda-1 using perchloric acid gave two enantiomers of [Ni(alpha-SS-L)](ClO4)2 (S-3) and [Ni(alpha-RR-L)](ClO4)2 (R-3).	Perchloric Acid	48-63	CD1d molecule	Homo sapiens	147-150
18394340-2	2008	METHODS: The gene encoding the extracellular region of hCD1d was amplified by PCR and cloned into prokaryotic expression vector pET28, then expressed in E.coli BL21 (DE3) with IPTG induction.	Isopropyl Thiogalactoside	176-180	CD1d molecule	Homo sapiens	55-60
17690880-1	2008	BACKGROUND: Human Valpha24 natural killer T (NKT) cells are activated by the specific ligand, alpha-galactosylceramide (alpha-GalCer), in a CD1d-dependent manner.	alpha-galactosylceramide	94-118	CD1d molecule	Homo sapiens	140-144
18253930-0	2008	Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.	alpha-galactosylceramide	79-103	CD1d molecule	Homo sapiens	144-148
18253930-3	2008	To monitor the ability of CD1d to present the glycolipids, we have used a phage display strategy to generate recombinant antibodies with T cell receptor-like (TCRL) specificity against the human CD1d (hCD1d)-alpha-GalCer complex.	Glycolipids	46-57	CD1d molecule	Homo sapiens	26-30
18253930-3	2008	To monitor the ability of CD1d to present the glycolipids, we have used a phage display strategy to generate recombinant antibodies with T cell receptor-like (TCRL) specificity against the human CD1d (hCD1d)-alpha-GalCer complex.	Glycolipids	46-57	CD1d molecule	Homo sapiens	195-199
18253930-3	2008	To monitor the ability of CD1d to present the glycolipids, we have used a phage display strategy to generate recombinant antibodies with T cell receptor-like (TCRL) specificity against the human CD1d (hCD1d)-alpha-GalCer complex.	Glycolipids	46-57	CD1d molecule	Homo sapiens	201-206
18292516-4	2008	In comparison to other sulfatides or alphaGalCer, lyso-sulfatide binds with lower affinity to CD1d.	psychosine-3'-sulfate ester	50-64	CD1d molecule	Homo sapiens	94-98
18292516-5	2008	Although plate-bound CD1d is inefficient in presenting lyso-sulfatide at neutral pH, it is efficiently presented at acidic pH and in the presence of saposin C. The lysosomal trafficking of mCD1d is required for alphaGalCer presentation to type I NKT cells, it is not important for presentation of lyso-sulfatide to type II NKT cells.	psychosine-3'-sulfate ester	55-69	CD1d molecule	Homo sapiens	21-25
18292516-5	2008	Although plate-bound CD1d is inefficient in presenting lyso-sulfatide at neutral pH, it is efficiently presented at acidic pH and in the presence of saposin C. The lysosomal trafficking of mCD1d is required for alphaGalCer presentation to type I NKT cells, it is not important for presentation of lyso-sulfatide to type II NKT cells.	psychosine-3'-sulfate ester	297-311	CD1d molecule	Homo sapiens	21-25
18292516-9	2008	Our data collectively suggest that weak CD1d-binding self-glycolipid ligands such as lyso-sulfatide can be presented via the secretory and endosomal compartments.	psychosine-3'-sulfate ester	85-99	CD1d molecule	Homo sapiens	40-44
18328185-3	2008	The recombinant protein hCD1d-alpha3 was purified with Ni(2+)-NTA agarose column and used as immunogen to immunize the rabbit.	Sepharose	66-73	CD1d molecule	Homo sapiens	24-29
18068183-1	2008	The alpha-galactosylceramide (alphaGalCer)-loaded CD1d tetramer remains the most powerful tool in identifying natural killer T (NKT) cells, a subpopulation of T cells that express an unusual semi-invariant T cell antigen receptor, and mediate a variety of proinflammatory and immunoregulatory functions.	alpha-galactosylceramide	4-28	CD1d molecule	Homo sapiens	50-54
18202973-1	2008	BACKGROUND: NKT cells recognize glycolipids presented by CD1d on antigen-presenting cells (APC) and have been largely characterized by their ability to be activated by alpha-galactosylceramide, a glycolipid not expressed on mammalian cells.	alpha-galactosylceramide	168-192	CD1d molecule	Homo sapiens	57-61
18202973-1	2008	BACKGROUND: NKT cells recognize glycolipids presented by CD1d on antigen-presenting cells (APC) and have been largely characterized by their ability to be activated by alpha-galactosylceramide, a glycolipid not expressed on mammalian cells.	Glycolipids	32-42	CD1d molecule	Homo sapiens	57-61
18024119-1	2007	The invariant (i) natural killer (NK)T cells consistently express the Valpha14 chain of the T cell receptor (TCR) and recognize alpha-galactosylceramide (alpha-GalCer) presented by the nonpolymorphic presentation molecule CD1d.	alpha-galactosylceramide	128-152	CD1d molecule	Homo sapiens	222-226
17600041-3	2007	Natural killer T (NKT) cells are a subset of regulatory T lymphocytes that recognize glycolipid antigens presented by the major histocompatibility complex class I-related glycoprotein CD1d.	Glycolipids	85-95	CD1d molecule	Homo sapiens	184-188
17972354-1	2007	The semi-invariant TCR on iNKT cells recognizes glycolipids bound to monomorphic CD1d molecules, leading to rapid cytokine production.	Glycolipids	48-59	CD1d molecule	Homo sapiens	81-85
17710651-2	2007	We showed that activation of Valpha-14(+) hybridomas by dendritic cells or other CD1d-expressing cells was altered by disruption of lipid rafts with the cholesterol chelator MbetaCD.	valpha	29-35	CD1d molecule	Homo sapiens	81-85
17599630-0	2007	Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. BACKGROUND/AIMS: The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines.	alpha-galactosylceramide	50-74	CD1d molecule	Homo sapiens	274-278
17599630-0	2007	Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. BACKGROUND/AIMS: The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines.	Glycosphingolipids	138-155	CD1d molecule	Homo sapiens	274-278
17599630-0	2007	Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. BACKGROUND/AIMS: The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines.	alpha-galactosylceramide	156-180	CD1d molecule	Homo sapiens	274-278
17710651-2	2007	We showed that activation of Valpha-14(+) hybridomas by dendritic cells or other CD1d-expressing cells was altered by disruption of lipid rafts with the cholesterol chelator MbetaCD.	Cholesterol	153-164	CD1d molecule	Homo sapiens	81-85
17710651-2	2007	We showed that activation of Valpha-14(+) hybridomas by dendritic cells or other CD1d-expressing cells was altered by disruption of lipid rafts with the cholesterol chelator MbetaCD.	mbetacd	174-181	CD1d molecule	Homo sapiens	81-85
17372201-8	2007	Saposin B was also the most efficient in mediating alpha-galactosylceramide binding to recombinant plate-bound CD1d and facilitating NKT cell activation.	alpha-galactosylceramide	51-75	CD1d molecule	Homo sapiens	111-115
17544671-4	2007	alpha-Sulfatide 1 was stimulatory for CD1d-restricted semi-invariant Natural Killer T (iNKT) cell clones, although less potent than alpha-GalCer, while it was not recognized by CD1a-restricted sulfatide-specific T cells.	alpha-sulfatide	0-15	CD1d molecule	Homo sapiens	38-42
20641382-7	2004	However, because of its immunogenicity, the (99m)Tc-labeled ior egf/r3 MAb had limited clinical utility, particularly if repeated imaging investigations were necessary (3).	Technetium	49-51	CD1d molecule	Homo sapiens	68-70
20641382-10	2004	The hR3 was subsequently labeled with (99m)Tc and investigated for its tissue distribution and imaging properties (3, 6).	Technetium	43-45	CD1d molecule	Homo sapiens	4-7
17428648-1	2007	Natural killer T (NKT) cells are innate-like T lymphocytes that recognize glycolipid antigens in the context of the MHC class I-related glycoprotein CD1d.	Glycolipids	74-84	CD1d molecule	Homo sapiens	149-153
17392484-1	2007	CD1d belongs to a group of nonclassical antigen-presenting molecules that present glycolipid antigens and thereby activate natural killer T (NKT) cells, a subset of bifunctional T cells.	Glycolipids	82-92	CD1d molecule	Homo sapiens	0-4
17392484-3	2007	Here we show that all-trans-retinoic acid (RA), the active metabolite of vitamin A, rapidly (1 hr after treatment) increases CD1d mRNA in human and rodent monocytic cells at a physiologic dose (10 nM).	Tretinoin	18-41	CD1d molecule	Homo sapiens	125-129
17392484-3	2007	Here we show that all-trans-retinoic acid (RA), the active metabolite of vitamin A, rapidly (1 hr after treatment) increases CD1d mRNA in human and rodent monocytic cells at a physiologic dose (10 nM).	Tretinoin	43-45	CD1d molecule	Homo sapiens	125-129
17392484-3	2007	Here we show that all-trans-retinoic acid (RA), the active metabolite of vitamin A, rapidly (1 hr after treatment) increases CD1d mRNA in human and rodent monocytic cells at a physiologic dose (10 nM).	Vitamin A	73-82	CD1d molecule	Homo sapiens	125-129
17392484-6	2007	A putative RA-response element was identified in the distal 5" flanking region of the CD1d gene, which binds nuclear retinoid receptors and was responsive to RA in both gel mobility shift assay and transient transfection assay in THP-1 cells.	Tretinoin	11-13	CD1d molecule	Homo sapiens	86-90
17392484-6	2007	A putative RA-response element was identified in the distal 5" flanking region of the CD1d gene, which binds nuclear retinoid receptors and was responsive to RA in both gel mobility shift assay and transient transfection assay in THP-1 cells.	Tretinoin	158-160	CD1d molecule	Homo sapiens	86-90
17392484-9	2007	These studies together provide evidence for a previously unknown mechanism of CD1d gene expression regulation by RA and suggest that RA is a significant modulator of NKT cell activation.	Tretinoin	113-115	CD1d molecule	Homo sapiens	78-82
17392484-9	2007	These studies together provide evidence for a previously unknown mechanism of CD1d gene expression regulation by RA and suggest that RA is a significant modulator of NKT cell activation.	Tretinoin	133-135	CD1d molecule	Homo sapiens	78-82
17510531-3	2007	Initial characterizations revealed that both cell lines expressed an invariant T cell antigen receptor, which could be readily detected with alpha-galactosylceramide-loaded CD1d : Ig fusion protein (alpha-GalCer/CD1d).	alpha-galactosylceramide	141-165	CD1d molecule	Homo sapiens	173-177
17510531-3	2007	Initial characterizations revealed that both cell lines expressed an invariant T cell antigen receptor, which could be readily detected with alpha-galactosylceramide-loaded CD1d : Ig fusion protein (alpha-GalCer/CD1d).	alpha-galactosylceramide	141-165	CD1d molecule	Homo sapiens	212-216
17581592-4	2007	Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid.	alpha-galactosylceramide	108-132	CD1d molecule	Homo sapiens	66-70
17581592-4	2007	Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid.	alpha-galactosylceramide	108-132	CD1d molecule	Homo sapiens	149-153
17581592-4	2007	Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid.	Glycolipids	165-175	CD1d molecule	Homo sapiens	66-70
17581592-4	2007	Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid.	Glycolipids	165-175	CD1d molecule	Homo sapiens	149-153
17363727-2	2007	CD4 is also expressed by invariant natural killer T cells (iNKT), which recognize natural and synthetic lipid antigens, such as alpha-galactosyl ceramide (alpha-GalCer), in association with the MHC class I-like CD1d molecule.	alpha-galactosylceramide	128-153	CD1d molecule	Homo sapiens	211-224
17362268-1	2007	CD1d-restricted invariant natural killer T (iNK T) cells activated by their experimental ligand alpha-galactosylceramide (alpha-GC) can produce both T helper 1 (Th1) and Th2 cytokines and display regulatory functions.	alpha-galactosylceramide	96-120	CD1d molecule	Homo sapiens	0-4
17362268-1	2007	CD1d-restricted invariant natural killer T (iNK T) cells activated by their experimental ligand alpha-galactosylceramide (alpha-GC) can produce both T helper 1 (Th1) and Th2 cytokines and display regulatory functions.	alpha-galactosylceramide	122-130	CD1d molecule	Homo sapiens	0-4
17518990-0	2007	In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions.	Adapalene	48-57	CD1d molecule	Homo sapiens	30-34
17518990-4	2007	The aim of our study was to investigate the new mechanisms of the anti-inflammatory activity of adapalene in vitro, and more specifically the modulatory effect of adapalene on the expression of TLR-2, CD1d, a cell surface glycoprotein that plays a role as antigen-presenting molecules and is responsible for the development of cutaneous inflammation, and also on the expression and the secretion of the anti-inflammatory interleukin (IL)-10 cytokine.	Adapalene	163-172	CD1d molecule	Homo sapiens	201-205
17518990-6	2007	On the contrary, adapalene increased CD1d expression in explants of acne patients.	Adapalene	17-26	CD1d molecule	Homo sapiens	37-41
17518990-7	2007	Thus, adapalene can modulate the epidermal immune system by increasing the CD1d expression and by decreasing the IL-10 expression by keratinocytes.	Adapalene	6-15	CD1d molecule	Homo sapiens	75-79
17475845-5	2007	Chloroquine treatment markedly inhibited exogenous Ag presentation by wild-type CD1d transfectants, but did not affect NKT autoreactive responses.	Chloroquine	0-11	CD1d molecule	Homo sapiens	80-84
17312126-3	2007	We show that IL-21 on its own enhances survival of NKT cells in vitro, and IL-21 increases the proliferation of NKT cells in combination with IL-2 or IL-15, and particularly with the CD1d-restricted glycosphingolipid Ag alpha-galactosylceramide.	alpha-galactosylceramide	220-244	CD1d molecule	Homo sapiens	183-187
17312118-3	2007	We found that dendritic cells (DCs) potentiated iNKT cells to respond to a minimal amount of ligand alpha-galactosylceramide (alphaGalCer) through CD1d-dependent autoreactive responses that require endosomal processing and CD1d trafficking.	alpha-galactosylceramide	100-124	CD1d molecule	Homo sapiens	147-151
17277112-3	2007	Hepatic (alpha-galactosyl-ceramide-loaded CD1d dimer binding) NKT cells produce predominantly IL-4 when stimulated with glycolipid-presenting HC but predominantly IFN-gamma when stimulated with glycolipid-presenting dendritic cells.	alpha-galactosylceramide	9-34	CD1d molecule	Homo sapiens	42-46
17312126-3	2007	We show that IL-21 on its own enhances survival of NKT cells in vitro, and IL-21 increases the proliferation of NKT cells in combination with IL-2 or IL-15, and particularly with the CD1d-restricted glycosphingolipid Ag alpha-galactosylceramide.	Glycosphingolipids	199-216	CD1d molecule	Homo sapiens	183-187
17277112-3	2007	Hepatic (alpha-galactosyl-ceramide-loaded CD1d dimer binding) NKT cells produce predominantly IL-4 when stimulated with glycolipid-presenting HC but predominantly IFN-gamma when stimulated with glycolipid-presenting dendritic cells.	Glycolipids	120-130	CD1d molecule	Homo sapiens	42-46
17277112-3	2007	Hepatic (alpha-galactosyl-ceramide-loaded CD1d dimer binding) NKT cells produce predominantly IL-4 when stimulated with glycolipid-presenting HC but predominantly IFN-gamma when stimulated with glycolipid-presenting dendritic cells.	Glycolipids	194-204	CD1d molecule	Homo sapiens	42-46
17277112-4	2007	These NKT cells prime naive CD8 T cells to a (K(b)-presented) peptide ligand if they simultaneously recognize a CD1d-binding glycolipid presented to them on the surface of the responding CD8 T cells that they prime.	Glycolipids	125-135	CD1d molecule	Homo sapiens	112-116
18197797-1	2007	NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules.	Glycolipids	56-66	CD1d molecule	Homo sapiens	89-93
17100636-12	2006	NKT lymphocytes are activated by interaction of their TCR with glycolipids presented by CD1d, a nonpolymorphic, MHC class I-like molecule expressed by antigen presenting cells, and also by hepatocytes.	Glycolipids	63-74	CD1d molecule	Homo sapiens	88-92
17593661-6	2007	Among the glycolipid reactive TCRs, the invariant TCR expressed by CD1d reactive NKT cells has been by far the most thoroughly studied, and in this article we emphasize the unique features of this antigen recognition system, including repertoire formation, fine specificity, TCR affinity, and TCR structure.	Glycolipids	10-20	CD1d molecule	Homo sapiens	67-71
17454263-1	2007	Invariant natural killer T (iNKT) cells are a subset of T lymphocytes that recognizes glycolipid antigens presented by the major histocompatibility complex class I-related protein CD1d.	Glycolipids	86-96	CD1d molecule	Homo sapiens	180-184
17454265-1	2007	CD1d-restricted invariant natural killer T (iNKT) cells are a unique subset of T cells that recognize glycolipid antigens presented by the CD1d molecule.	Glycolipids	102-112	CD1d molecule	Homo sapiens	0-4
17454265-1	2007	CD1d-restricted invariant natural killer T (iNKT) cells are a unique subset of T cells that recognize glycolipid antigens presented by the CD1d molecule.	Glycolipids	102-112	CD1d molecule	Homo sapiens	139-152
18989404-9	2007	The generation of tetramers of alpha Galactosyl ceramide (a-Galcer) with CD1d has significant insight into the biology of NKT cells.	alpha-galactosylceramide	31-56	CD1d molecule	Homo sapiens	73-77
18989407-4	2007	The advent of CD1d tetramer technology, a technique developed by the Kronenberg lab, is critical for the sorting and identification of subsets of specific glycolipid-reactive T cells.	Glycolipids	155-165	CD1d molecule	Homo sapiens	14-18
18989407-5	2007	Mitch explains how glycolipid agonists are being used as therapeutic agents to activate NKT cells in cancer patients and how CD1d tetramers can be used to assess the state of the NKT cell population in vivo following glycolipid agonist therapy.	Glycolipids	217-227	CD1d molecule	Homo sapiens	125-129
17071611-0	2006	An N-linked glycan modulates the interaction between the CD1d heavy chain and beta 2-microglobulin.	n-linked glycan	3-18	CD1d molecule	Homo sapiens	57-61
17071611-4	2006	There are four N-linked glycans on the CD1d heavy chain, and we mutated them individually to ascertain their importance for the assembly and function of CD1d-beta(2)m heterodimers.	n-linked glycans	15-31	CD1d molecule	Homo sapiens	39-43
17071611-4	2006	There are four N-linked glycans on the CD1d heavy chain, and we mutated them individually to ascertain their importance for the assembly and function of CD1d-beta(2)m heterodimers.	n-linked glycans	15-31	CD1d molecule	Homo sapiens	153-157
17071611-7	2006	However, one glycan, glycan 2 at Asn-42, proved to be of particular importance for the stability of the CD1d-beta(2)m heterodimer.	Polysaccharides	13-19	CD1d molecule	Homo sapiens	104-108
17071611-7	2006	However, one glycan, glycan 2 at Asn-42, proved to be of particular importance for the stability of the CD1d-beta(2)m heterodimer.	Asparagine	33-36	CD1d molecule	Homo sapiens	104-108
17071611-11	2006	Modeling the glycans on the published structure indicated that glycan 2 interacts significantly with both the CD1d heavy chain and beta(2)m, which may explain these unusual properties.	Polysaccharides	13-20	CD1d molecule	Homo sapiens	110-114
17071611-11	2006	Modeling the glycans on the published structure indicated that glycan 2 interacts significantly with both the CD1d heavy chain and beta(2)m, which may explain these unusual properties.	glycan 2	63-71	CD1d molecule	Homo sapiens	110-114
18989404-6	2007	The Natural Killer T (NKT) cells use their TCR to recognize glycolipids bound to or presented by CD1d.	Glycolipids	60-71	CD1d molecule	Homo sapiens	97-101
17014832-1	2006	alpha-Galactosyl-ceramide (1) has been identified as a powerful modulator of immunological processes through its capacity to bind CD1d molecules and specifically activate invariant natural killer (NK)-like T cells (iNKT cells).	alpha-galactosylceramide	0-25	CD1d molecule	Homo sapiens	130-134
17107055-1	2006	Thio-isoglobotrihexosylceramide (S-iGb3) might be resistant to alpha-galactosidases in antigen-presenting cells and have a longer retaining time in the lysosome before being loaded to CD1d.	thioisoglobotrihexosylceramide	0-31	CD1d molecule	Homo sapiens	184-188
17100636-13	2006	Several possible ligands for NKT cells have recently been suggested including CD1d bound Glucocerebroside.	Glucosylceramides	89-105	CD1d molecule	Homo sapiens	78-82
17100636-18	2006	CD1d-bound glucocerebroside does not activate NKT cells directly, and may inhibit activation of NKT cells by alpha-GalCer.	Glucosylceramides	11-27	CD1d molecule	Homo sapiens	0-4
16458002-1	2006	Glycoceramides can activate NKT cells by binding with CD1d to produce IFN-gamma, IL-4, and other cytokines.	glycoceramides	0-14	CD1d molecule	Homo sapiens	54-58
17028247-1	2006	PURPOSE: Human Valpha24 natural killer T (Valpha24 NKT) cells bearing an invariant Valpha24JalphaQ antigen receptor are activated by a glicolipid ligand alpha-galactosylceramide (alphaGalCer; KRN7000) in a CD1d-dependent manner.	glicolipid	135-145	CD1d molecule	Homo sapiens	206-210
17028247-1	2006	PURPOSE: Human Valpha24 natural killer T (Valpha24 NKT) cells bearing an invariant Valpha24JalphaQ antigen receptor are activated by a glicolipid ligand alpha-galactosylceramide (alphaGalCer; KRN7000) in a CD1d-dependent manner.	alpha-galactosylceramide	153-177	CD1d molecule	Homo sapiens	206-210
16982809-0	2006	PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells.	Tretinoin	49-62	CD1d molecule	Homo sapiens	19-23
16982809-7	2006	The retinoic acid-induced elevated expression of CD1d is coupled to enhanced iNKT cell activation.	Tretinoin	4-17	CD1d molecule	Homo sapiens	49-53
16982809-8	2006	Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit retinoid signaling leading to CD1d up-regulation.	Retinoids	94-102	CD1d molecule	Homo sapiens	124-128
17015708-4	2006	Schwann cells activated iNKT cells in a CD1d-dependent manner in the presence of alpha-galactosylceramide.	alpha-galactosylceramide	81-105	CD1d molecule	Homo sapiens	40-44
17015708-5	2006	Surprisingly, the cytokine production of iNKT cells stimulated by alpha-galactosylceramide presented by CD1d+ Schwann cells showed a predominance of Th2-associated cytokines such as IL-5 and IL-13 with a marked deficiency of proinflammatory Th1 cytokines such as IFN-gamma or TNF-alpha.	alpha-galactosylceramide	66-90	CD1d molecule	Homo sapiens	104-108
16914507-1	2006	CD1d-restricted NKT cells are activated by TCR-mediated stimulation via CD1d plus lipid antigens such as alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	105-129	CD1d molecule	Homo sapiens	0-4
16848769-2	2006	In contrast to conventional or other types of regulatory T cells, they are activated by glycolipid and phospholipid ligands that are presented to them by the non-polymorphic, major histocompatibility complex class I-like molecule CD1d.	Glycolipids	88-98	CD1d molecule	Homo sapiens	230-234
16848769-2	2006	In contrast to conventional or other types of regulatory T cells, they are activated by glycolipid and phospholipid ligands that are presented to them by the non-polymorphic, major histocompatibility complex class I-like molecule CD1d.	Phospholipids	103-115	CD1d molecule	Homo sapiens	230-234
16794785-0	2006	Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands.	Glycolipids	0-11	CD1d molecule	Homo sapiens	41-45
16794785-0	2006	Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands.	Phospholipids	16-29	CD1d molecule	Homo sapiens	41-45
16794785-3	2006	Some of these glycolipid/phospholipid ligands have now been crystallized in forms bound to CD1d molecules, and the tertiary structure of these complexes has finally been revealed.	Glycolipids	14-24	CD1d molecule	Homo sapiens	91-95
16794785-3	2006	Some of these glycolipid/phospholipid ligands have now been crystallized in forms bound to CD1d molecules, and the tertiary structure of these complexes has finally been revealed.	Phospholipids	25-37	CD1d molecule	Homo sapiens	91-95
16834361-0	2006	Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity.	Glycolipids	29-40	CD1d molecule	Homo sapiens	45-49
16569772-1	2006	Natural killer T (NKT) cells are CD1d-restricted glycolipid reactive innate lymphocytes that play an important role in protection from pathogens and tumors.	Glycolipids	49-59	CD1d molecule	Homo sapiens	33-37
16569772-7	2006	Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors.	Lenalidomide	37-40	CD1d molecule	Homo sapiens	67-71
16569772-7	2006	Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors.	Glycolipids	97-107	CD1d molecule	Homo sapiens	67-71
16647712-1	2006	CD1d presentation of alpha-galactosyl ceramides to natural killer T cells has been a focal point of the study of regulatory T cells.	alpha-galactosylceramide	21-47	CD1d molecule	Homo sapiens	0-4
16651387-1	2006	Mouse and human natural killer T (NKT) cells recognize a restricted set of glycosphingolipids presented by CD1d molecules, including self iGb3 and microbial alpha-glycuronosylceramides.	Glycosphingolipids	75-93	CD1d molecule	Homo sapiens	107-111
16675349-0	2006	Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells.	phosphatidylethanolamine	30-55	CD1d molecule	Homo sapiens	65-69
16675349-6	2006	RESULTS: Cloned gammadelta T lymphocytes from subjects with allergy, but not normal controls, were found to recognize pollen-derived phosphatidyl-ethanolamine (PE) in a CD1d-restricted fashion.	phosphatidylethanolamine	133-158	CD1d molecule	Homo sapiens	169-173
16675349-6	2006	RESULTS: Cloned gammadelta T lymphocytes from subjects with allergy, but not normal controls, were found to recognize pollen-derived phosphatidyl-ethanolamine (PE) in a CD1d-restricted fashion.	phosphatidylethanolamine	160-162	CD1d molecule	Homo sapiens	169-173
16675349-9	2006	CONCLUSION: CD1d-restricted gammadelta T cells specific for phospholipids can represent a key mucosal regulatory subset for the control of early host reactivity against tree pollens.	Phospholipids	60-73	CD1d molecule	Homo sapiens	12-16
16373666-6	2006	CD1d-expressing HSCs display short- and long-term clonogenic potential and can present the glycolipid alpha-galactosylceramide to iNKT cells.	Glycolipids	91-101	CD1d molecule	Homo sapiens	0-4
16373666-6	2006	CD1d-expressing HSCs display short- and long-term clonogenic potential and can present the glycolipid alpha-galactosylceramide to iNKT cells.	alpha-galactosylceramide	102-126	CD1d molecule	Homo sapiens	0-4
16505140-7	2006	We propose a model of NKT TCR-CD1d-glycolipid interaction in which the invariant CDR3alpha loop is predicted to play a major role in determining the inherent bias toward CD1d.	Glycolipids	35-45	CD1d molecule	Homo sapiens	30-34
16505140-7	2006	We propose a model of NKT TCR-CD1d-glycolipid interaction in which the invariant CDR3alpha loop is predicted to play a major role in determining the inherent bias toward CD1d.	Glycolipids	35-45	CD1d molecule	Homo sapiens	170-174
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr1beta	137-145	CD1d molecule	Homo sapiens	52-56
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr1beta	137-145	CD1d molecule	Homo sapiens	181-185
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr1beta	137-145	CD1d molecule	Homo sapiens	181-185
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr2beta	195-203	CD1d molecule	Homo sapiens	52-56
16456021-0	2006	Ceramide-dependent regulation of human epidermal keratinocyte CD1d expression during terminal differentiation.	Ceramides	0-8	CD1d molecule	Homo sapiens	62-66
16456021-4	2006	Time-course studies of CD1d gene expression indicated that KC slowly increased gene expression with CaCl(2)-induced terminal differentiation.	Calcium Chloride	100-107	CD1d molecule	Homo sapiens	23-27
16456021-5	2006	Increased CD1d gene expression was dependent on ceramide synthesis, because fumonisin B1, a ceramide synthetase inhibitor, blocked the increase in CD1d gene expression during terminal differentiation.	Ceramides	48-56	CD1d molecule	Homo sapiens	10-14
16456021-5	2006	Increased CD1d gene expression was dependent on ceramide synthesis, because fumonisin B1, a ceramide synthetase inhibitor, blocked the increase in CD1d gene expression during terminal differentiation.	Ceramides	48-56	CD1d molecule	Homo sapiens	147-151
16456021-6	2006	Similarly, exogenous ceramide or the ceramidase inhibitor, B13, induced CD1d gene expression by undifferentiated, but not terminally differentiated, KC.	Ceramides	21-29	CD1d molecule	Homo sapiens	72-76
16456021-7	2006	A protein kinase C-zeta (PKC-zeta) inhibitor (a pseudosubstrate oligopeptide), but not a PKC-alphabeta inhibitor, significantly decreased CD1d gene expression by undifferentiated or ceramide-stimulated cultured, undifferentiated KC.	Ceramides	182-190	CD1d molecule	Homo sapiens	138-142
16456021-9	2006	The calcineurin phosphatase inhibitor cyclosporine A, which blocks KC terminal differentiation, also blocked CD1d gene expression by cultured KC.	Cyclosporine	38-52	CD1d molecule	Homo sapiens	109-113
16412042-5	2006	The non-classical antigen presenting molecule CD1d presents lipids and glycolipids to this highly specialized subset of T lymphocytes found in both humans and mice.	Glycolipids	71-82	CD1d molecule	Homo sapiens	46-50
16277640-2	2006	In contrast to conventional T cells, NKT cells express an invariant TCR and respond to glycolipids presented by CD1d.	Glycolipids	87-98	CD1d molecule	Homo sapiens	112-116
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr3beta	123-131	CD1d molecule	Homo sapiens	52-56
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr3beta	123-131	CD1d molecule	Homo sapiens	181-185
16520393-5	2006	The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3alpha, CDR3beta, and CDR1beta interact with ligands presented by CD1d, whereas CDR2beta binds to the CD1d alpha1 helix.	cdr3beta	123-131	CD1d molecule	Homo sapiens	181-185
16517731-1	2006	CD1d-restricted NKT cells use structurally conserved TCRs and recognize both self and foreign glycolipids, but the TCR features that determine these Ag specificities remain unclear.	Glycolipids	94-105	CD1d molecule	Homo sapiens	0-4
16517731-9	2006	These results highlight the variation in Ag recognition among CD1d-restricted TCRs and suggest that TCR alpha-chain elements contribute to alpha-linked glycosphingolipid specificity, whereas TCR beta-chains can confer heterogeneous additional reactivities.	alpha-linked glycosphingolipid	139-169	CD1d molecule	Homo sapiens	62-66
17132506-2	2006	NKT cells use their TCR to recognize glycolipids bound to or presented by CD1d.	Glycolipids	37-48	CD1d molecule	Homo sapiens	74-78
16505600-3	2006	iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation.	Glycolipids	21-31	CD1d molecule	Homo sapiens	98-102
16505600-3	2006	iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation.	alpha-galactosylceramide	49-73	CD1d molecule	Homo sapiens	98-102
16505600-3	2006	iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation.	alpha-galactosylceramide	75-83	CD1d molecule	Homo sapiens	98-102
16380959-1	2006	Human Valpha24(+)Vbeta11(+) NKT cells are a unique T cell population specifically and potently activated by alpha-galactosylceramide (alphaGalCer; KRN7000) presented by CD1d.	alpha-galactosylceramide	108-132	CD1d molecule	Homo sapiens	169-173
16210612-5	2005	Using MLR assays we demonstrate that in the presence of the CD1d-presented glycolipid alpha-galactosylceramide (alphaGC) alloreactivity is enhanced (37 +/- 12%; p < 0.001) in an iNKT cell-dependent manner.	Glycolipids	75-85	CD1d molecule	Homo sapiens	60-64
16323834-1	2005	[structures: see text] The phytosphingosine-containing alpha-galactosylceramides (alpha-GalCers), KRN7000 and OCH, have been shown to activate NKT cells via interaction with CD1d, a member of the CD1 family of antigen presenting proteins.	phytosphingosine	27-43	CD1d molecule	Homo sapiens	174-178
16323834-1	2005	[structures: see text] The phytosphingosine-containing alpha-galactosylceramides (alpha-GalCers), KRN7000 and OCH, have been shown to activate NKT cells via interaction with CD1d, a member of the CD1 family of antigen presenting proteins.	alpha-galactosylceramide	55-80	CD1d molecule	Homo sapiens	174-178
16305684-5	2005	Such changes in the alpha2 domain may alter the characteristics of the SIV-derived glycolipid/lipid antigens presented by each CD1d molecule to innate natural killer T cells.	Glycolipids	83-93	CD1d molecule	Homo sapiens	127-131
16301636-4	2005	In the absence of the endogenous mouse CD1d (mCD1d), the expression of hCD1d on thymocytes, but not on APCs, was sufficient to select Valpha14i NKT cells that proved functional when activated ex vivo with the Ag alpha-galactosyl ceramide.	alpha-galactosylceramide	212-237	CD1d molecule	Homo sapiens	71-76
16210612-5	2005	Using MLR assays we demonstrate that in the presence of the CD1d-presented glycolipid alpha-galactosylceramide (alphaGC) alloreactivity is enhanced (37 +/- 12%; p < 0.001) in an iNKT cell-dependent manner.	alpha-galactosylceramide	86-110	CD1d molecule	Homo sapiens	60-64
15916690-0	2005	Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model.	Sphingolipids	28-40	CD1d molecule	Homo sapiens	70-74
16091469-1	2005	Natural killer T cells (NKT cells) expressing a semi-invariant CD1d-reactive T cell receptor (invariant NKT, iNKT) can be rapidly activated by monocytes or immature dendritic cells (iDCs) bearing a CD1d-presented glycolipid antigen and can in turn stimulate these myeloid cells to mature and produce IL-12.	Glycolipids	213-223	CD1d molecule	Homo sapiens	63-67
16091469-1	2005	Natural killer T cells (NKT cells) expressing a semi-invariant CD1d-reactive T cell receptor (invariant NKT, iNKT) can be rapidly activated by monocytes or immature dendritic cells (iDCs) bearing a CD1d-presented glycolipid antigen and can in turn stimulate these myeloid cells to mature and produce IL-12.	Glycolipids	213-223	CD1d molecule	Homo sapiens	198-202
16177088-7	2005	From normal and diabetic PLN, one-third of CD1d tetramer+-sorted T cell clones were reactive with CD1d transfectants or proliferated/secreted cytokine in response to alpha-galactosylceramide-pulsed PBMCs; tetramer-staining T cell clones from diabetic PLN did not secrete IL-4.	alpha-galactosylceramide	166-190	CD1d molecule	Homo sapiens	43-47
16025562-1	2005	Human Valpha24+ Vbeta11+ natural killer T cells (NKT cells) are "natural memory" T cells that detect glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) presented on CD1d.	alpha-galactosylceramide	129-153	CD1d molecule	Homo sapiens	182-186
16025562-1	2005	Human Valpha24+ Vbeta11+ natural killer T cells (NKT cells) are "natural memory" T cells that detect glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) presented on CD1d.	Galactosylceramides	160-167	CD1d molecule	Homo sapiens	182-186
15894589-9	2005	Consistent with this, FTY-P caused an increase in percentage of MZ B cells expressing activation markers CD9, CD1d, and CD24.	FTY 720P	22-27	CD1d molecule	Homo sapiens	110-114
16007090-0	2005	The crystal structure of human CD1d with and without alpha-galactosylceramide.	alpha-galactosylceramide	53-77	CD1d molecule	Homo sapiens	31-35
16007090-1	2005	The glycolipid alpha-galactosylceramide binds with high affinity to CD1d and stimulates natural killer T cells.	Glycolipids	4-14	CD1d molecule	Homo sapiens	68-72
16007090-1	2005	The glycolipid alpha-galactosylceramide binds with high affinity to CD1d and stimulates natural killer T cells.	alpha-galactosylceramide	15-39	CD1d molecule	Homo sapiens	68-72
16007090-2	2005	Here we report the crystal structure of human CD1d in complex with synthetic alpha-galactosylceramide at a resolution of 3.0 A.	alpha-galactosylceramide	77-101	CD1d molecule	Homo sapiens	46-50
16007090-3	2005	The structure shows a tightly fit lipid in the CD1d binding groove, with the sphingosine chain bound in the C" pocket and the longer acyl chain anchored in the A" pocket.	Sphingosine	77-88	CD1d molecule	Homo sapiens	47-51
16007091-1	2005	Natural killer T cells express a conserved, semi-invariant alphabeta T cell receptor that has specificity for self glycosphingolipids and microbial cell wall alpha-glycuronosylceramide antigens presented by CD1d molecules.	Glycosphingolipids	115-133	CD1d molecule	Homo sapiens	207-211
16007091-1	2005	Natural killer T cells express a conserved, semi-invariant alphabeta T cell receptor that has specificity for self glycosphingolipids and microbial cell wall alpha-glycuronosylceramide antigens presented by CD1d molecules.	alpha-glycuronosylceramide	158-184	CD1d molecule	Homo sapiens	207-211
16007091-2	2005	Here we report the crystal structure of CD1d in complex with a short-chain synthetic variant of alpha-galactosylceramide at a resolution of 2.2 A.	alpha-galactosylceramide	96-120	CD1d molecule	Homo sapiens	40-44
15925541-0	2005	Development and function of CD1d-restricted NKT cells: influence of sphingolipids, SAP and sex.	Sphingolipids	68-81	CD1d molecule	Homo sapiens	28-32
15916690-3	2005	We now show that GluCerase-deficient monocytes from GD patients or monocytes from healthy subjects treated with conduritol-B-epoxide (CBE), an irreversible inhibitor of GluCerase activity, display high levels of surface expression of the lipid-binding molecule CD1d.	conduritol epoxide	112-132	CD1d molecule	Homo sapiens	261-265
15722411-0	2005	Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides.	alpha-galactosylceramide	77-102	CD1d molecule	Homo sapiens	14-18
15814694-1	2005	Va14Ja18 natural T (iNKT) cells are innate, immunoregulatory lymphocytes that recognize CD1d-restricted lipid Ags such as alpha-galactosylceramide (alpha GalCer).	alpha-galactosylceramide	122-146	CD1d molecule	Homo sapiens	88-92
15744356-3	2005	CD1d is a monomorphic molecule that provides a suitable target for immunotherapy in view of the characterization of a glycolipid, alpha-galactosylceramide (alpha-GalCer), capable of being presented to CD1d-restricted T cells with cytotoxic potential.	Galactosylceramides	136-154	CD1d molecule	Homo sapiens	0-4
15744356-3	2005	CD1d is a monomorphic molecule that provides a suitable target for immunotherapy in view of the characterization of a glycolipid, alpha-galactosylceramide (alpha-GalCer), capable of being presented to CD1d-restricted T cells with cytotoxic potential.	Galactosylceramides	136-154	CD1d molecule	Homo sapiens	201-205
15744356-8	2005	CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d.	alpha-galactosylceramide	43-55	CD1d molecule	Homo sapiens	0-4
15744356-8	2005	CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d.	alpha-galactosylceramide	43-55	CD1d molecule	Homo sapiens	60-64
15744356-8	2005	CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d.	alpha-galactosylceramide	43-55	CD1d molecule	Homo sapiens	60-64
15744356-8	2005	CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d.	alpha-galactosylceramide	43-55	CD1d molecule	Homo sapiens	60-64
15668717-1	2005	Resveratrol (R-3), a trihydroxy trans-stilbene from grape, inhibits multistage carcinogenesis in animal models.	Resveratrol	0-11	CD1d molecule	Homo sapiens	13-16
15668717-1	2005	Resveratrol (R-3), a trihydroxy trans-stilbene from grape, inhibits multistage carcinogenesis in animal models.	trihydroxystilbene	21-46	CD1d molecule	Homo sapiens	13-16
15665086-6	2005	Moreover, CD1d-dimer staining revealed human NKT cell reactivity toward these GSLs and to the sulfatides in a fashion comparable with alpha-GalCer.	Glycosphingolipids	78-82	CD1d molecule	Homo sapiens	10-14
15634340-0	2005	Altered expression of CD1d molecules and lipid accumulation in the human hepatoma cell line HepG2 after iron loading.	Iron	104-108	CD1d molecule	Homo sapiens	22-26
15634340-4	2005	Iron loading of HepG2 cells resulted in increased expression of Nor3.2-reactive CD1d molecules at the plasma membrane.	Iron	0-4	CD1d molecule	Homo sapiens	80-84
15634340-7	2005	Interestingly, increased expression of CD1d molecules by iron-loaded HepG2 cells was associated with increased phosphatidylserine expression in the outer leaflet of the plasma membrane and the presence of many intracellular lipid droplets.	Iron	57-61	CD1d molecule	Homo sapiens	39-43
15634340-8	2005	These data describe a new relationship between iron loading, lipid accumulation and altered expression of CD1d, an unconventional MHC class I molecule reported to monitor intracellular and plasma membrane lipid metabolism, in the human hepatoma cell line HepG2.	Iron	47-51	CD1d molecule	Homo sapiens	106-110
16178273-4	2005	Moreover, in the same patients we studied the intrahepatic and peripheral NKT cell recognition of alpha-galactosyl ceramide antigen in the context of CD1d.	alpha-galactosylceramide	98-123	CD1d molecule	Homo sapiens	150-154
16178273-7	2005	In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens.	Glycolipids	173-184	CD1d molecule	Homo sapiens	51-55
16178273-7	2005	In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens.	Glycolipids	173-184	CD1d molecule	Homo sapiens	157-161
16178273-7	2005	In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens.	alpha-galactosylceramide	193-218	CD1d molecule	Homo sapiens	51-55
16178273-7	2005	In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens.	alpha-galactosylceramide	193-218	CD1d molecule	Homo sapiens	157-161
15778340-5	2005	Interestingly, in this context, macrophage participation in the CD1d Ag presentation of alpha-galactosylceramide to NK T cells is not necessary.	alpha-galactosylceramide	88-112	CD1d molecule	Homo sapiens	64-68
15639652-1	2005	CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000).	Glycolipids	203-213	CD1d molecule	Homo sapiens	0-4
15639652-1	2005	CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000).	alpha-galactosylceramide	214-238	CD1d molecule	Homo sapiens	0-4
15771592-1	2005	Natural killer T (NKT) cells constitute a conserved T cell sublineage with unique properties, including reactivity for a synthetic glycolipid presented by CD1d, expression of an invariant T cell antigen receptor (TCR) alpha chain, and unusual requirements for thymic selection.	Glycolipids	131-141	CD1d molecule	Homo sapiens	155-159
15722411-1	2005	A form of alpha-galactosylceramide, KRN7000, activates CD1d-restricted Valpha14-invariant (Valpha14i) natural killer (NK) T cells and initiates multiple downstream immune reactions.	alpha-galactosylceramide	10-34	CD1d molecule	Homo sapiens	55-59
15493902-1	2004	Glycolipid presentation by CD1 proteins has emerged as an important aspect of antigen recognition, and presentation of alpha-glycosylceramides by CD1d to natural killer T cells has become a central focus in understanding how glycolipid presentation can influence immune responses.	alpha-glycosylceramides	119-142	CD1d molecule	Homo sapiens	146-150
15599405-1	2004	Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation.	alpha-galactosylceramide	119-143	CD1d molecule	Homo sapiens	24-28
15599405-1	2004	Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation.	Sphingosine	166-177	CD1d molecule	Homo sapiens	24-28
15493902-1	2004	Glycolipid presentation by CD1 proteins has emerged as an important aspect of antigen recognition, and presentation of alpha-glycosylceramides by CD1d to natural killer T cells has become a central focus in understanding how glycolipid presentation can influence immune responses.	Glycolipids	225-235	CD1d molecule	Homo sapiens	146-150
15493902-2	2004	An alpha-galactosylceramide containing relatively long lipid chains has been the subject of intense study because, when presented by CD1d to natural killer T cells, it stimulates the release of both proinflammatory and immunomodulatory cytokines.	alpha-galactosylceramide	3-27	CD1d molecule	Homo sapiens	133-137
15173890-2	2004	We demonstrate here that the NKT cell production of IFN-gamma is more susceptible to the sphingosine length of glycolipid ligand than that of IL-4 and that the length of the sphingosine chain determines the duration of NKT cell stimulation by CD1d-associated glycolipids.	Sphingosine	174-185	CD1d molecule	Homo sapiens	243-247
15304644-2	2004	They react to the glycolipid alpha-galactosyl ceramide (alpha-GalCer) presented by CD1d, and they may have important regulatory functions.	Glycolipids	18-28	CD1d molecule	Homo sapiens	83-87
15304644-2	2004	They react to the glycolipid alpha-galactosyl ceramide (alpha-GalCer) presented by CD1d, and they may have important regulatory functions.	alpha-galactosylceramide	29-54	CD1d molecule	Homo sapiens	83-87
15304644-2	2004	They react to the glycolipid alpha-galactosyl ceramide (alpha-GalCer) presented by CD1d, and they may have important regulatory functions.	alpha-galactosylceramide	56-68	CD1d molecule	Homo sapiens	83-87
15265953-1	2004	A subset of CD161(+)CD56(+/-) NKT cells can recognize glycolipids presented by CD1d and positively or negatively regulate inflammatory responses, including those implicated in several models of hepatitis.	Glycolipids	54-65	CD1d molecule	Homo sapiens	79-83
15186260-3	2004	One subset of canonical T cells is restricted by CD1d, a non-classical antigen presenting molecule that presents lipids and glycolipids.	Glycolipids	124-135	CD1d molecule	Homo sapiens	49-53
15243159-0	2004	Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells.	Phosphatidylinositols	14-34	CD1d molecule	Homo sapiens	70-74
15243159-0	2004	Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells.	Mannosides	35-44	CD1d molecule	Homo sapiens	70-74
15243159-4	2004	Of the mycobacterial lipids tested, only a phosphatidylinositol mannoside (PIM) fulfilled the requirements for CD1d binding and NKT cell stimulation.	phosphatidylinositol mannoside	43-73	CD1d molecule	Homo sapiens	111-115
15243159-4	2004	Of the mycobacterial lipids tested, only a phosphatidylinositol mannoside (PIM) fulfilled the requirements for CD1d binding and NKT cell stimulation.	phosphatidylinositol mannoside	75-78	CD1d molecule	Homo sapiens	111-115
15243159-6	2004	This phospholipid, therefore, represents a mycobacterial antigen recognized by T cells in the context of CD1d.	Phospholipids	5-17	CD1d molecule	Homo sapiens	105-109
15187105-10	2004	Incubation of target cells with the ligands for CD1d, alpha-galactosylceramide (alpha-GalCer), and beta-GalCer abolishes the protective effect of CD1d in our in vitro killing assays.	alpha-galactosylceramide	54-78	CD1d molecule	Homo sapiens	146-150
15187105-10	2004	Incubation of target cells with the ligands for CD1d, alpha-galactosylceramide (alpha-GalCer), and beta-GalCer abolishes the protective effect of CD1d in our in vitro killing assays.	alpha-galactosylceramide	80-92	CD1d molecule	Homo sapiens	146-150
14961579-3	2004	The synthetic lipid alpha-galactosylceramide (alpha-GalCer) has been characterized as a potent stimulator of CD1d-restricted T cells.	alpha-galactosylceramide	20-44	CD1d molecule	Homo sapiens	109-113
15185366-0	2004	Loading of the antigen-presenting protein CD1d with synthetic glycolipids.	Glycolipids	62-73	CD1d molecule	Homo sapiens	42-46
14961579-0	2004	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.	alpha-galactosylceramide	71-95	CD1d molecule	Homo sapiens	0-4
15185366-8	2004	All four glycolipids were found to bind to CD1d but with different selectivity.	Glycolipids	9-20	CD1d molecule	Homo sapiens	43-47
15185366-9	2004	The loading was dose dependent and could be inhibited by an established CD1d ligand, alpha-galactosylceramide.	alpha-galactosylceramide	85-109	CD1d molecule	Homo sapiens	72-76
15185366-10	2004	Through use of this procedure, glycolipids were selectively loaded onto CD1d expressed on professional antigen-presenting cells for future use as cellular vaccines.	Glycolipids	31-42	CD1d molecule	Homo sapiens	72-76
12928408-8	2003	CD1d-restricted T cell clones responded to chemokine ligands for CXCR1/2, CXCR3, CXCR4, CXCR6, CCR4, and CCR5 in calcium flux and/or chemotaxis assays.	Calcium	113-120	CD1d molecule	Homo sapiens	0-4
20705005-3	2004	While iNKT cells show high autoreactivity, the only cellular lipid shown to be presented by CD1d has been phosphatidyl inositol, which does not activate iNKT cells by itself.	Phosphatidylinositols	106-127	CD1d molecule	Homo sapiens	92-96
14716312-4	2004	Here we show that saposins, although not required for the autoreactive recognition of CD1d by natural killer T cells, are indispensable for the binding of an exogenous lipid antigen, alpha-galactosylceramide, to CD1d in the endocytic pathway.	alpha-galactosylceramide	183-207	CD1d molecule	Homo sapiens	212-216
14512316-1	2004	Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells.	alpha-galactosylceramide	139-163	CD1d molecule	Homo sapiens	68-72
14512316-1	2004	Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells.	alpha-galactosylceramide	139-163	CD1d molecule	Homo sapiens	202-206
14512316-1	2004	Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells.	alpha-galactosylceramide	165-177	CD1d molecule	Homo sapiens	68-72
14512316-1	2004	Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells.	alpha-galactosylceramide	165-177	CD1d molecule	Homo sapiens	202-206
12963715-0	2003	Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell.	Phospholipids	53-65	CD1d molecule	Homo sapiens	91-95
12963715-9	2003	These data illustrate the potential importance of the acyl chain structure for phospholipid antigen binding to CD1d.	Phospholipids	79-91	CD1d molecule	Homo sapiens	111-115
14530322-1	2003	NKT cells are enigmatic lymphocytes that respond to glycolipid Ags presented by CD1d.	Glycolipids	52-62	CD1d molecule	Homo sapiens	80-84
12960397-1	2003	CD1d-restricted natural killer T (NKT) cells are a subset of regulatory T cells that react with glycolipid antigens.	Glycolipids	96-106	CD1d molecule	Homo sapiens	0-4
12952923-1	2003	CD1d is expressed on the surface of professional and nonprofessional APCs, including intestinal epithelial cells (IECs), for a role in the presentation of glycolipid-based antigens to subsets of T cells.	Glycolipids	155-165	CD1d molecule	Homo sapiens	0-4
14719188-1	2003	OBJECTIVE: To examine whether the expression of intact CD1d, a critical molecule for the presentation of glycolipid antigens to natural killer T (NKT) cells, and its variants differs between patients with autoimmune diseases including rheumatoid arthritis (RA) and healthy subjects.	Glycolipids	105-115	CD1d molecule	Homo sapiens	55-59
14719188-6	2003	Alternatively spliced CD1d variants were quantified by TaqMan PCR using polymerase chain reaction with confronting 2-pair primers (PCR-CTPP) based amplification.	ctpp	135-139	CD1d molecule	Homo sapiens	22-26
12239218-0	2002	Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain.	Disulfides	47-56	CD1d molecule	Homo sapiens	81-85
14607868-2	2003	A well-characterized subclass of these NKT cells expresses biased TCR and recognizes glycolipids such as alpha-galactoceramide, which is found naturally only in marine sponges and presented by the cell surface glycoprotein CD1d.	Glycolipids	85-96	CD1d molecule	Homo sapiens	223-227
14607868-2	2003	A well-characterized subclass of these NKT cells expresses biased TCR and recognizes glycolipids such as alpha-galactoceramide, which is found naturally only in marine sponges and presented by the cell surface glycoprotein CD1d.	alpha-galactoceramide	105-126	CD1d molecule	Homo sapiens	223-227
12764370-1	2003	Natural killer T (NKT) cells with an invariant T-cell receptor for alpha-galactosylceramide (alphaGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells.	alpha-galactosylceramide	67-91	CD1d molecule	Homo sapiens	127-131
12764370-1	2003	Natural killer T (NKT) cells with an invariant T-cell receptor for alpha-galactosylceramide (alphaGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells.	alpha-galactosylceramide	93-104	CD1d molecule	Homo sapiens	127-131
12730881-1	2003	BACKGROUND & AIMS: CD1d, a major histocompatibility complex (MHC) class I-related molecule that is responsible for the presentation of glycolipid antigens to subsets of natural killer T (NK-T) cells, is expressed by intestinal epithelial cells (IECs).	Adenosine Monophosphate	12-15	CD1d molecule	Homo sapiens	23-27
12730881-4	2003	RESULTS: MODE-K and freshly isolated human IECs exhibited dose-dependent, CD1d-restricted presentation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK-T cell hybridoma, DN32.D3.	Glycolipids	121-131	CD1d molecule	Homo sapiens	74-78
12730881-4	2003	RESULTS: MODE-K and freshly isolated human IECs exhibited dose-dependent, CD1d-restricted presentation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK-T cell hybridoma, DN32.D3.	alpha-galactosylceramide	141-165	CD1d molecule	Homo sapiens	74-78
12695492-1	2003	Invariant natural killer T (NKT) cells are a highly conserved subset of T lymphocytes expressing a semi-invariant T cell receptor (TCR), which is restricted to CD1d and specific for the glycosphingolipid antigen alpha-galactosylceramide.	Glycosphingolipids	186-203	CD1d molecule	Homo sapiens	160-164
12239218-7	2002	Complete disulfide bond formation in the CD1d heavy chain was substantially impaired if the chaperone interactions were blocked by the glucosidase inhibitors castanospermine or N-butyldeoxynojirimycin.	miglustat	177-200	CD1d molecule	Homo sapiens	41-45
12239218-8	2002	The formation of at least one of the disulfide bonds in the CD1d heavy chain is coupled to its glucose trimming-dependent association with ERp57, calnexin, and calreticulin.	Disulfides	37-46	CD1d molecule	Homo sapiens	60-64
12239218-8	2002	The formation of at least one of the disulfide bonds in the CD1d heavy chain is coupled to its glucose trimming-dependent association with ERp57, calnexin, and calreticulin.	Glucose	95-102	CD1d molecule	Homo sapiens	60-64
12757612-1	2003	This review attempts to illuminate the glycolipid antigen presentation properties of CD1d, how CD1d controls the function of natural T (iNKT) cells and how CD1d and iNKT cells interact to jump-start the immune system.	Glycolipids	39-49	CD1d molecule	Homo sapiens	85-89
12763683-2	2003	Following recognition of CD1d-presented glycosphingolipid antigens invariant NKT promptly release high amount of diverse cytokines concurring to the activation of the actors of both innate and acquired immune responses.	Glycosphingolipids	40-57	CD1d molecule	Homo sapiens	25-29
12803920-3	2003	Fluorescent tetrameric complexes made from soluble recombinant CD1d/alpha-galactosylceramide complexes allowed highly sensitive and specific ex vivo and in vitro detection and functional characterization of novel human T-lymphocyte populations.	alpha-galactosylceramide	68-92	CD1d molecule	Homo sapiens	63-67
12707346-0	2003	The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs.	alpha-galactosylceramide	47-71	CD1d molecule	Homo sapiens	107-111
12594262-12	2003	NKT cells, which home preferentially to the liver and respond to the CD1d-restricted ligand alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	92-116	CD1d molecule	Homo sapiens	69-73
12505720-1	2003	Human CD1d-restricted natural killer T (NKT) cells, which are postulated to regulate the immune response in several clinical settings, can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen presenting cells (APCs).	alpha-galactosylceramide	155-179	CD1d molecule	Homo sapiens	6-10
12505720-1	2003	Human CD1d-restricted natural killer T (NKT) cells, which are postulated to regulate the immune response in several clinical settings, can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen presenting cells (APCs).	alpha-galactosylceramide	155-179	CD1d molecule	Homo sapiens	208-212
12890950-3	2003	They are CD1d-dependent and can be stimulated by alpha-galactosylceramide.	alpha-galactosylceramide	49-73	CD1d molecule	Homo sapiens	9-13
12239218-6	2002	Here we show that CD1d associates in the ER with both calnexin and calreticulin and with the thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of its N-linked glycans.	Glucose	145-152	CD1d molecule	Homo sapiens	18-22
12239218-6	2002	Here we show that CD1d associates in the ER with both calnexin and calreticulin and with the thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of its N-linked glycans.	n-linked glycans	169-185	CD1d molecule	Homo sapiens	18-22
12239218-7	2002	Complete disulfide bond formation in the CD1d heavy chain was substantially impaired if the chaperone interactions were blocked by the glucosidase inhibitors castanospermine or N-butyldeoxynojirimycin.	Disulfides	9-18	CD1d molecule	Homo sapiens	41-45
12239218-7	2002	Complete disulfide bond formation in the CD1d heavy chain was substantially impaired if the chaperone interactions were blocked by the glucosidase inhibitors castanospermine or N-butyldeoxynojirimycin.	castanospermine	158-173	CD1d molecule	Homo sapiens	41-45
12360465-3	2002	METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC).	alpha-galactosylceramide	124-148	CD1d molecule	Homo sapiens	25-29
12360465-3	2002	METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC).	alpha-galactosylceramide	124-148	CD1d molecule	Homo sapiens	31-36
12360465-3	2002	METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC).	alpha-galactosylceramide	124-148	CD1d molecule	Homo sapiens	32-36
12023346-0	2002	Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes.	alpha-galactosylceramide	61-85	CD1d molecule	Homo sapiens	30-34
12034704-3	2002	To understand how EPCR accomplishes these multiple tasks, we solved the crystal structure of EPCR alone and in complex with the phospholipid binding domain of protein C. The structures were strikingly similar to CD1d.	Phospholipids	128-140	CD1d molecule	Homo sapiens	212-216
12213347-5	2002	The recent generation of tetramers of alpha-galactosyl ceramide (alpha-GalCer) with CD1d has already permitted significant insight into the biology of NKT cells.	alpha-galactosylceramide	38-63	CD1d molecule	Homo sapiens	84-88
12213347-5	2002	The recent generation of tetramers of alpha-galactosyl ceramide (alpha-GalCer) with CD1d has already permitted significant insight into the biology of NKT cells.	alpha-galactosylceramide	65-77	CD1d molecule	Homo sapiens	84-88
12023346-1	2002	Human CD1d molecules present an unknown ligand, mimicked by the synthetic glycosphingolipid alpha-galactosylceramide (alphaGC), to a highly conserved NKT cell subset expressing an invariant TCR Valpha24-JalphaQ paired with Vbeta11 chain (Valpha24(+)Vbeta11(+) invariant NK T cell (NKT(inv))).	Glycosphingolipids	74-91	CD1d molecule	Homo sapiens	6-10
12023346-1	2002	Human CD1d molecules present an unknown ligand, mimicked by the synthetic glycosphingolipid alpha-galactosylceramide (alphaGC), to a highly conserved NKT cell subset expressing an invariant TCR Valpha24-JalphaQ paired with Vbeta11 chain (Valpha24(+)Vbeta11(+) invariant NK T cell (NKT(inv))).	alpha-galactosylceramide	92-116	CD1d molecule	Homo sapiens	6-10
12023346-6	2002	In conclusion, our results demonstrate that, contrary to the currently held view, recognition of CD1d-alphaGC complex in humans is not uniformly restricted to the Valpha24-JalphaQ/Vbeta11 NKT cell subset, but can be mediated by a diverse range of Valpha and Vbeta domains.	valpha	163-169	CD1d molecule	Homo sapiens	97-101
11754812-0	2001	CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain.	Tyrosine	83-91	CD1d molecule	Homo sapiens	0-4
11869900-2	2002	The recent development of fluorescent CD1d tetramers loaded with the synthetic glycolipid alpha-galactosyl-ceramide has led to a clearer definition of NKT-cell subsets as well as important insights into their developmental origin.	Glycolipids	79-89	CD1d molecule	Homo sapiens	38-42
11869900-2	2002	The recent development of fluorescent CD1d tetramers loaded with the synthetic glycolipid alpha-galactosyl-ceramide has led to a clearer definition of NKT-cell subsets as well as important insights into their developmental origin.	alpha-galactosylceramide	90-115	CD1d molecule	Homo sapiens	38-42
11877485-5	2002	In contrast, CD4(+) CD1d-restricted NKT cells potently produced both Th1 and Th2 cytokines, up-regulated perforin in response to stimulation by phorbol myristate acetate and ionomycin but not IL-2 or IL-12, and could be induced to express CD95L.	Tetradecanoylphorbol Acetate	144-169	CD1d molecule	Homo sapiens	20-24
11877485-5	2002	In contrast, CD4(+) CD1d-restricted NKT cells potently produced both Th1 and Th2 cytokines, up-regulated perforin in response to stimulation by phorbol myristate acetate and ionomycin but not IL-2 or IL-12, and could be induced to express CD95L.	Ionomycin	174-183	CD1d molecule	Homo sapiens	20-24
11830474-1	2002	The antimetastatic effect of the CD1d-binding glycolipid, alpha-galactosylceramide (alpha-GalCer), is mediated by NK1.1(+)T (NKT) cells; however, the mechanisms behind this process are poorly defined.	Glycolipids	46-56	CD1d molecule	Homo sapiens	33-37
11830474-1	2002	The antimetastatic effect of the CD1d-binding glycolipid, alpha-galactosylceramide (alpha-GalCer), is mediated by NK1.1(+)T (NKT) cells; however, the mechanisms behind this process are poorly defined.	alpha-galactosylceramide	58-82	CD1d molecule	Homo sapiens	33-37
11830474-1	2002	The antimetastatic effect of the CD1d-binding glycolipid, alpha-galactosylceramide (alpha-GalCer), is mediated by NK1.1(+)T (NKT) cells; however, the mechanisms behind this process are poorly defined.	alpha-galactosylceramide	84-96	CD1d molecule	Homo sapiens	33-37
11754812-0	2001	CD1d endosomal trafficking is independently regulated by an intrinsic CD1d-encoded tyrosine motif and by the invariant chain.	Tyrosine	83-91	CD1d molecule	Homo sapiens	70-74
11754812-2	2001	We demonstrate that CD1d access to endosomal compartments is under dual regulation by an intrinsic tyrosine-based motif, which governs intense recycling between the plasma membrane and the endosome, and by the invariant chain, with which CD1d associates in the endoplasmic reticulum.	Tyrosine	99-107	CD1d molecule	Homo sapiens	20-24
11754812-2	2001	We demonstrate that CD1d access to endosomal compartments is under dual regulation by an intrinsic tyrosine-based motif, which governs intense recycling between the plasma membrane and the endosome, and by the invariant chain, with which CD1d associates in the endoplasmic reticulum.	Tyrosine	99-107	CD1d molecule	Homo sapiens	238-242
11591738-7	2001	To further characterize CD1d-restricted NKT cells, we generated an alpha-GalCer-responsive NKT cell line from thymocytes.	methylphenyl carbinol	67-73	CD1d molecule	Homo sapiens	24-28
11714786-1	2001	CD1d-dependent accumulation of alphabeta T cells bearing a canonical Valpha14Jalpha281 alpha-chain (Valpha14+ T cells) is thought to model positive selection of lipid-specific T cells, based on their ability to recognize CD1d-presented self glycolipid(s).	valpha14jalpha281	69-86	CD1d molecule	Homo sapiens	0-4
11714786-1	2001	CD1d-dependent accumulation of alphabeta T cells bearing a canonical Valpha14Jalpha281 alpha-chain (Valpha14+ T cells) is thought to model positive selection of lipid-specific T cells, based on their ability to recognize CD1d-presented self glycolipid(s).	valpha14jalpha281	69-86	CD1d molecule	Homo sapiens	221-225
11714786-1	2001	CD1d-dependent accumulation of alphabeta T cells bearing a canonical Valpha14Jalpha281 alpha-chain (Valpha14+ T cells) is thought to model positive selection of lipid-specific T cells, based on their ability to recognize CD1d-presented self glycolipid(s).	Glycolipids	241-251	CD1d molecule	Homo sapiens	0-4
11714786-1	2001	CD1d-dependent accumulation of alphabeta T cells bearing a canonical Valpha14Jalpha281 alpha-chain (Valpha14+ T cells) is thought to model positive selection of lipid-specific T cells, based on their ability to recognize CD1d-presented self glycolipid(s).	Glycolipids	241-251	CD1d molecule	Homo sapiens	221-225
11714786-2	2001	However, it has been difficult to demonstrate self ligand specificity in this system, as most Valpha14+ T cells do not exhibit significant autoreactivity despite high reactivity to alpha-galactosylceramide presented by CD1d (alpha-GalCer/CD1d).	alpha-galactosylceramide	181-205	CD1d molecule	Homo sapiens	219-223
11714786-2	2001	However, it has been difficult to demonstrate self ligand specificity in this system, as most Valpha14+ T cells do not exhibit significant autoreactivity despite high reactivity to alpha-galactosylceramide presented by CD1d (alpha-GalCer/CD1d).	alpha-galactosylceramide	181-205	CD1d molecule	Homo sapiens	238-242
11550008-5	2001	These results confirm the existence of a DP intermediate for CD1d-reactive NKT cells.	dp	41-43	CD1d molecule	Homo sapiens	61-65
11586362-2	2001	Here we report that a synthetic glycolipid ligand for CD1d-restricted natural killer T (NKT) cells expressing the semi-invariant T-cell receptor (Valpha14+) is preventive against EAE.	Glycolipids	32-42	CD1d molecule	Homo sapiens	54-58
11564825-3	2001	Invariant NK T cells were markedly decreased in peripheral blood from advanced prostate cancer patients, and their ex vivo expansion with a CD1d-presented lipid Ag (alpha-galactosylceramide) was diminished compared with healthy donors.	alpha-galactosylceramide	165-189	CD1d molecule	Homo sapiens	140-144
11248072-2	2001	We here report the construction of CD1d-glycolipid tetramers from fully denatured human CD1d molecules by using the technique of oxidative refolding chromatography.	Glycolipids	40-50	CD1d molecule	Homo sapiens	35-39
11313548-1	2001	Rubidium molybdenum selenide, Rb(4)Mo(21)Se(24), crystallizes in the trigonal space group R-3.	rubidium molybdenum selenide	0-28	CD1d molecule	Homo sapiens	90-93
11264173-1	2001	Human Valpha24NKT cells are activated by alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells in a CD1d-dependent and a T-cell receptor-mediated manner.	alpha-galactosylceramide	41-65	CD1d molecule	Homo sapiens	109-113
11264173-1	2001	Human Valpha24NKT cells are activated by alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells in a CD1d-dependent and a T-cell receptor-mediated manner.	alpha-galactosylceramide	67-79	CD1d molecule	Homo sapiens	109-113
11248072-2	2001	We here report the construction of CD1d-glycolipid tetramers from fully denatured human CD1d molecules by using the technique of oxidative refolding chromatography.	Glycolipids	40-50	CD1d molecule	Homo sapiens	88-92
11315191-4	2001	This review attempts to illuminate the glycolipid antigen presentation properties of CD1d, how CD1d controls the function of natural T cells and how CD1d and natural T cells interact to jump start the immune system.	Glycolipids	39-49	CD1d molecule	Homo sapiens	85-89
11113096-7	2000	Upon in vitro stimulation with PDB/ionomycin, they showed predominantly interferon gamma and interleukin (IL)-4 but also tumor necrosis factor alpha and IL-10 production and did not specifically lyse autologous T-cell blasts, B-cell lines, or other autologous or allogeneic target or CD1d-transfected cells.	Ionomycin	35-44	CD1d molecule	Homo sapiens	284-288
11260318-1	2001	Human Valpha24 natural killer T (Valpha24NKT) cells are activated by alpha-glycosylceramide-pulsed dendritic cells (DCs) in a CD1d-dependent and T-cell receptor-mediated manner.	alpha-glycosylceramide	69-91	CD1d molecule	Homo sapiens	126-130
11164462-9	2000	Another subset of T cells that expresses the NK receptors is the alpha-galactosyl-ceramide specific T cell subset defined by the expression of canonical Valpha24JalphaQ TCR, recognition of CD1d and secretion of high amounts of IL-4 and IFN-gamma.	alpha-galactosylceramide	65-90	CD1d molecule	Homo sapiens	189-193
10779745-1	2000	Human V alpha 24+ NKT cells with an invariant TCR (V alpha 24-J alpha Q) have been shown to be specifically activated by synthetic glycolipids such as alpha-galactosylceramide and alpha-glucosylceramide in a CD1d-restricted and V alpha 24 TCR-mediated manner.	Glycolipids	131-142	CD1d molecule	Homo sapiens	208-212
11145860-3	2000	They recognize a glycolipid antigen (alpha -galactosylceramide) or parasitic glycophosphatidylinositols (GPI) in association with a monomorphic class Ib, CD1d, and perform various functions such as Th1 and Th2 cytokine production as well as perforin/granzyme B-mediated cytotoxicity.	Glycolipids	17-27	CD1d molecule	Homo sapiens	154-158
11145860-3	2000	They recognize a glycolipid antigen (alpha -galactosylceramide) or parasitic glycophosphatidylinositols (GPI) in association with a monomorphic class Ib, CD1d, and perform various functions such as Th1 and Th2 cytokine production as well as perforin/granzyme B-mediated cytotoxicity.	alpha-galactosylceramide	37-62	CD1d molecule	Homo sapiens	154-158
11145860-3	2000	They recognize a glycolipid antigen (alpha -galactosylceramide) or parasitic glycophosphatidylinositols (GPI) in association with a monomorphic class Ib, CD1d, and perform various functions such as Th1 and Th2 cytokine production as well as perforin/granzyme B-mediated cytotoxicity.	glycophosphatidylinositols	77-103	CD1d molecule	Homo sapiens	154-158
11145860-3	2000	They recognize a glycolipid antigen (alpha -galactosylceramide) or parasitic glycophosphatidylinositols (GPI) in association with a monomorphic class Ib, CD1d, and perform various functions such as Th1 and Th2 cytokine production as well as perforin/granzyme B-mediated cytotoxicity.	GPI 1046	105-108	CD1d molecule	Homo sapiens	154-158
11257307-8	2000	To study if either one or both biochemical forms of CD1d contained hydroxyproline residues, amino acid composition analysis of the 37 and 48 kDa was performed, and demonstrated that only the 37-kDa, but not the 48-kDa form of CD1d, contained hydroxyproline residues.	Hydroxyproline	67-81	CD1d molecule	Homo sapiens	52-56
11257307-9	2000	These studies demonstrate that CD1d exhibits a prolonged association with P4H and that the 37-kDa form contains hydroxyproline residues.	Hydroxyproline	112-126	CD1d molecule	Homo sapiens	31-35
10974042-0	2000	CD1d-glycolipid tetramers: A new tool to monitor natural killer T cells in health and disease.	Glycolipids	5-15	CD1d molecule	Homo sapiens	0-4
10779745-1	2000	Human V alpha 24+ NKT cells with an invariant TCR (V alpha 24-J alpha Q) have been shown to be specifically activated by synthetic glycolipids such as alpha-galactosylceramide and alpha-glucosylceramide in a CD1d-restricted and V alpha 24 TCR-mediated manner.	alpha-galactosylceramide	151-175	CD1d molecule	Homo sapiens	208-212
10779745-1	2000	Human V alpha 24+ NKT cells with an invariant TCR (V alpha 24-J alpha Q) have been shown to be specifically activated by synthetic glycolipids such as alpha-galactosylceramide and alpha-glucosylceramide in a CD1d-restricted and V alpha 24 TCR-mediated manner.	alpha-glucosylceramide	180-202	CD1d molecule	Homo sapiens	208-212
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	Glycolipids	44-54	CD1d molecule	Homo sapiens	17-21
10822576-1	1999	[formula: see text] A representative alpha-galactosylceramide (alpha-GalCer), KRN7000, can activate NKT cells through CD1d molecules, which play an essential role in the generation of the strong antitumor activity of KRN7000.	alpha-galactosylceramide	37-61	CD1d molecule	Homo sapiens	118-122
10360961-1	1999	Murine NKT cells can recognize alpha-galactosylceramide (alpha-GalCer) in the context of a class Ib CD1d molecule.	alpha-galactosylceramide	31-55	CD1d molecule	Homo sapiens	100-113
10360961-1	1999	Murine NKT cells can recognize alpha-galactosylceramide (alpha-GalCer) in the context of a class Ib CD1d molecule.	alpha-galactosylceramide	57-69	CD1d molecule	Homo sapiens	100-113
10884613-2	2000	Group II CD1 or CD1d molecules are recognized by the specialized NK T-cell subset, and this reactivity can be greatly augmented by alpha-galactosylceramide, a glycosphingolipid derived from a marine sponge.	alpha-galactosylceramide	131-155	CD1d molecule	Homo sapiens	16-20
10884613-2	2000	Group II CD1 or CD1d molecules are recognized by the specialized NK T-cell subset, and this reactivity can be greatly augmented by alpha-galactosylceramide, a glycosphingolipid derived from a marine sponge.	Glycosphingolipids	159-176	CD1d molecule	Homo sapiens	16-20
10884613-3	2000	Human CD1b, which is only distantly related to the CD1d molecules, can present mammalian glycosphingolipids (gangliosides) to autoreactive T-cell clones derived from multiple sclerosis patients.	Glycosphingolipids	89-107	CD1d molecule	Homo sapiens	51-55
10884613-3	2000	Human CD1b, which is only distantly related to the CD1d molecules, can present mammalian glycosphingolipids (gangliosides) to autoreactive T-cell clones derived from multiple sclerosis patients.	Gangliosides	109-121	CD1d molecule	Homo sapiens	51-55
10760785-6	2000	Collectively our data suggest that CD1d-dependent NKT cells regulate innate immunity by sampling blood-borne glycolipid antigens and rapidly activating NK cells.	Glycolipids	109-119	CD1d molecule	Homo sapiens	35-39
10692041-1	2000	Human Valpha24 + NKT cells, a subpopulation of natural killer cell receptor (NKR-P1A) expressing T cells with an invariant T-cell receptor (TCR; Valpha24JalphaQ) are stimulated by the glycolipid, alpha-galactosylceramide (KRN7000), in a CD1d-dependent, TCR-mediated fashion.	Glycolipids	184-194	CD1d molecule	Homo sapiens	237-241
10631954-2	1999	All four of the known human CD1 proteins (CD1a, CD1b, CD1c and CD1d) as well as murine CD1d have now been shown to mediate T-cell recognition of lipid or glycolipid antigens.	Glycolipids	154-164	CD1d molecule	Homo sapiens	63-67
10631954-4	1999	The CD1b and CD1d-presented antigens differ in their fine structures but reveal a general motif in which a rigid hydrophilic cap is bound to two aliphatic hydrocarbon chains.	Hydrocarbons	155-166	CD1d molecule	Homo sapiens	13-17
10570177-5	1999	Although wild-type CD1d was readily activated (tyrosine phosphorylation), no demonstrable signal was evident in cell lines expressing the chimeric molecule.	Tyrosine	47-55	CD1d molecule	Homo sapiens	19-23
10570177-6	1999	Subsequent studies revealed that anti-CD1d crosslinking specifically induces epithelial IL-10 mRNA and protein and is blocked by the tyrosine kinase inhibitor genistein.	Genistein	159-168	CD1d molecule	Homo sapiens	38-42
10600006-8	1999	However, CD1d was the restriction element only for those clones with the conservative substitution of threonine or asparagine for serine at the V/J junction.	Threonine	102-111	CD1d molecule	Homo sapiens	9-13
10600006-8	1999	However, CD1d was the restriction element only for those clones with the conservative substitution of threonine or asparagine for serine at the V/J junction.	Asparagine	115-125	CD1d molecule	Homo sapiens	9-13
10600006-8	1999	However, CD1d was the restriction element only for those clones with the conservative substitution of threonine or asparagine for serine at the V/J junction.	Serine	130-136	CD1d molecule	Homo sapiens	9-13
10523605-0	1999	Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules.	Ceramides	36-44	CD1d molecule	Homo sapiens	95-99
10523605-0	1999	Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules.	Glycolipids	56-67	CD1d molecule	Homo sapiens	95-99
10523605-4	1999	The CD1d molecules can also bind both to the nonantigenic beta-GalCer and to phosphatidylethanolamine, indicating that diverse lipids can bind to CD1d.	beta-GalCer	58-69	CD1d molecule	Homo sapiens	4-8
10523605-4	1999	The CD1d molecules can also bind both to the nonantigenic beta-GalCer and to phosphatidylethanolamine, indicating that diverse lipids can bind to CD1d.	beta-GalCer	58-69	CD1d molecule	Homo sapiens	146-150
10523605-4	1999	The CD1d molecules can also bind both to the nonantigenic beta-GalCer and to phosphatidylethanolamine, indicating that diverse lipids can bind to CD1d.	phosphatidylethanolamine	77-101	CD1d molecule	Homo sapiens	4-8
10523605-4	1999	The CD1d molecules can also bind both to the nonantigenic beta-GalCer and to phosphatidylethanolamine, indicating that diverse lipids can bind to CD1d.	phosphatidylethanolamine	77-101	CD1d molecule	Homo sapiens	146-150
10487527-10	1999	In Scatchard analyses, the isothiocyanate derivatives R-3, R-4, and R-6 showed significant and progressive reduction in Bmax at increasing concentrations.	isothiocyanic acid	27-41	CD1d molecule	Homo sapiens	54-57
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	Glycolipids	44-54	CD1d molecule	Homo sapiens	115-119
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	alpha-galactosylceramide	72-96	CD1d molecule	Homo sapiens	17-21
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	alpha-galactosylceramide	72-96	CD1d molecule	Homo sapiens	115-119
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	alpha-galactosylceramide	98-110	CD1d molecule	Homo sapiens	17-21
10450506-3	1999	Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells.	alpha-galactosylceramide	98-110	CD1d molecule	Homo sapiens	115-119
10233754-6	1999	In this study we examined the expression of CD1D in human trophoblast cell lines and placentally derived trophoblast cells by reverse transcriptase-polymerase chain reaction using CD1D-specific oligonucleotide primers.	Oligonucleotides	194-209	CD1d molecule	Homo sapiens	44-48
11674335-3	1999	Benzoate was introduced as a protecting group at the 1,3-O-disubstituent stage and was removed under basic conditions after the incorporation of the third alkyl group (R(3)) with R(3)X and NaH.	Benzoates	0-8	CD1d molecule	Homo sapiens	168-172
11674335-3	1999	Benzoate was introduced as a protecting group at the 1,3-O-disubstituent stage and was removed under basic conditions after the incorporation of the third alkyl group (R(3)) with R(3)X and NaH.	sodium bisulfide	189-192	CD1d molecule	Homo sapiens	168-172
10233754-6	1999	In this study we examined the expression of CD1D in human trophoblast cell lines and placentally derived trophoblast cells by reverse transcriptase-polymerase chain reaction using CD1D-specific oligonucleotide primers.	Oligonucleotides	194-209	CD1d molecule	Homo sapiens	180-184
9880256-0	1999	CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells.	Glycosylphosphatidylinositols	46-49	CD1d molecule	Homo sapiens	0-4
9880256-2	1999	Immunoglobulin G responses to glycosylphosphatidylinositol (GPI)- anchored protein antigens, however, were found to be regulated in part through CD1d-restricted recognition of the GPI moiety by thymus-dependent, interleukin-4-producing CD4(+), natural killer cell antigen 1.1 [(NK1.1)+] helper T cells.	Glycosylphosphatidylinositols	30-58	CD1d molecule	Homo sapiens	145-149
9880256-2	1999	Immunoglobulin G responses to glycosylphosphatidylinositol (GPI)- anchored protein antigens, however, were found to be regulated in part through CD1d-restricted recognition of the GPI moiety by thymus-dependent, interleukin-4-producing CD4(+), natural killer cell antigen 1.1 [(NK1.1)+] helper T cells.	Glycosylphosphatidylinositols	60-63	CD1d molecule	Homo sapiens	145-149
9880256-2	1999	Immunoglobulin G responses to glycosylphosphatidylinositol (GPI)- anchored protein antigens, however, were found to be regulated in part through CD1d-restricted recognition of the GPI moiety by thymus-dependent, interleukin-4-producing CD4(+), natural killer cell antigen 1.1 [(NK1.1)+] helper T cells.	Glycosylphosphatidylinositols	180-183	CD1d molecule	Homo sapiens	145-149
9874567-8	1999	Antigen presentation to the Valpha14(+) NK1.1(+) cells requires endosomal targeting of CD1d through a tail-encoded tyrosine-based motif, whereas antigen presentation to the Valpha14(-) NK1.1(-) cells does not.	Tyrosine	115-123	CD1d molecule	Homo sapiens	87-91
9782130-4	1998	Responses of human NK T cells to these synthetic glycolipids, consisting of certain alpha-anomeric sugars conjugated to an acylated phytosphingosine base, required presentation by antigen-presenting cells expressing the major histocompatibility complex class I-like CD1d protein.	Glycolipids	49-60	CD1d molecule	Homo sapiens	266-270
9782129-0	1998	CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution.	alpha-galactosylceramide	32-56	CD1d molecule	Homo sapiens	0-4
9952023-0	1999	Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner.	alpha-glycosylceramide	41-63	CD1d molecule	Homo sapiens	69-73
9952023-6	1999	The Valpha24NKT cells were CD3+ CD4-CD8-Valpha24+Vbeta11+NKRP1A+ and specifically proliferated in response to alpha-glycosylceramide in CD1d-restricted and Valpha24TCR-mediated manner.	alpha-glycosylceramide	110-132	CD1d molecule	Homo sapiens	136-140
9576945-4	1998	Indeed, the cytotoxic index obtained by alpha-GalCer-activated Valpha14 NKT cells was reduced by the addition of cold target tumor cells or by treatment with concanamycin A, which inhibits activation and secretion of perforin, but not by mAbs against molecules involved in the NKT cell recognition and conventional cytotoxicity, such as CD1d, Vbeta8, NK1.	concanamycin A	158-172	CD1d molecule	Homo sapiens	337-341
15045406-1	1996	Nitrate radical (NO(3)) reactions with benzene (R-1), toluene (R-2), p-xylene (R-3), p-cresol (R-4) and mesitylene (R-5) have been studied by laser photolysis/long path laser absorption (LP-LPLA) in aqueous solution.	nitrate radical	0-15	CD1d molecule	Homo sapiens	69-82
9374463-0	1997	CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.	glycosylceramides	69-86	CD1d molecule	Homo sapiens	0-4
9374463-3	1997	Glycosylceramide-mediated proliferative responses of Valpha14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1d/Vbeta8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein.	Soyacerebroside I	0-16	CD1d molecule	Homo sapiens	168-172
34953481-3	2021	Invariant Natural Killer T (iNKT) cells are a subpopulation of T lymphocytes, activated by recognition of glycolipid ligands such as alpha-Galactosylceramide presented by CD1d, produce and secrete several cytokines, including IFN-gamma and IL-4.	alpha-galactosylceramide	133-157	CD1d molecule	Homo sapiens	171-175
1534272-9	1992	An RA-resistant clone, designated HL-60/R3, constitutively expressed larger amounts of alpha-actinin, vinculin, lipocortin I, and lipocortin II than parental HL-60 cells.	Tretinoin	3-5	CD1d molecule	Homo sapiens	34-42
1534272-10	1992	Treatment of HL-60/R3 with RA resulted in decreases in the amounts of these actin-binding proteins.	Tretinoin	27-29	CD1d molecule	Homo sapiens	13-21
34953481-3	2021	Invariant Natural Killer T (iNKT) cells are a subpopulation of T lymphocytes, activated by recognition of glycolipid ligands such as alpha-Galactosylceramide presented by CD1d, produce and secrete several cytokines, including IFN-gamma and IL-4.	Glycolipids	106-116	CD1d molecule	Homo sapiens	171-175
34936686-10	2021	IL-15 enhanced CD69, CD1d and CD11a expression on alpha-Galcer treated iNKT cells; 7.	alpha-galactosylceramide	50-62	CD1d molecule	Homo sapiens	21-25
34706265-3	2021	The most common stimulant is the glycolipid alpha-Galactosyl Ceramide (alpha-GalCer), which stimulates iNKT cells when presented by CD1d, an MHC class I-like molecule expressed by antigen-presenting cells (APC).	Glycolipids	33-43	CD1d molecule	Homo sapiens	132-136
34706265-3	2021	The most common stimulant is the glycolipid alpha-Galactosyl Ceramide (alpha-GalCer), which stimulates iNKT cells when presented by CD1d, an MHC class I-like molecule expressed by antigen-presenting cells (APC).	alpha-galactosylceramide	44-69	CD1d molecule	Homo sapiens	132-136
34706265-3	2021	The most common stimulant is the glycolipid alpha-Galactosyl Ceramide (alpha-GalCer), which stimulates iNKT cells when presented by CD1d, an MHC class I-like molecule expressed by antigen-presenting cells (APC).	alpha-galactosylceramide	71-83	CD1d molecule	Homo sapiens	132-136
34706265-4	2021	Another stimulant used is alpha-GalCer-loaded DimerX, a CD1d-Ig fusion protein which stimulates iNKT cells in an APC-independent fashion.	alpha-galactosylceramide	26-38	CD1d molecule	Homo sapiens	56-60
34706265-5	2021	Here, we demonstrate use of the PBS-57-loaded CD1d-tetramer as an APC-independent stimulant, where PBS-57 is an alpha-GalCer analogue.	Lead	32-35	CD1d molecule	Homo sapiens	46-50
34706265-5	2021	Here, we demonstrate use of the PBS-57-loaded CD1d-tetramer as an APC-independent stimulant, where PBS-57 is an alpha-GalCer analogue.	Lead	99-102	CD1d molecule	Homo sapiens	46-50
34706265-11	2021	SIGNIFICANCE: This study supports PBS-57-loaded CD1d-tetramer as an effective in vitro APC-independent iNKT cell stimulant, which is comparable to or even more effective than alpha-GalCer and DimerX.	Lead	34-37	CD1d molecule	Homo sapiens	48-52
33193386-1	2020	Murine and human invariant natural killer T (iNKT) lymphocytes are activated by alpha-galactosylceramide (alpha-GalCer) presented on CD1d.	alpha-galactosylceramide	80-104	CD1d molecule	Homo sapiens	133-137
34417291-0	2021	Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.	benzofuran sulfonates	0-21	CD1d molecule	Homo sapiens	83-87
34417291-8	2021	By trapping a CD1d-type II NKT TCR complex for direct mass-spectrometric analysis, we detected molecules that allow the binding of CD1d to TCRs, finding that both selected PBF family members and short-chain sphingomyelin lipids are present in these complexes.	sphingomyelin lipids	207-227	CD1d molecule	Homo sapiens	14-18
34417291-8	2021	By trapping a CD1d-type II NKT TCR complex for direct mass-spectrometric analysis, we detected molecules that allow the binding of CD1d to TCRs, finding that both selected PBF family members and short-chain sphingomyelin lipids are present in these complexes.	sphingomyelin lipids	207-227	CD1d molecule	Homo sapiens	131-135
34417291-9	2021	Furthermore, the combination of PPBF and short-chain sphingomyelin enhances CD1d tetramer staining of PPBF-reactive T cell lines over either molecule alone.	Sphingomyelins	53-66	CD1d molecule	Homo sapiens	76-80
34417291-10	2021	This study demonstrates that nonlipidic small molecules, which resemble sulfa drugs implicated in systemic hypersensitivity and drug allergy reactions, are targeted by a polyclonal population of type II NKT cells in a CD1d-restricted manner.	sulfa	72-77	CD1d molecule	Homo sapiens	218-222
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	characellide a	48-62	CD1d molecule	Homo sapiens	76-80
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	characellide a	48-62	CD1d molecule	Homo sapiens	101-105
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	1,2-bis(diphenylphosphino)ethane (dppe)-polyethylene glycolmonomethylether	118-192	CD1d molecule	Homo sapiens	76-80
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	1,2-bis(diphenylphosphino)ethane (dppe)-polyethylene glycolmonomethylether	118-192	CD1d molecule	Homo sapiens	101-105
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	monomethoxypolyethylene glycol	194-197	CD1d molecule	Homo sapiens	76-80
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	monomethoxypolyethylene glycol	194-197	CD1d molecule	Homo sapiens	101-105
34241784-6	2021	Moreover, cytokine/chemokine release induced by characellide A from PBMC is CD1d-dependent because a CD1d antagonist, 1,2-bis(diphenylphosphino)ethane (DPPE)-polyethylene glycolmonomethylether (PEG), specifically inhibits characellide A-induced activation of PBMC.	characellide a	222-236	CD1d molecule	Homo sapiens	101-105
34172580-3	2021	Here, we show that the human DP10.7 gammadeltaTCR specific for the sulfoglycolipid sulfatide bound to CD1d only sustains a significant load and undergoes force-induced structural transitions when the binding interface-distal gammadelta constant domain (C) module is replaced with that of alphabeta.	sulfoglycolipid sulfatide	67-92	CD1d molecule	Homo sapiens	102-106
35063813-2	2022	Invariant natural killer T (iNKT) cells are a kind of special T lymphocytes characterized by expressing invariant TCR of Valpha24Vbeta11 to recognize CD1d-presented glycolipid antigens, which bridge innate and adaptive immune responses.	Glycolipids	165-175	CD1d molecule	Homo sapiens	150-154
33483371-1	2021	CD1d-restricted invariant natural killer T cells (iNKT cells) mediate strong anti-tumor immunity when stimulated by glycolipid agonists.	Glycolipids	116-126	CD1d molecule	Homo sapiens	0-4
33361143-7	2021	Several molecules with the capacity to bind to CD1d have been discovered, including alpha-galactosylceramide.	alpha-galactosylceramide	84-108	CD1d molecule	Homo sapiens	47-51
34524657-5	2021	NKT cells are divided into Type I (or invariant) and Type II, with either limited or broad TCR repertoires, respectively, that generally respond to glycolipids presented on the nonclassical MHC, CD1d.	Glycolipids	148-159	CD1d molecule	Homo sapiens	195-199
34524668-2	2021	They recognize lipid antigens presented by CD1d molecules and can be specifically activated by alpha-galactosylceramide (alpha-GalCer) in vitro.	alpha-galactosylceramide	95-119	CD1d molecule	Homo sapiens	43-47
34524668-2	2021	They recognize lipid antigens presented by CD1d molecules and can be specifically activated by alpha-galactosylceramide (alpha-GalCer) in vitro.	alpha-galactosylceramide	121-133	CD1d molecule	Homo sapiens	43-47
34524672-4	2021	Importantly, recombinant CD1d fusion proteins loaded with alpha-GalCer demonstrated sustained activation of iNKT cells upon repeated injections and superior tumor control, as compared to alpha-GalCer treatment.	alpha-galactosylceramide	58-70	CD1d molecule	Homo sapiens	25-29
33942544-2	2021	alpha-Galactosylceramide (alpha-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	162-166
33942544-2	2021	alpha-Galactosylceramide (alpha-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner.	alpha-galactosylceramide	26-34	CD1d molecule	Homo sapiens	162-166
33942544-2	2021	alpha-Galactosylceramide (alpha-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner.	Glycolipids	51-61	CD1d molecule	Homo sapiens	162-166
33128583-6	2021	Glioblastoma cells from 10 of 15 patients expressed CD1d, and CD1d-positive glioblastoma cells pulsed with glycolipid ligand induced iNKT cell-mediated cytotoxicity in vitro.	Glycolipids	107-117	CD1d molecule	Homo sapiens	62-66
33128583-7	2021	Although CD1d expression was low on glioblastoma stem-like cells, retinoic acid, which is the most common differentiating agent, upregulated CD1d expression in these cells and induced iNKT cell-mediated cytotoxicity.	Tretinoin	66-79	CD1d molecule	Homo sapiens	141-145
33451981-7	2021	The expression of CD1d on CLL cells is upregulated by all-trans retinoic acid, and sensitizes the malignant cells to bispecific VHH-induced lysis.	Tretinoin	64-77	CD1d molecule	Homo sapiens	18-22
33499253-6	2021	Interestingly, when stimulated only via CD1d+ dendritic cells (DCs) loaded with alpha-galactosylceramide (alpha-GalCer), both CD38- and BCMA-CAR iNKT cells expanded well, without losing their CAR- or TCR-dependent cytotoxic activities.	alpha-galactosylceramide	80-104	CD1d molecule	Homo sapiens	40-44
33499253-6	2021	Interestingly, when stimulated only via CD1d+ dendritic cells (DCs) loaded with alpha-galactosylceramide (alpha-GalCer), both CD38- and BCMA-CAR iNKT cells expanded well, without losing their CAR- or TCR-dependent cytotoxic activities.	alpha-galactosylceramide	106-118	CD1d molecule	Homo sapiens	40-44
32463330-2	2020	Natural killer T (NKT) cells are unconventional T lymphocytes, and their TCRs recognize glycolipids bound to the MHC-I-like molecule, CD1d.	Glycolipids	88-99	CD1d molecule	Homo sapiens	134-138
33193386-1	2020	Murine and human invariant natural killer T (iNKT) lymphocytes are activated by alpha-galactosylceramide (alpha-GalCer) presented on CD1d.	alpha-galactosylceramide	106-118	CD1d molecule	Homo sapiens	133-137
32324315-2	2020	iNKT cells specifically recognize glycolipid antigens such as a-galactosylceramide (aGalCer) presented by CD1d.	Glycolipids	34-44	CD1d molecule	Homo sapiens	106-110
32324315-2	2020	iNKT cells specifically recognize glycolipid antigens such as a-galactosylceramide (aGalCer) presented by CD1d.	a-galactosylceramide	62-82	CD1d molecule	Homo sapiens	106-110
32324315-3	2020	iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens.	glycolipid antigens	100-119	CD1d molecule	Homo sapiens	43-47
32324315-3	2020	iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens.	glycolipid antigens	100-119	CD1d molecule	Homo sapiens	86-90
32560408-3	2020	iNKT cell activation commonly requires engagement of the invariant T cell receptor (iTCR) by CD1d presenting glycolipid antigens.	glycolipid antigens	109-128	CD1d molecule	Homo sapiens	93-97
32714765-8	2020	Together, the data demonstrate a new mechanism through which alpha-GalCer-diol induces stronger Th1-type responses by stimulating CD11b+ leukocyte expansion and DC-conducted CD1d-restricted and TCR-mediated iNKT activation.	alpha-galcer-diol	61-78	CD1d molecule	Homo sapiens	174-178
32714765-0	2020	A Designed alpha-GalCer Analog Promotes Considerable Th1 Cytokine Response by Activating the CD1d-iNKT Axis and CD11b-Positive Monocytes/Macrophages.	alpha-galactosylceramide	11-23	CD1d molecule	Homo sapiens	93-97
31982233-1	2020	alpha-Galactosylceramide (alpha-GalCer) is recognized by the CD1d proteins on antigen-presenting cells at the ceramide moiety and the galactose moiety is presented to iNKT cells, which stimulates the immune responses.	Ceramides	16-24	CD1d molecule	Homo sapiens	61-65
32714765-4	2020	Structural analyses reveal stronger affinity between alpha-GalCer-diol and cluster of differentiation 1d (CD1d), leading to enhanced antigen presentation by dendritic cells (DCs) and self-activation, as reflected by tight binding of the T-cell receptor (TCR)/KRN7000/CD1d ternary complex and elevated production of interleukin 12 (IL-12) and interferon-gamma (IFN-gamma).	alpha-galcer-diol	53-70	CD1d molecule	Homo sapiens	75-104
32714765-4	2020	Structural analyses reveal stronger affinity between alpha-GalCer-diol and cluster of differentiation 1d (CD1d), leading to enhanced antigen presentation by dendritic cells (DCs) and self-activation, as reflected by tight binding of the T-cell receptor (TCR)/KRN7000/CD1d ternary complex and elevated production of interleukin 12 (IL-12) and interferon-gamma (IFN-gamma).	alpha-galcer-diol	53-70	CD1d molecule	Homo sapiens	106-110
32714765-4	2020	Structural analyses reveal stronger affinity between alpha-GalCer-diol and cluster of differentiation 1d (CD1d), leading to enhanced antigen presentation by dendritic cells (DCs) and self-activation, as reflected by tight binding of the T-cell receptor (TCR)/KRN7000/CD1d ternary complex and elevated production of interleukin 12 (IL-12) and interferon-gamma (IFN-gamma).	alpha-galcer-diol	53-70	CD1d molecule	Homo sapiens	267-271
32512511-0	2020	Low oxygen saturation during sleep reduces CD1D and RAB20 expressions that are reversed by CPAP therapy.	Oxygen	4-10	CD1d molecule	Homo sapiens	43-47
32244759-7	2020	We also found lipid- and pH-dependent dynamic changes in three exposed tryptophans unique to CD1d among the five human CD1 isotypes.	Tryptophan	71-82	CD1d molecule	Homo sapiens	93-97
32078695-7	2020	Cisplatin caused a significant reduction of CD1d expression by esophageal tumor cell lines.	Cisplatin	0-9	CD1d molecule	Homo sapiens	44-48
32078695-8	2020	Cisplatin, 5-fluorouracil and carboplatin induced dose-dependent apoptosis in primary lines of iNKT cells and inhibited CD1d-dependent interferon-gamma production and cytolytic degranulation by viable iNKT cells.	Cisplatin	0-9	CD1d molecule	Homo sapiens	120-124
32078695-8	2020	Cisplatin, 5-fluorouracil and carboplatin induced dose-dependent apoptosis in primary lines of iNKT cells and inhibited CD1d-dependent interferon-gamma production and cytolytic degranulation by viable iNKT cells.	Fluorouracil	11-25	CD1d molecule	Homo sapiens	120-124
32078695-8	2020	Cisplatin, 5-fluorouracil and carboplatin induced dose-dependent apoptosis in primary lines of iNKT cells and inhibited CD1d-dependent interferon-gamma production and cytolytic degranulation by viable iNKT cells.	Carboplatin	30-41	CD1d molecule	Homo sapiens	120-124
31190065-5	2020	METHODS: In a cross-sectional study of 101 HIV-infected and -uninfected South African patients with active TB and controls, iNKT cells were enumerated using alpha-galactosylceramide-loaded CD1d tetramers and subsequently functionally characterised by flow cytometry.	alpha-galactosylceramide	157-181	CD1d molecule	Homo sapiens	189-193
31935280-1	2020	Human invariant natural killer T (iNKT) cells are a rare innate-like lymphocyte population that recognizes glycolipids presented on CD1d.	Glycolipids	107-118	CD1d molecule	Homo sapiens	132-136
31982233-0	2020	Photo effect on the CD1d-binding ability of azobenzene-attached analogues of alpha-GalCer.	azobenzene	44-54	CD1d molecule	Homo sapiens	20-24
31982233-1	2020	alpha-Galactosylceramide (alpha-GalCer) is recognized by the CD1d proteins on antigen-presenting cells at the ceramide moiety and the galactose moiety is presented to iNKT cells, which stimulates the immune responses.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	61-65
31982233-3	2020	To overcome the shortcoming by spatiotemporal restriction of its exposure, we synthesized the photochromic azobenzene-incorporated analogues and tested the photo-immunoregulation effect in its binding to CD1d.	azobenzene	107-117	CD1d molecule	Homo sapiens	204-208
31544285-1	2020	alpha-Galactosylceramide (alpha-GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	82-86
31939653-2	2020	An alpha-galactosyl ceramide (alpha-GalCer, KRN7000) is the representative CD1d ligand that can bind to the CD1d protein.	Galactosylceramides	3-28	CD1d molecule	Homo sapiens	75-79
31939653-2	2020	An alpha-galactosyl ceramide (alpha-GalCer, KRN7000) is the representative CD1d ligand that can bind to the CD1d protein.	Galactosylceramides	3-28	CD1d molecule	Homo sapiens	108-112
31939653-5	2020	We focused on the Cys residue of the large hydrophobic pockets of CD1d (A" pocket) and developed alpha-GalCer derivatives containing groups that can form covalent bonds.	cysteinylcysteine	18-21	CD1d molecule	Homo sapiens	66-70
31939653-7	2020	Furthermore, the LC-MS/MS analysis indicated that the chloroacetylamide-containing ligand was covalently bound to Cys12 of CD1d, which suggests that the enhanced activities result from the formation of a stable CD1d-ligand complex.	chloroacetylamide	54-71	CD1d molecule	Homo sapiens	123-127
31939653-7	2020	Furthermore, the LC-MS/MS analysis indicated that the chloroacetylamide-containing ligand was covalently bound to Cys12 of CD1d, which suggests that the enhanced activities result from the formation of a stable CD1d-ligand complex.	chloroacetylamide	54-71	CD1d molecule	Homo sapiens	211-215
31939653-7	2020	Furthermore, the LC-MS/MS analysis indicated that the chloroacetylamide-containing ligand was covalently bound to Cys12 of CD1d, which suggests that the enhanced activities result from the formation of a stable CD1d-ligand complex.	cysteinylcysteine	114-117	CD1d molecule	Homo sapiens	123-127
31939653-7	2020	Furthermore, the LC-MS/MS analysis indicated that the chloroacetylamide-containing ligand was covalently bound to Cys12 of CD1d, which suggests that the enhanced activities result from the formation of a stable CD1d-ligand complex.	cysteinylcysteine	114-117	CD1d molecule	Homo sapiens	211-215
31544285-1	2020	alpha-Galactosylceramide (alpha-GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells.	alpha-galactosylceramide	26-38	CD1d molecule	Homo sapiens	82-86
31544285-1	2020	alpha-Galactosylceramide (alpha-GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells.	KRN 7000	40-47	CD1d molecule	Homo sapiens	82-86
31738132-6	2020	RESULTS: Interestingly, our findings revealed that AH10-7 exhibited higher affinity binding and structural effects on hTCR-CD1d, as mediated by the incorporated hydrocinnamoyl ester moiety which accounted for stronger intermolecular interactions with "non-common" binding site residues.	hydrocinnamoyl-1-valyl pyrrolidine	161-181	CD1d molecule	Homo sapiens	123-127
31619536-4	2019	In particular, farnesol increases the expression of the Ag-presenting glycoprotein CD1d through the nuclear receptors PPARgamma and RARalpha, as well as p38 MAPK.	Farnesol	15-23	CD1d molecule	Homo sapiens	83-87
32238625-5	2020	This review describes three topics for developing functional compounds derived from natural products for prospective involvement in pharmaceutical research: 1) direct construction of the ergot alkaloid scaffold by palladium catalyzed domino cyclization of amino allenes; 2) identification of novel sphingosine kinase inhibitors through a structure-activity relationship study of jaspine B; and 3) design, synthesis and biological evaluation of novel CD1d glycolipid ligands containing modified lipid moieties.	Ergot Alkaloids	187-201	CD1d molecule	Homo sapiens	450-454
32238625-5	2020	This review describes three topics for developing functional compounds derived from natural products for prospective involvement in pharmaceutical research: 1) direct construction of the ergot alkaloid scaffold by palladium catalyzed domino cyclization of amino allenes; 2) identification of novel sphingosine kinase inhibitors through a structure-activity relationship study of jaspine B; and 3) design, synthesis and biological evaluation of novel CD1d glycolipid ligands containing modified lipid moieties.	Palladium	214-223	CD1d molecule	Homo sapiens	450-454
31636468-0	2019	Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin.	Sphingomyelins	68-81	CD1d molecule	Homo sapiens	11-15
31636468-2	2019	CD1d can also bind non-activating lipids, such as sphingomyelin.	Sphingomyelins	50-63	CD1d molecule	Homo sapiens	0-4
31636468-7	2019	Together, these results demonstrate that control of non-agonistic CD1d-associated lipids is critical for iNKT cell development and function in vivo and represents a tight link between cellular sphingolipid metabolism and immunity.	Sphingolipids	193-205	CD1d molecule	Homo sapiens	66-70
31748533-3	2019	Here we describe a population of type II NKT cells that recognise and respond to the microbial antigen, alpha-glucuronosyl-diacylglycerol (alpha-GlcADAG) presented by CD1d, but not the prototypical type I NKT cell agonist, alpha-galactosylceramide.	glucuronosyl diacylglycerol	104-137	CD1d molecule	Homo sapiens	167-171
31748533-3	2019	Here we describe a population of type II NKT cells that recognise and respond to the microbial antigen, alpha-glucuronosyl-diacylglycerol (alpha-GlcADAG) presented by CD1d, but not the prototypical type I NKT cell agonist, alpha-galactosylceramide.	alpha-galactosylceramide	223-247	CD1d molecule	Homo sapiens	167-171
31748533-4	2019	Surprisingly, the crystal structure of a type II NKT TCR-CD1d-alpha-GlcADAG complex reveals a CD1d F"-pocket-docking mode that contrasts sharply with the previously determined A"-roof positioning of a sulfatide-reactive type II NKT TCR.	Sulfoglycosphingolipids	201-210	CD1d molecule	Homo sapiens	57-61
31667358-6	2019	Of the four saposin proteins, the importance of Saposin B (SapB) for loading of CD1d is the most well-characterised.	Saposins	48-57	CD1d molecule	Homo sapiens	80-84
31667358-6	2019	Of the four saposin proteins, the importance of Saposin B (SapB) for loading of CD1d is the most well-characterised.	Saposins	59-63	CD1d molecule	Homo sapiens	80-84
31667358-7	2019	However, a direct interaction between CD1d and SapB has yet to be described.	Saposins	47-51	CD1d molecule	Homo sapiens	38-42
31667358-8	2019	Methods: In order to determine how SapB might load lipids onto CD1d, we used purified, recombinant CD1d and SapB and carried out a series of highly sensitive binding assays to monitor direct interactions.	Saposins	35-39	CD1d molecule	Homo sapiens	63-67
31185411-3	2019	Following our previous work related to the modification of the hydrogen bond network between alpha-GalCer and CD1d, we have now focused our attention on the synthesis of 3-deoxy-3,3-difluoro- and 3,4-dideoxy-3,3,4,4-tetrafluoro-alpha-GalCer analogues, and studied their ability to stimulate human iNKT cells.	Hydrogen	63-71	CD1d molecule	Homo sapiens	110-114
31615552-5	2019	Their proliferative capacity and cytokine production were investigated following activation with CD1d ligand alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	109-133	CD1d molecule	Homo sapiens	97-101
31649670-0	2019	Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d.	alpha-galactosylceramide	80-104	CD1d molecule	Homo sapiens	105-109
31649670-0	2019	Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d.	alpha-galactosylceramide	80-104	CD1d molecule	Homo sapiens	169-173
31649670-0	2019	Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d.	5alpha-pregnane-3beta,11beta,20beta,21-tetrol	131-152	CD1d molecule	Homo sapiens	105-109
31649670-0	2019	Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d.	5alpha-pregnane-3beta,11beta,20beta,21-tetrol	131-152	CD1d molecule	Homo sapiens	169-173
31649670-8	2019	Detection with anti-CD1d-alpha-GalCer mAbs indicates that the interface of the beta-ManCer-CD1d complex exposed to the iNKT cell TCR can assume a structure like that of CD1d-alpha-GalCer, despite its disparate carbohydrate structure.	Carbohydrates	210-222	CD1d molecule	Homo sapiens	20-24
31649670-8	2019	Detection with anti-CD1d-alpha-GalCer mAbs indicates that the interface of the beta-ManCer-CD1d complex exposed to the iNKT cell TCR can assume a structure like that of CD1d-alpha-GalCer, despite its disparate carbohydrate structure.	Carbohydrates	210-222	CD1d molecule	Homo sapiens	91-95
31649670-8	2019	Detection with anti-CD1d-alpha-GalCer mAbs indicates that the interface of the beta-ManCer-CD1d complex exposed to the iNKT cell TCR can assume a structure like that of CD1d-alpha-GalCer, despite its disparate carbohydrate structure.	Carbohydrates	210-222	CD1d molecule	Homo sapiens	91-95
31185411-3	2019	Following our previous work related to the modification of the hydrogen bond network between alpha-GalCer and CD1d, we have now focused our attention on the synthesis of 3-deoxy-3,3-difluoro- and 3,4-dideoxy-3,3,4,4-tetrafluoro-alpha-GalCer analogues, and studied their ability to stimulate human iNKT cells.	3-deoxy-3,3-difluoro-	170-191	CD1d molecule	Homo sapiens	110-114
31185411-3	2019	Following our previous work related to the modification of the hydrogen bond network between alpha-GalCer and CD1d, we have now focused our attention on the synthesis of 3-deoxy-3,3-difluoro- and 3,4-dideoxy-3,3,4,4-tetrafluoro-alpha-GalCer analogues, and studied their ability to stimulate human iNKT cells.	3,4-dideoxy-3,3,4,4-tetrafluoro-alpha-galcer	196-240	CD1d molecule	Homo sapiens	110-114
30864713-2	2019	CD1d is considered to present phospholipid and glycosphingolipid antigens to NKT cells.	Phospholipids	30-42	CD1d molecule	Homo sapiens	0-4
31316500-8	2019	Analogous to human iNKT cells, in vitro stimulation of porcine leukocytes with the CD1d ligand alpha-galactosylceramide resulted in rapid iNKT cell proliferation, evidenced by an increase in frequency and Ki-67 expression.	alpha-galactosylceramide	95-119	CD1d molecule	Homo sapiens	83-87
30900367-3	2019	PNH clones likely arise as immune escape mechanisms in aAA by preventing CD1D-restricted T-cell recognition of GPI anchors and GPI-linked autoantigens.	Glycosylphosphatidylinositols	111-114	CD1d molecule	Homo sapiens	73-77
30900367-3	2019	PNH clones likely arise as immune escape mechanisms in aAA by preventing CD1D-restricted T-cell recognition of GPI anchors and GPI-linked autoantigens.	Glycosylphosphatidylinositols	127-130	CD1d molecule	Homo sapiens	73-77
31141185-3	2019	Type I NKT cells, most extensively studied, are identified by a semi-invariant Valpha14-Jalpha18 (mouse, Valpha24-Jalpha18 in humans) TCR reactive to the prototypic ligand alpha-galactosylceramide presented on CD1d.	alpha-galactosylceramide	172-196	CD1d molecule	Homo sapiens	210-214
31296659-1	2019	Natural killer T (NKT) cells are a subset of T lymphocytes that recognize glycolipid antigens presented by the CD1d molecule (CD1d).	Glycolipids	74-84	CD1d molecule	Homo sapiens	111-124
31296659-1	2019	Natural killer T (NKT) cells are a subset of T lymphocytes that recognize glycolipid antigens presented by the CD1d molecule (CD1d).	Glycolipids	74-84	CD1d molecule	Homo sapiens	111-115
30817180-8	2019	Duodenal tissues from patients with alcohol-use disorder have been found to have increased levels of CD1d compared with tissues from patients without alcohol overuse.	Alcohols	36-43	CD1d molecule	Homo sapiens	101-105
30817180-13	2019	Patients with alcohol use disorder have increased expression of CD1d in the small intestine.	Alcohols	14-21	CD1d molecule	Homo sapiens	64-68
30864713-2	2019	CD1d is considered to present phospholipid and glycosphingolipid antigens to NKT cells.	Glycosphingolipids	47-64	CD1d molecule	Homo sapiens	0-4
30858151-6	2019	Once loaded with the iNKT cell lipid agonist alpha-galactosyl ceramide (alphaGC), the CD1d-CD19 fusion induces robust in vitro activation of and cytokine production by human iNKT cells.	alpha-galactosylceramide	45-70	CD1d molecule	Homo sapiens	86-90
31097998-0	2019	Development of alpha-GalCer Analogues with an alpha-Fluorocarbonyl Moiety as Th2-Selective Ligands of CD1d.	th2	77-80	CD1d molecule	Homo sapiens	102-106
31097998-3	2019	The biased activity of ligands could be caused by the hydrogen-bonding interaction between ligands and CD1d according to the Th2-selective cytokine secretion and molecular docking studies.	Hydrogen	54-62	CD1d molecule	Homo sapiens	103-107
31097989-2	2019	To selectively induce the secretion of certain cytokines via introducing hydrogen-bonding interaction with polar amino acid residues in the binding pocket of CD1d, a series of alpha-GalCer analogues with diether moiety in the acyl chain were designed and synthesized.	Hydrogen	73-81	CD1d molecule	Homo sapiens	158-162
30824201-1	2019	CD1d is a non-polymorphic antigen-presenting glycoprotein that recognizes glycolipids as ligands.	Glycolipids	74-85	CD1d molecule	Homo sapiens	0-4
30824201-5	2019	The assays reveal that the Bz amide-containing CD1d ligands function as NKT cell modulators displaying Th2 cytokine biasing responses.	bz amide	27-35	CD1d molecule	Homo sapiens	47-51
30824201-6	2019	Furthermore, molecular dynamics simulation studies suggest that the phenyl groups can interact with the aromatic amino acid residues in the lipid binding pocket of CD1d.	Amino Acids, Aromatic	104-123	CD1d molecule	Homo sapiens	164-168
30822302-7	2019	Thus, both synthetic GM3 and GD3 comprising a d18:1-C24:1 ceramide backbone were able to activate iNKT cells in a CD1d-dependent manner.	Ceramides	58-66	CD1d molecule	Homo sapiens	114-118
30711929-3	2019	The aim of this study was to examine the tumoricidal effect of a CD1d-binding glycolipid, called 7DW8-5, against a highly invasive human breast cancer cell line both in vitro and in vivo.	Glycolipids	78-88	CD1d molecule	Homo sapiens	65-69
30711929-3	2019	The aim of this study was to examine the tumoricidal effect of a CD1d-binding glycolipid, called 7DW8-5, against a highly invasive human breast cancer cell line both in vitro and in vivo.	11-(4-Fluorophenyl)-N-[(2s,3s,4r)-1-(Alpha-D-Galactopyranosyloxy)-3,4-Dihydroxyoctadecan-2-Yl]undecanamide	97-103	CD1d molecule	Homo sapiens	65-69
30783507-2	2019	In this Letter, we designed and synthesized a novel series of CD1d ligand alpha-galactosylceramides (alpha-GalCers) in which the acyl chain backbone of the lipid was incorporated with fluorine atoms.	alpha-galactosylceramide	74-99	CD1d molecule	Homo sapiens	62-66
30549010-1	2019	Invariant NKT cells were stimulated with cholesteryl O-acyl alpha-glycosides in the context of CD1d.	cholesteryl o-acyl alpha-glycosides	41-76	CD1d molecule	Homo sapiens	95-99
30783507-2	2019	In this Letter, we designed and synthesized a novel series of CD1d ligand alpha-galactosylceramides (alpha-GalCers) in which the acyl chain backbone of the lipid was incorporated with fluorine atoms.	alpha-galactosylceramide	101-114	CD1d molecule	Homo sapiens	62-66
30783507-2	2019	In this Letter, we designed and synthesized a novel series of CD1d ligand alpha-galactosylceramides (alpha-GalCers) in which the acyl chain backbone of the lipid was incorporated with fluorine atoms.	Fluorine	184-192	CD1d molecule	Homo sapiens	62-66
30519237-0	2018	Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond.	alpha-galactosylceramide	78-102	CD1d molecule	Homo sapiens	13-17
30085659-3	2018	These bound efficiently to the glycolipid antigen presenting protein CD1d, and upon photoactivation formed stable CD1d-glycolipid covalent conjugates.	Glycolipids	31-41	CD1d molecule	Homo sapiens	69-73
30322965-6	2018	moDCs but not moLCs produced inflammatory cytokines after stimulation with CD1b and CD1d ligands mycolic acid and alpha-galactosylceramide, respectively.	Mycolic Acids	97-109	CD1d molecule	Homo sapiens	84-88
30322965-6	2018	moDCs but not moLCs produced inflammatory cytokines after stimulation with CD1b and CD1d ligands mycolic acid and alpha-galactosylceramide, respectively.	alpha-galactosylceramide	114-138	CD1d molecule	Homo sapiens	84-88
30417862-2	2018	To overcome this difficulty, we used imaging flow cytometry and transcriptomic profiling (RNA-seq) to determine altered subcellular localization of the cluster of differentiation 1d protein (CD1d) associated with impaired endocytic gene expression in human dendritic cells (DCs), which were exposed to the common lipophilic air pollutant benzo[a]pyrene.	Benzo(a)pyrene	338-352	CD1d molecule	Homo sapiens	191-195
30417862-5	2018	The enhanced CD1d and Lamp1 colocalization upon BaP exposure was further demonstrated using thresholded scatterplots, tested with Mander"s coefficients for co-localized intensity, and plotted based on the percentage of co-localized areas using ImageJ-Fiji.	Benzo(a)pyrene	48-51	CD1d molecule	Homo sapiens	13-17
30300581-5	2018	CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19+ chronic lymphocytic leukemia cells.	Tretinoin	48-61	CD1d molecule	Homo sapiens	0-4
30085659-3	2018	These bound efficiently to the glycolipid antigen presenting protein CD1d, and upon photoactivation formed stable CD1d-glycolipid covalent conjugates.	Glycolipids	31-41	CD1d molecule	Homo sapiens	114-118
30085659-3	2018	These bound efficiently to the glycolipid antigen presenting protein CD1d, and upon photoactivation formed stable CD1d-glycolipid covalent conjugates.	Glycolipids	119-129	CD1d molecule	Homo sapiens	69-73
30085659-3	2018	These bound efficiently to the glycolipid antigen presenting protein CD1d, and upon photoactivation formed stable CD1d-glycolipid covalent conjugates.	Glycolipids	119-129	CD1d molecule	Homo sapiens	114-118
30085659-4	2018	Conjugates of benzophenone alpha-GCs with soluble or cell-bound CD1d proteins retained potent iNKT cell activating properties, with biologic effects that were modulated by acyl chain length and the resulting affinities of conjugates for iNKT cell antigen receptors.	benzophenone	14-26	CD1d molecule	Homo sapiens	64-68
30085659-5	2018	Analysis by mass spectrometry identified a unique covalent attachment site for the glycolipid ligands in the hydrophobic ligand binding pocket of CD1d.	Glycolipids	83-93	CD1d molecule	Homo sapiens	146-150
29688330-1	2018	Invariant natural killer T (iNKT) cells recognize glycolipid antigens bound to CD1d molecules on antigen-presenting cells.	Glycolipids	50-60	CD1d molecule	Homo sapiens	79-83
30245690-1	2018	Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to T-cell receptor (TCR) stimulation by recognizing antigens such as alpha-galactosylceramide (alpha-GalCer) presented on CD1d; thus, orchestrating other immune cells to fight against pathogen infection and tumors.	alpha-galactosylceramide	158-182	CD1d molecule	Homo sapiens	211-215
30051730-5	2018	iNKT cells have potent in vivo and in vitro anti-tumor activities against CD1d-positve gastric cancer in the presence of alpha-galactosylceramide.	alpha-galactosylceramide	121-145	CD1d molecule	Homo sapiens	74-78
30051730-6	2018	Cisplatin could upregulate CD1d expression in gastric cancer cells and make them more vulnerable to iNKT cell-mediated cytotoxicity.	Cisplatin	0-9	CD1d molecule	Homo sapiens	27-31
29863807-3	2018	Herein, a series of novel Th2-biasing CD1d glycolipid ligands, based on modification of their lipid part, have been identified.	Glycolipids	43-53	CD1d molecule	Homo sapiens	38-42
29863807-5	2018	Importantly, the truncated acyl chain containing variants still retain their binding affinities and agonistic activities, which can be associated with an "anchoring effect," that is, formation of a buried hydrogen bond between a polar group on the acyl chain and the CD1d lipid-binding pocket.	Hydrogen	205-213	CD1d molecule	Homo sapiens	267-271
30030044-2	2018	GM2 is a glycosphingolipid abundant in cellular membranes and known to bind CD1d molecules, but the functional consequences of this binding are not completely clarified.	gm2	0-3	CD1d molecule	Homo sapiens	76-80
30030044-2	2018	GM2 is a glycosphingolipid abundant in cellular membranes and known to bind CD1d molecules, but the functional consequences of this binding are not completely clarified.	Glycosphingolipids	9-26	CD1d molecule	Homo sapiens	76-80
30030044-7	2018	An explanation for this effect could be a direct competition of GM2 with antigenic lipids for CD1d binding.	gm2	64-67	CD1d molecule	Homo sapiens	94-98
30158927-11	2018	Newly improved sulfatide-CD1d tetramers are starting to allow better characterization of the elusive type II NKT cells to better understand their function and control it to overcome immunosuppression.	Sulfoglycosphingolipids	15-24	CD1d molecule	Homo sapiens	25-29
30013569-0	2018	CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond.	alpha-galactosylceramide	65-89	CD1d molecule	Homo sapiens	0-4
29688330-3	2018	We synthesized a series of thioglycoside analogs of alpha-GalCer with different substituents to the galactose residue and found that two of these compounds, XZ7 and XZ11, bound to CD1d-transfected HeLa cells and activated lines of expanded human iNKT cells.	Thioglycosides	27-40	CD1d molecule	Homo sapiens	180-184
29688330-3	2018	We synthesized a series of thioglycoside analogs of alpha-GalCer with different substituents to the galactose residue and found that two of these compounds, XZ7 and XZ11, bound to CD1d-transfected HeLa cells and activated lines of expanded human iNKT cells.	Galactose	100-109	CD1d molecule	Homo sapiens	180-184
29904582-3	2018	We and others have found a glycolipid, called alpha-galactosylceramide (alpha-GalCer), which could be presented on CD1d expressed by antigen-presenting cells (APCs) and stimulate natural killer T (NKT) cells.	Glycolipids	27-37	CD1d molecule	Homo sapiens	115-119
30046564-2	2018	Invariant NKT (iNKT) cells bear an invariant TCR and recognize a small variety of glycolipid antigens presented by CD1d (nonclassical MHC-I).	Glycolipids	82-92	CD1d molecule	Homo sapiens	115-119
29904582-3	2018	We and others have found a glycolipid, called alpha-galactosylceramide (alpha-GalCer), which could be presented on CD1d expressed by antigen-presenting cells (APCs) and stimulate natural killer T (NKT) cells.	alpha-galactosylceramide	46-70	CD1d molecule	Homo sapiens	115-119
29904582-3	2018	We and others have found a glycolipid, called alpha-galactosylceramide (alpha-GalCer), which could be presented on CD1d expressed by antigen-presenting cells (APCs) and stimulate natural killer T (NKT) cells.	alpha-galactosylceramide	72-84	CD1d molecule	Homo sapiens	115-119
29775592-2	2018	Here, we identify a class of compounds derived from dietary, microbial, and industrial sources that are characterized by the presence of a five-membered oxazole ring and induce CD1d-dependent intestinal inflammation.	Oxazoles	153-160	CD1d molecule	Homo sapiens	177-181
29671585-2	2018	Here, we have employed molecular dynamics (MD) simulations (adding to 14 mus in total) to study conformational changes triggered by the inverse agonist R-(-)-3-quinuclidinyl-benzilate (QNB) in the structure of the active M2 receptor (PBD ID 4MQS ) after replacement of the agonist iperoxo by the inverse agonist QNB.	3-quinuclidinyl 4-fluoromethylbenzilate	312-315	CD1d molecule	Homo sapiens	152-159
29576533-1	2018	Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections.	glycosylceramides	0-17	CD1d molecule	Homo sapiens	32-36
29671585-2	2018	Here, we have employed molecular dynamics (MD) simulations (adding to 14 mus in total) to study conformational changes triggered by the inverse agonist R-(-)-3-quinuclidinyl-benzilate (QNB) in the structure of the active M2 receptor (PBD ID 4MQS ) after replacement of the agonist iperoxo by the inverse agonist QNB.	3-quinuclidinyl 4-fluoromethylbenzilate	185-188	CD1d molecule	Homo sapiens	152-159
29671585-2	2018	Here, we have employed molecular dynamics (MD) simulations (adding to 14 mus in total) to study conformational changes triggered by the inverse agonist R-(-)-3-quinuclidinyl-benzilate (QNB) in the structure of the active M2 receptor (PBD ID 4MQS ) after replacement of the agonist iperoxo by the inverse agonist QNB.	iperoxo	281-288	CD1d molecule	Homo sapiens	152-159
29775592-4	2018	CD1d-restricted production of interleukin 10 by IECs is limited through activity of the aryl hydrocarbon receptor (AhR) pathway in response to oxazole induction of tryptophan metabolites.	Tryptophan	164-174	CD1d molecule	Homo sapiens	0-4
29775592-6	2018	In summary, we identify environmentally derived oxazoles as triggers of CD1d-dependent intestinal inflammatory responses that occur via activation of the AhR in the intestinal epithelium.	Oxazoles	48-56	CD1d molecule	Homo sapiens	72-76
29775592-3	2018	We observe that minimal oxazole structures modulate natural killer T cell-dependent inflammation by regulating lipid antigen presentation by CD1d on intestinal epithelial cells (IECs).	Oxazoles	24-31	CD1d molecule	Homo sapiens	141-145
29775592-4	2018	CD1d-restricted production of interleukin 10 by IECs is limited through activity of the aryl hydrocarbon receptor (AhR) pathway in response to oxazole induction of tryptophan metabolites.	Oxazoles	143-150	CD1d molecule	Homo sapiens	0-4
29520280-1	2018	Vaccination with CD1d-binding glycolipid adjuvants and co-administered protein, lipid, and carbohydrate antigens leads to invariant natural killer T (NKT) cell-dependent enhancement of protective B cell responses.	Glycolipids	30-40	CD1d molecule	Homo sapiens	17-21
29520280-1	2018	Vaccination with CD1d-binding glycolipid adjuvants and co-administered protein, lipid, and carbohydrate antigens leads to invariant natural killer T (NKT) cell-dependent enhancement of protective B cell responses.	Carbohydrates	91-103	CD1d molecule	Homo sapiens	17-21
29520280-5	2018	CD1d/glycolipid-activated NKT cells are able to provide help to B cells in a manner dependent on cognate and non-cognate interactions.	Glycolipids	5-15	CD1d molecule	Homo sapiens	0-4
29389901-2	2018	These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules.	Glycolipids	41-52	CD1d molecule	Homo sapiens	99-103
29163493-3	2017	Systemic treatments with the CD1d-antitumor fusion proteins loaded with the agonist alpha-galactosylceramide (alphaGalCer) led to specific iNKT cell activation, resulting in a sustained growth inhibition of established tumors expressing HER2 or CEA, while treatment with the free alphaGalCer was ineffective.	alpha-galactosylceramide	84-108	CD1d molecule	Homo sapiens	29-33
29312339-1	2017	Type I natural killer T (NKT) cells are innate-like T lymphocytes that recognize glycolipid antigens presented by the MHC class I-like protein CD1d.	Glycolipids	81-91	CD1d molecule	Homo sapiens	143-147
29179729-9	2017	The mRNA expression of CD1d and MR1 were increased in stable and exacerbating COPD patients; however both molecules were decreased upon antibiotic and systemic steroid treatments.	Steroids	160-167	CD1d molecule	Homo sapiens	23-27
28573337-2	2017	For this purpose, the mimetic 1 was properly conjugated to a stearic acid containing glycerol-based phospholipid (compound 5) to be presented, in the context of the conserved non polymorphic major histocompatibility complex class I-like molecules (CD1d), to iNKT cells.	Phospholipids	100-112	CD1d molecule	Homo sapiens	248-252
28780376-0	2017	Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8+ invariant natural killer T cells.	Tretinoin	0-13	CD1d molecule	Homo sapiens	27-31
28780376-1	2017	Invariant natural killer T (iNKT) cells are cytotoxic T cells that respond to glycolipid antigens presented by CD1d.	Glycolipids	78-88	CD1d molecule	Homo sapiens	111-115
28633979-0	2017	Zerumbone modulates CD1d expression and lipid antigen presentation pathway in breast cancer cells.	zerumbone	0-9	CD1d molecule	Homo sapiens	20-24
28633979-8	2017	The alpha-galactosylceramide, a ligand for CD1d, showed increased CD1d expression as well as cell proliferation which was opposite to the effects of ZER.	alpha-galactosylceramide	4-28	CD1d molecule	Homo sapiens	43-47
28633979-8	2017	The alpha-galactosylceramide, a ligand for CD1d, showed increased CD1d expression as well as cell proliferation which was opposite to the effects of ZER.	alpha-galactosylceramide	4-28	CD1d molecule	Homo sapiens	66-70
28655912-0	2017	Galactosylsphingamides: new alpha-GalCer analogues to probe the F"-pocket of CD1d.	galactosylsphingamides	0-22	CD1d molecule	Homo sapiens	77-81
28440548-4	2017	Exposure of human antigen-presenting cells such as monocyte-derived dendritic cells and THP-1 cells to the prototypical contact sensitizer dinitrochlorobenzene potentiated the response of CD1a- and CD1d-autoreactive T cells, which released a vast array of cytokines in a CD1- and TCR-dependent manner.	Dinitrochlorobenzene	139-159	CD1d molecule	Homo sapiens	198-202
28526683-6	2017	Apolipoprotein E isolated from human cerebrospinal fluid carries sulfatide that can be captured by APCs and presented by CD1d to iNKT cells.	Sulfoglycosphingolipids	65-74	CD1d molecule	Homo sapiens	121-125
28798749-2	2017	This "innate-like" T lymphocyte subset has the unique ability to recognize foreign and self-derived glycolipid antigens in association with the CD1d molecule expressed by antigen-presenting cells.	Glycolipids	100-110	CD1d molecule	Homo sapiens	144-157
28655912-1	2017	Invariant Natural Killer T-cells (iNKT-cells) are an attractive target for immune response modulation, as upon CD1d-mediated stimulation with KRN7000, a synthetic alpha-galactosylceramide, they produce a vast amount of cytokines.	KRN 7000	142-149	CD1d molecule	Homo sapiens	111-115
28655912-1	2017	Invariant Natural Killer T-cells (iNKT-cells) are an attractive target for immune response modulation, as upon CD1d-mediated stimulation with KRN7000, a synthetic alpha-galactosylceramide, they produce a vast amount of cytokines.	alpha-galactosylceramide	163-187	CD1d molecule	Homo sapiens	111-115
28655912-4	2017	While introduction of the amide-motif in the phytosphingosine chain is tolerated for CD1d binding and TCR recognition, the studied alpha-galactosylsphingamides showed compromised antigenic properties.	Amides	26-31	CD1d molecule	Homo sapiens	85-89
28655912-4	2017	While introduction of the amide-motif in the phytosphingosine chain is tolerated for CD1d binding and TCR recognition, the studied alpha-galactosylsphingamides showed compromised antigenic properties.	phytosphingosine	45-61	CD1d molecule	Homo sapiens	85-89
28933361-4	2017	It has been shown that two major sphingolipids that accumulate in GD, namely, beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	Sphingolipids	33-46	CD1d molecule	Homo sapiens	192-196
28522830-4	2017	Our results demonstrated that the expression of CD1a and CD1d proteins, and the activation of CD1a- and CD1d-restricted T cells were sensitively inhibited by benzo[a]pyrene even at the low concentrations detectable in exposed human populations.	Benzo(a)pyrene	158-172	CD1d molecule	Homo sapiens	57-61
28522830-4	2017	Our results demonstrated that the expression of CD1a and CD1d proteins, and the activation of CD1a- and CD1d-restricted T cells were sensitively inhibited by benzo[a]pyrene even at the low concentrations detectable in exposed human populations.	Benzo(a)pyrene	158-172	CD1d molecule	Homo sapiens	104-108
28549432-1	2017	BACKGROUND: Invariant natural killer T (iNKT) cells are a small population of lymphocytes with unique specificity for glycolipid antigens presented by non-polymorphic CD1d receptor on dendritic cells (DCs).	Glycolipids	118-128	CD1d molecule	Homo sapiens	167-171
28522830-7	2017	Imaging flow cytometry also showed that CD1a and CD1d proteins were retained in early and late endosomal compartments, respectively, supporting an impaired endocytic lipid antigen presentation for T cell activation upon benzo[a]pyrene exposure.	benzo[a]	220-228	CD1d molecule	Homo sapiens	49-53
28522830-7	2017	Imaging flow cytometry also showed that CD1a and CD1d proteins were retained in early and late endosomal compartments, respectively, supporting an impaired endocytic lipid antigen presentation for T cell activation upon benzo[a]pyrene exposure.	pyrene	228-234	CD1d molecule	Homo sapiens	49-53
27984752-8	2017	Most importantly, PLS regression accurately determined the anthracene and TFE enantiomer concentrations with an average low error of 2.31% for anthracene, 4.44% for R-TFE and 3.60% for S-TFE.	anthracene	59-69	CD1d molecule	Homo sapiens	165-176
27984752-8	2017	Most importantly, PLS regression accurately determined the anthracene and TFE enantiomer concentrations with an average low error of 2.31% for anthracene, 4.44% for R-TFE and 3.60% for S-TFE.	Trifluoroethanol	74-77	CD1d molecule	Homo sapiens	165-176
28933361-4	2017	It has been shown that two major sphingolipids that accumulate in GD, namely, beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	beta-glucosylceramide	78-99	CD1d molecule	Homo sapiens	192-196
28933361-4	2017	It has been shown that two major sphingolipids that accumulate in GD, namely, beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	sphingosyl beta-glucoside	122-141	CD1d molecule	Homo sapiens	192-196
27385422-1	2017	In this review, we discuss small-molecule, carbohydrate-based immunostimulants that target Toll-like receptor 4 (TLR-4) and cluster of differentiation 1D (CD1d) receptors.	Carbohydrates	43-55	CD1d molecule	Homo sapiens	124-153
27385422-1	2017	In this review, we discuss small-molecule, carbohydrate-based immunostimulants that target Toll-like receptor 4 (TLR-4) and cluster of differentiation 1D (CD1d) receptors.	Carbohydrates	43-55	CD1d molecule	Homo sapiens	155-159
26969612-0	2016	The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction.	n-glycolyl-gm3	18-32	CD1d molecule	Homo sapiens	44-48
28003379-7	2017	The Arg/Ser substitution also influenced Ag recognition as determined by CD1d multimer staining and CD1d-restricted functional responses.	Arginine	4-7	CD1d molecule	Homo sapiens	73-77
28003379-7	2017	The Arg/Ser substitution also influenced Ag recognition as determined by CD1d multimer staining and CD1d-restricted functional responses.	Arginine	4-7	CD1d molecule	Homo sapiens	100-104
28003379-7	2017	The Arg/Ser substitution also influenced Ag recognition as determined by CD1d multimer staining and CD1d-restricted functional responses.	Serine	8-11	CD1d molecule	Homo sapiens	73-77
28003379-7	2017	The Arg/Ser substitution also influenced Ag recognition as determined by CD1d multimer staining and CD1d-restricted functional responses.	Serine	8-11	CD1d molecule	Homo sapiens	100-104
27312006-4	2016	Two clones induced maturation of dendritic cells, one clone induced early apoptosis in CD1d-expressing B lymphoblasts and multiple myeloma cells, and another clone blocked recognition of glycolipid-loaded CD1d by CD1d-restricted invariant natural killer T (iNKT) cells.	Glycolipids	187-197	CD1d molecule	Homo sapiens	205-209
27312006-4	2016	Two clones induced maturation of dendritic cells, one clone induced early apoptosis in CD1d-expressing B lymphoblasts and multiple myeloma cells, and another clone blocked recognition of glycolipid-loaded CD1d by CD1d-restricted invariant natural killer T (iNKT) cells.	Glycolipids	187-197	CD1d molecule	Homo sapiens	205-209
27393665-2	2016	NKT cells possess a classic alphabeta T cell receptor (TCR) that is able to recognize self and foreign glycolipid antigens presented by the nonclassical class I major histocompatibility complex (MHC) molecule, CD1d.	Glycolipids	103-113	CD1d molecule	Homo sapiens	210-214
30562870-1	2017	CD1d-restricted invariant natural killer T (iNKI) cells are the unique lymphocyte subpopu- lation that interacts with glycolipid via the invariant T cell receptor.	Glycolipids	118-128	CD1d molecule	Homo sapiens	0-4
27648599-1	2016	The CD1d protein is a nonpolymorphic MHC class I-like protein that controls the activation of natural killer T (NKT) cells through the presentation of self- and foreign-lipid ligands, glycolipids, or phospholipids, leading to the secretion of various cytokines.	Glycolipids	184-195	CD1d molecule	Homo sapiens	4-8
27648599-1	2016	The CD1d protein is a nonpolymorphic MHC class I-like protein that controls the activation of natural killer T (NKT) cells through the presentation of self- and foreign-lipid ligands, glycolipids, or phospholipids, leading to the secretion of various cytokines.	Phospholipids	200-213	CD1d molecule	Homo sapiens	4-8
27648599-4	2016	A series of the ligands, alpha-galactosyl ceramide (alpha-GalCer) derivatives containing polar groups in the acyl chain, was synthesized, and the structure-activity relationship studies demonstrated that simple modification from a methylene to an amide group in the long fatty acyl chain, when introduced at optimal positions, enhanced the CD1d recognition of the glycolipid ligands.	alpha-galactosylceramide	25-50	CD1d molecule	Homo sapiens	340-344
27648599-4	2016	A series of the ligands, alpha-galactosyl ceramide (alpha-GalCer) derivatives containing polar groups in the acyl chain, was synthesized, and the structure-activity relationship studies demonstrated that simple modification from a methylene to an amide group in the long fatty acyl chain, when introduced at optimal positions, enhanced the CD1d recognition of the glycolipid ligands.	alpha-galactosylceramide	52-64	CD1d molecule	Homo sapiens	340-344
27648599-4	2016	A series of the ligands, alpha-galactosyl ceramide (alpha-GalCer) derivatives containing polar groups in the acyl chain, was synthesized, and the structure-activity relationship studies demonstrated that simple modification from a methylene to an amide group in the long fatty acyl chain, when introduced at optimal positions, enhanced the CD1d recognition of the glycolipid ligands.	Amides	45-50	CD1d molecule	Homo sapiens	340-344
27614429-5	2016	Pre-treatment with Trichostatin-A, a pan-HDACi, rapidly enhanced both CD1d- and MHC class II-mediated antigen presentation.	trichostatin A	19-33	CD1d molecule	Homo sapiens	70-74
27513300-6	2016	In vitro treatment of CML mDCs with the Rho-associated protein kinase (ROCK) inhibitor Y-27632 partially restored both cell surface CD1d expression and CD1d-mediated antigen presentation, whereas it had no effect on HD mDCs.	Y 27632	87-94	CD1d molecule	Homo sapiens	132-136
27513300-6	2016	In vitro treatment of CML mDCs with the Rho-associated protein kinase (ROCK) inhibitor Y-27632 partially restored both cell surface CD1d expression and CD1d-mediated antigen presentation, whereas it had no effect on HD mDCs.	Y 27632	87-94	CD1d molecule	Homo sapiens	152-156
27513300-8	2016	Similar recovery of CD1d expression occurred with fasudil, another ROCK inhibitor that is commonly used in clinical trials.	fasudil	50-57	CD1d molecule	Homo sapiens	20-24
27297969-7	2016	Pretreatment with 2-deoxyglucose, cobalt chloride, AICAR and metformin significantly enhanced CD1d-mediated NKT-cell activation.	Deoxyglucose	18-32	CD1d molecule	Homo sapiens	94-98
27297969-7	2016	Pretreatment with 2-deoxyglucose, cobalt chloride, AICAR and metformin significantly enhanced CD1d-mediated NKT-cell activation.	cobaltous chloride	34-49	CD1d molecule	Homo sapiens	94-98
27297969-7	2016	Pretreatment with 2-deoxyglucose, cobalt chloride, AICAR and metformin significantly enhanced CD1d-mediated NKT-cell activation.	AICA ribonucleotide	51-56	CD1d molecule	Homo sapiens	94-98
27297969-7	2016	Pretreatment with 2-deoxyglucose, cobalt chloride, AICAR and metformin significantly enhanced CD1d-mediated NKT-cell activation.	Metformin	61-70	CD1d molecule	Homo sapiens	94-98
26969612-7	2016	We also showed that paraformaldehyde treatment of cells expressing CD1d affects the presentation.	paraform	20-36	CD1d molecule	Homo sapiens	67-71
26599805-5	2015	In this study, we investigated the influence of different surfactants (Triton X-100, Tween 20, Tyloxapol) on in vitro loading of CD1d molecules derived from four different species (human, mouse, rat and cotton rat) with alphaGC and derivatives carrying modifications of the acyl-chain (DB01-1, PBS44) and a 6-acetamido-6-deoxy-addition at the galactosyl head group (PBS57).	Octoxynol	71-83	CD1d molecule	Homo sapiens	129-133
26426881-0	2016	Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner.	globotriaosylceramide	0-21	CD1d molecule	Homo sapiens	57-61
26481266-1	2015	Conventional dendritic cells (cDCs) present alpha-galactosylceramide (alphaGC) to invariant natural killer T (iNKT) cells through CD1d.	alpha-galactosylceramide	44-68	CD1d molecule	Homo sapiens	130-134
27195112-3	2016	The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with alpha-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d.	Glycolipids	68-79	CD1d molecule	Homo sapiens	222-226
27195112-3	2016	The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with alpha-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d.	Glycosphingolipids	94-112	CD1d molecule	Homo sapiens	222-226
27195112-3	2016	The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with alpha-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d.	alpha-anomeric	118-132	CD1d molecule	Homo sapiens	222-226
27195112-3	2016	The antigen receptors of these cells specifically recognize certain glycolipids, most notably glycosphingolipids with alpha-anomeric monosaccharides, presented by the major histocompatibility complex class I-like molecule CD1d.	Monosaccharides	133-148	CD1d molecule	Homo sapiens	222-226
26875526-3	2016	We describe an atypical population of CD1d-alpha-galactosylceramide (alpha-GalCer)-reactive human NKT cells that differ markedly from the prototypical TRAV10-TRAJ18-TRBV25-1(+) type I NKT cell repertoire.	alpha-galactosylceramide	43-67	CD1d molecule	Homo sapiens	38-42
26875526-3	2016	We describe an atypical population of CD1d-alpha-galactosylceramide (alpha-GalCer)-reactive human NKT cells that differ markedly from the prototypical TRAV10-TRAJ18-TRBV25-1(+) type I NKT cell repertoire.	alpha-galactosylceramide	69-81	CD1d molecule	Homo sapiens	38-42
27013448-3	2015	Invariant natural killer T (iNKT) cells are innate-like T cells that recognize glycolipids presented by CD1d.	Glycolipids	79-90	CD1d molecule	Homo sapiens	104-108
26141240-5	2015	Using a combination of biological assays and new technological approaches, we have unequivocally demonstrated that alpha glycosylceramides were constitutively produced by mammalian immune cells, loaded onto CD1d and presented to NKT cells both in the thymus and in the periphery.	alpha glycosylceramides	115-138	CD1d molecule	Homo sapiens	207-211
26599805-5	2015	In this study, we investigated the influence of different surfactants (Triton X-100, Tween 20, Tyloxapol) on in vitro loading of CD1d molecules derived from four different species (human, mouse, rat and cotton rat) with alphaGC and derivatives carrying modifications of the acyl-chain (DB01-1, PBS44) and a 6-acetamido-6-deoxy-addition at the galactosyl head group (PBS57).	Polysorbates	85-93	CD1d molecule	Homo sapiens	129-133
26599805-5	2015	In this study, we investigated the influence of different surfactants (Triton X-100, Tween 20, Tyloxapol) on in vitro loading of CD1d molecules derived from four different species (human, mouse, rat and cotton rat) with alphaGC and derivatives carrying modifications of the acyl-chain (DB01-1, PBS44) and a 6-acetamido-6-deoxy-addition at the galactosyl head group (PBS57).	tyloxapol	95-104	CD1d molecule	Homo sapiens	129-133
26260288-0	2015	STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.	Glycosphingolipids	89-106	CD1d molecule	Homo sapiens	15-19
28717498-4	2015	We present here the synthesis and analysis of vaccines based on conjugation of MHC-binding peptide epitopes to alpha-galactosylceramide, a glycolipid presented by the nonpolymorphic antigen-presenting molecule CD1d to provoke the stimulatory activity of type I natural killer T (NKT) cells.	alpha-galactosylceramide	111-135	CD1d molecule	Homo sapiens	210-214
26254340-6	2015	Further, although mammalian phosphatidylglycerol-loaded CD1d tetramers did not stain dNKT cells, the Listeria-derived phosphatidylglycerol-loaded tetramers did.	Phosphatidylglycerols	28-48	CD1d molecule	Homo sapiens	56-60
26254340-8	2015	CD1d-binding lipid-displacement studies revealed that the microbial phosphatidylglycerol Ag binds significantly better to CD1d than do counterparts with the same headgroup.	Phosphatidylglycerols	68-88	CD1d molecule	Homo sapiens	0-4
26254340-8	2015	CD1d-binding lipid-displacement studies revealed that the microbial phosphatidylglycerol Ag binds significantly better to CD1d than do counterparts with the same headgroup.	Phosphatidylglycerols	68-88	CD1d molecule	Homo sapiens	122-126
26107189-1	2015	Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is a unique adjuvant that enables a strong antitumor effect to be induced via activation of natural killer T cells.	alpha-galactosylceramide	0-24	CD1d molecule	Homo sapiens	58-62
26107189-1	2015	Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is a unique adjuvant that enables a strong antitumor effect to be induced via activation of natural killer T cells.	alpha-galactosylceramide	26-28	CD1d molecule	Homo sapiens	58-62
26041373-3	2015	According to the IMGT unique numbering for G domain, CD1D*03 has one nucleotide transition c136 > t in codon 46, with an arginine-to-cysteine amino acid change (R46 > C) in the D-STRAND, whereas CD1D*04 has one transition c98 > t in codon 33, with a threonine-to-methionine amino acid change (T33 > M) in the C-STRAND.	Arginine	124-132	CD1d molecule	Homo sapiens	53-57
26041373-3	2015	According to the IMGT unique numbering for G domain, CD1D*03 has one nucleotide transition c136 > t in codon 46, with an arginine-to-cysteine amino acid change (R46 > C) in the D-STRAND, whereas CD1D*04 has one transition c98 > t in codon 33, with a threonine-to-methionine amino acid change (T33 > M) in the C-STRAND.	Cysteine	136-144	CD1d molecule	Homo sapiens	53-57
26041373-3	2015	According to the IMGT unique numbering for G domain, CD1D*03 has one nucleotide transition c136 > t in codon 46, with an arginine-to-cysteine amino acid change (R46 > C) in the D-STRAND, whereas CD1D*04 has one transition c98 > t in codon 33, with a threonine-to-methionine amino acid change (T33 > M) in the C-STRAND.	Threonine	259-268	CD1d molecule	Homo sapiens	53-57
26041373-3	2015	According to the IMGT unique numbering for G domain, CD1D*03 has one nucleotide transition c136 > t in codon 46, with an arginine-to-cysteine amino acid change (R46 > C) in the D-STRAND, whereas CD1D*04 has one transition c98 > t in codon 33, with a threonine-to-methionine amino acid change (T33 > M) in the C-STRAND.	methionine amino acid	272-293	CD1d molecule	Homo sapiens	53-57
26078271-7	2015	Therefore, our data are consistent with a model whereby augmented and or prolonged presentation of a glycolipid Ag leads to increased activation of NK cells and a Th1-skewed immune response, which may result, in part, from enhanced loading into CD1d.	Glycolipids	101-111	CD1d molecule	Homo sapiens	245-249
26271453-7	2015	We find a rather unexpected deviation from the extrapolated boundaries of the hR3 phase of lithium.	Lithium	91-98	CD1d molecule	Homo sapiens	78-81
25796193-2	2015	As cancer patients are frequently treated with aminobisphosphonates (NBP), it is relevant to determine possible effects of NBP on CD1d-restricted glycolipid Ag-presentation to iNKT cells.	aminobisphosphonates	47-67	CD1d molecule	Homo sapiens	130-134
26068127-3	2015	Invariant natural killer T (iNKT) cells are innate-like T cells that recognize glycolipids presented by CD1d.	Glycolipids	79-90	CD1d molecule	Homo sapiens	104-108
25955524-0	2015	4,5-cis unsaturated alpha-GalCer analogues distinctly lead to CD1d-mediated Th1-biased NKT cell responses.	4,5-cis unsaturated alpha-galcer	0-32	CD1d molecule	Homo sapiens	62-66
25796193-0	2015	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.	aminobisphosphonates	0-20	CD1d molecule	Homo sapiens	84-88
25618030-0	2015	CD1d serves as a surface receptor for oxidized cholesterol induction of peroxisome proliferator-activated receptor-gamma.	Cholesterol	47-58	CD1d molecule	Homo sapiens	0-4
25796193-1	2015	CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) and initiate antitumor immune responses.	Glycolipids	150-160	CD1d molecule	Homo sapiens	0-4
25796193-1	2015	CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) and initiate antitumor immune responses.	alpha-galactosylceramide	161-185	CD1d molecule	Homo sapiens	0-4
25796193-1	2015	CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) and initiate antitumor immune responses.	alpha-galactosylceramide	187-199	CD1d molecule	Homo sapiens	0-4
25618030-12	2015	The PPARgamma agonist PGJ2 enhances the 7K stimulatory effect on PPARgamma expression and activity but the antagonist GW9662 inhibits the 7K effect on the CD1d-expressing cells.	2-chloro-5-nitrobenzanilide	118-124	CD1d molecule	Homo sapiens	155-159
25248321-0	2015	All-trans-retinoic acid and CD38 ligation differentially regulate CD1d expression and alpha-galactosylceramide-induced immune responses.	Tretinoin	0-23	CD1d molecule	Homo sapiens	66-70
25618030-13	2015	CONCLUSIONS: CD1d acts as a cell surface receptor that recognizes and binds oxysterols and initializes a pathway connecting oxysterol binding to PPARgamma activation.	Oxysterols	76-86	CD1d molecule	Homo sapiens	13-17
25618030-13	2015	CONCLUSIONS: CD1d acts as a cell surface receptor that recognizes and binds oxysterols and initializes a pathway connecting oxysterol binding to PPARgamma activation.	Oxysterols	76-85	CD1d molecule	Homo sapiens	13-17
25499455-3	2015	Here, we report that beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), 2 major sphingolipids accumulated in GD, can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	beta-glucosylceramide	21-42	CD1d molecule	Homo sapiens	176-180
25499455-3	2015	Here, we report that beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), 2 major sphingolipids accumulated in GD, can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	betagl1	49-56	CD1d molecule	Homo sapiens	176-180
25499455-3	2015	Here, we report that beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), 2 major sphingolipids accumulated in GD, can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	sphingosyl beta-glucoside	65-84	CD1d molecule	Homo sapiens	176-180
25499455-3	2015	Here, we report that beta-glucosylceramide 22:0 (betaGL1-22) and glucosylsphingosine (LGL1), 2 major sphingolipids accumulated in GD, can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells.	Sphingolipids	101-114	CD1d molecule	Homo sapiens	176-180
25248321-1	2015	The MHC class-I like molecule CD1d presents glycolipid antigens and thereby activates invariant natural killer-T (NKT) cells.	Glycolipids	44-54	CD1d molecule	Homo sapiens	30-34
25248321-5	2015	Whereas a physiological concentration (20 nM) of RA alone rapidly and markedly increased CD1d protein in THP-1 cells, there was a marked synergy between RA and ligation of CD38 with antibody to CD38.	Tretinoin	49-51	CD1d molecule	Homo sapiens	89-93
24337356-4	2014	Alkoxyamines (R(1)R(2)NOR(3)) are labile molecules that homolyze into nitroxides (R(1)R(2)NO ) and reactive alkyl radicals (R(3) ).	alkoxyamines	0-12	CD1d molecule	Homo sapiens	24-28
25751125-5	2015	Together with data showing that NIB.2 inhibited stimulation via CD1d loaded with different glycolipids, this supports a mechanism whereby NIB.2 inhibits NKT cell activation by inhibiting Type 1 NKT cell receptor beta-chain interactions with CD1d, independent of the lipid antigen in the CD1d antigen-binding cleft.	Glycolipids	91-102	CD1d molecule	Homo sapiens	64-68
25751125-5	2015	Together with data showing that NIB.2 inhibited stimulation via CD1d loaded with different glycolipids, this supports a mechanism whereby NIB.2 inhibits NKT cell activation by inhibiting Type 1 NKT cell receptor beta-chain interactions with CD1d, independent of the lipid antigen in the CD1d antigen-binding cleft.	Glycolipids	91-102	CD1d molecule	Homo sapiens	241-245
25452463-4	2014	Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as alpha-glucosylceramide, was distinct from type I NKT cells.	alpha-galactosylceramide	106-130	CD1d molecule	Homo sapiens	48-52
25452463-4	2014	Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as alpha-glucosylceramide, was distinct from type I NKT cells.	alpha-galactosylceramide	132-144	CD1d molecule	Homo sapiens	48-52
25452463-4	2014	Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as alpha-glucosylceramide, was distinct from type I NKT cells.	alpha-glucosylceramide	226-248	CD1d molecule	Homo sapiens	48-52
25256626-3	2014	Highly selective 1,2-migration referring to the two substituents R(3) and R(4) (R(4) =H, alkyl, and aryl group) was observed: (1) In the presence of both H and alkyl groups, 1,2-hydrogen migration is exclusive; (2) in the presence of a methyl group (R(3) ), propyl, isopropyl, 4-methylphenyl, and 4-chlorophenyl groups (R(4) ) migrate exclusively.	Hydrogen	178-186	CD1d molecule	Homo sapiens	236-254
25255287-3	2014	In this study we adopted a previously described approach of incorporating glycolipids that activate CD1d-restricted natural killer T (NKT) cells to enhance priming of CD8+ T cells by rBCG strains expressing an SIV Gag antigen (rBCG-SIV gag).	Glycolipids	74-85	CD1d molecule	Homo sapiens	100-104
25014535-1	2014	Structural studies of ternary complexes of CD1d/glycosyl ceramides/iNKT cells and CD1d/sulfatide/sulfatide reactive Type II NKT cells have shown how the polar moieties on the glycolipids interact with both the antigen presenting protein (CD1d) and the T cell receptors.	Sulfoglycosphingolipids	87-96	CD1d molecule	Homo sapiens	82-86
25014535-1	2014	Structural studies of ternary complexes of CD1d/glycosyl ceramides/iNKT cells and CD1d/sulfatide/sulfatide reactive Type II NKT cells have shown how the polar moieties on the glycolipids interact with both the antigen presenting protein (CD1d) and the T cell receptors.	Sulfoglycosphingolipids	87-96	CD1d molecule	Homo sapiens	82-86
25014535-1	2014	Structural studies of ternary complexes of CD1d/glycosyl ceramides/iNKT cells and CD1d/sulfatide/sulfatide reactive Type II NKT cells have shown how the polar moieties on the glycolipids interact with both the antigen presenting protein (CD1d) and the T cell receptors.	Glycolipids	175-186	CD1d molecule	Homo sapiens	43-47
25014535-1	2014	Structural studies of ternary complexes of CD1d/glycosyl ceramides/iNKT cells and CD1d/sulfatide/sulfatide reactive Type II NKT cells have shown how the polar moieties on the glycolipids interact with both the antigen presenting protein (CD1d) and the T cell receptors.	Glycolipids	175-186	CD1d molecule	Homo sapiens	82-86
25014535-1	2014	Structural studies of ternary complexes of CD1d/glycosyl ceramides/iNKT cells and CD1d/sulfatide/sulfatide reactive Type II NKT cells have shown how the polar moieties on the glycolipids interact with both the antigen presenting protein (CD1d) and the T cell receptors.	Glycolipids	175-186	CD1d molecule	Homo sapiens	82-86
24675550-4	2014	Several positively selected sites involve positions of fundamental importance to the protein function (e.g. the TAP1 peptide-binding domains, the sugar binding interface of langerin, and the CD1D trafficking signal region).	Sugars	146-151	CD1d molecule	Homo sapiens	191-195
25381357-1	2014	CD1d is a nonpolymorphic, MHC class I-like molecule that presents phospholipid and glycosphingolipid Ags to a subset of CD1d-restricted T cells called invariant NKT (iNKT) cells.	Phospholipids	66-78	CD1d molecule	Homo sapiens	0-4
25381357-1	2014	CD1d is a nonpolymorphic, MHC class I-like molecule that presents phospholipid and glycosphingolipid Ags to a subset of CD1d-restricted T cells called invariant NKT (iNKT) cells.	Glycosphingolipids	83-100	CD1d molecule	Homo sapiens	0-4
25381357-1	2014	CD1d is a nonpolymorphic, MHC class I-like molecule that presents phospholipid and glycosphingolipid Ags to a subset of CD1d-restricted T cells called invariant NKT (iNKT) cells.	Glycosphingolipids	83-100	CD1d molecule	Homo sapiens	120-124
25390653-0	2014	Simplexide induces CD1d-dependent cytokine and chemokine production from human monocytes.	simplexide	0-10	CD1d molecule	Homo sapiens	19-23
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	42-52	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	42-52	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	42-52	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	42-52	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	bis(diphenylphosphine)ethane	118-152	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	bis(diphenylphosphine)ethane	118-152	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	bis(diphenylphosphine)ethane	118-152	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	bis(diphenylphosphine)ethane	118-152	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	dppe	154-158	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	dppe	154-158	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	dppe	154-158	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	dppe	154-158	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	monomethoxypolyethylene glycol	160-194	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	monomethoxypolyethylene glycol	160-194	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	monomethoxypolyethylene glycol	160-194	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	monomethoxypolyethylene glycol	160-194	CD1d molecule	Homo sapiens	101-105
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	monomethoxypolyethylene glycol	196-199	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	222-232	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	222-232	CD1d molecule	Homo sapiens	84-88
25390653-6	2014	Cytokine and chemokine release induced by simplexide from monocytes is dependent on CD1d since: i) a CD1d antagonist, 1,2-bis (diphenylphosphino) ethane [DPPE]-polyethylene glycolmonomethylether [PEG], specifically blocks simplexide-induced activation of monocytes; ii) CD1d knockdown inhibits monocyte activation by simplexide and iii) simplexide induces cytokine production from CD1d-transfected but not parental C1R cell line.	simplexide	222-232	CD1d molecule	Homo sapiens	84-88
25376021-10	2014	These theoretical tools provide a structural basis for predicting the very different dynamical behaviors of alpha-glycosphingolipids in CD1d and might aid in the future design of new analogues of 1.	alpha-glycosphingolipids	108-132	CD1d molecule	Homo sapiens	136-140
25261475-3	2014	Recent structural studies have shown a distinct mode of recognition of a self-glycolipid sulfatide bound to CD1d by a type II NKT TCR.	glycolipid sulfatide	78-98	CD1d molecule	Homo sapiens	108-112
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Phospholipids	74-87	CD1d molecule	Homo sapiens	18-22
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Phospholipids	74-87	CD1d molecule	Homo sapiens	197-201
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Lysophosphatidylcholines	96-119	CD1d molecule	Homo sapiens	18-22
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Lysophosphatidylcholines	96-119	CD1d molecule	Homo sapiens	197-201
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Lysophosphatidylcholines	121-124	CD1d molecule	Homo sapiens	18-22
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Lysophosphatidylcholines	121-124	CD1d molecule	Homo sapiens	197-201
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Sulfoglycosphingolipids	144-153	CD1d molecule	Homo sapiens	18-22
25261475-5	2014	Using plate-bound CD1d and APC-based Ag presentation assay, we found that phospholipids such as lysophosphatidylcholine (LPC) can stimulate the sulfatide-reactive type II NKT hybridoma Hy19.3 in a CD1d-dependent manner.	Sulfoglycosphingolipids	144-153	CD1d molecule	Homo sapiens	197-201
24934445-6	2014	However, this does not result from de novo synthesis of CD1d by Vgamma9Vdelta2-T, but critically depends on trogocytosis of CD1d-containing membrane fragments from pAg-expressing cells.	pag	164-167	CD1d molecule	Homo sapiens	124-128
24652424-1	2014	Isoglobotrihexosylceramide (iGb3, 1) is an immunomodulatory glycolipid that binds to CD1d and is presented to the T-cell receptor (TCR) of invariant natural killer T (iNKT) cells.	isoglobotrihexosylceramide	0-26	CD1d molecule	Homo sapiens	85-89
24652424-1	2014	Isoglobotrihexosylceramide (iGb3, 1) is an immunomodulatory glycolipid that binds to CD1d and is presented to the T-cell receptor (TCR) of invariant natural killer T (iNKT) cells.	Glycolipids	60-70	CD1d molecule	Homo sapiens	85-89
24337356-4	2014	Alkoxyamines (R(1)R(2)NOR(3)) are labile molecules that homolyze into nitroxides (R(1)R(2)NO ) and reactive alkyl radicals (R(3) ).	Hydroxylamine	70-80	CD1d molecule	Homo sapiens	24-28
24900836-0	2014	Design and Evaluation of omega-Hydroxy Fatty Acids Containing alpha-GalCer Analogues for CD1d-Mediated NKT Cell Activation.	omega-hydroxy fatty acids	25-50	CD1d molecule	Homo sapiens	89-93
24900836-1	2014	CD1d molecules recognize glycolipid antigens with straight chain fatty acid moieties.	Glycolipids	25-35	CD1d molecule	Homo sapiens	0-4
24900836-1	2014	CD1d molecules recognize glycolipid antigens with straight chain fatty acid moieties.	straight chain fatty acid	50-75	CD1d molecule	Homo sapiens	0-4
24337356-4	2014	Alkoxyamines (R(1)R(2)NOR(3)) are labile molecules that homolyze into nitroxides (R(1)R(2)NO ) and reactive alkyl radicals (R(3) ).	alkyl radicals	108-122	CD1d molecule	Homo sapiens	24-28
24900836-2	2014	Although most of the residues in the CD1d binding groove are hydrophobic, some of the amino acids can form hydrogen bonds.	Hydrogen	107-115	CD1d molecule	Homo sapiens	37-41
24498010-1	2014	Many analogues of the glycolipid alpha-galactosylceramide (alpha-GalCer) are known to activate iNKT cells through their interaction with CD1d-expressing antigen-presenting cells, inducing the release of Th1 and Th2 cytokines.	Glycolipids	22-32	CD1d molecule	Homo sapiens	137-141
24900836-3	2014	Consequently, we have designed omega-hydroxy fatty acid-containing glycolipid derivatives of the prototypical CD1d ligand alpha-GalCer.	glycolic acid	31-55	CD1d molecule	Homo sapiens	110-114
24900836-3	2014	Consequently, we have designed omega-hydroxy fatty acid-containing glycolipid derivatives of the prototypical CD1d ligand alpha-GalCer.	Glycolipids	67-77	CD1d molecule	Homo sapiens	110-114
24498010-1	2014	Many analogues of the glycolipid alpha-galactosylceramide (alpha-GalCer) are known to activate iNKT cells through their interaction with CD1d-expressing antigen-presenting cells, inducing the release of Th1 and Th2 cytokines.	alpha-galactosylceramide	33-57	CD1d molecule	Homo sapiens	137-141
24498010-1	2014	Many analogues of the glycolipid alpha-galactosylceramide (alpha-GalCer) are known to activate iNKT cells through their interaction with CD1d-expressing antigen-presenting cells, inducing the release of Th1 and Th2 cytokines.	alpha-galactosylceramide	59-71	CD1d molecule	Homo sapiens	137-141
24762075-2	2014	In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d.	Glycolipids	178-188	CD1d molecule	Homo sapiens	241-245
24360828-1	2014	RCAI-147 is one of the hydroxylated analogues of KRN7000 which is known as a ligand for the activation of CD1d mediated invariant natural killer T cells (iNKT cells) and releases both T helper 1 (Th1) cytokines such as IFN-gamma and T helper 2 (Th2) cytokines such as IL-4.	rcai-147	0-8	CD1d molecule	Homo sapiens	106-110
24360828-1	2014	RCAI-147 is one of the hydroxylated analogues of KRN7000 which is known as a ligand for the activation of CD1d mediated invariant natural killer T cells (iNKT cells) and releases both T helper 1 (Th1) cytokines such as IFN-gamma and T helper 2 (Th2) cytokines such as IL-4.	KRN 7000	49-56	CD1d molecule	Homo sapiens	106-110
24118614-4	2014	Sphingolipids (SLs) are presented via the CD1d molecule on the INKTs surface.	Sphingolipids	0-13	CD1d molecule	Homo sapiens	42-55
24118614-4	2014	Sphingolipids (SLs) are presented via the CD1d molecule on the INKTs surface.	Sphingolipids	15-18	CD1d molecule	Homo sapiens	42-55
24482817-0	2014	CD1d favors MHC neighborhood, GM1 ganglioside proximity and low detergent sensitive membrane regions on the surface of B lymphocytes.	G(M1) Ganglioside	30-45	CD1d molecule	Homo sapiens	0-4
24482817-8	2014	Treatment of B cells with methyl-beta-cyclodextrin (MbetaCD) / simvastatin caused protein rearrangement; however, FRET demonstrated only minimal effect of these chemicals on the association between CD1d and GM1 ganglioside on cell-surface.Likewise, a modest effect was only observed in a co-culture assay between MbetaCD/simvastatin treated C1R-CD1d cells and invariant natural killer T cells on measuring secreted cytokines (IFNgamma and IL4).	methyl-beta-cyclodextrin	26-50	CD1d molecule	Homo sapiens	345-349
24482817-8	2014	Treatment of B cells with methyl-beta-cyclodextrin (MbetaCD) / simvastatin caused protein rearrangement; however, FRET demonstrated only minimal effect of these chemicals on the association between CD1d and GM1 ganglioside on cell-surface.Likewise, a modest effect was only observed in a co-culture assay between MbetaCD/simvastatin treated C1R-CD1d cells and invariant natural killer T cells on measuring secreted cytokines (IFNgamma and IL4).	methyl-beta-cyclodextrin	52-59	CD1d molecule	Homo sapiens	198-202
24482817-8	2014	Treatment of B cells with methyl-beta-cyclodextrin (MbetaCD) / simvastatin caused protein rearrangement; however, FRET demonstrated only minimal effect of these chemicals on the association between CD1d and GM1 ganglioside on cell-surface.Likewise, a modest effect was only observed in a co-culture assay between MbetaCD/simvastatin treated C1R-CD1d cells and invariant natural killer T cells on measuring secreted cytokines (IFNgamma and IL4).	methyl-beta-cyclodextrin	52-59	CD1d molecule	Homo sapiens	345-349
24482817-8	2014	Treatment of B cells with methyl-beta-cyclodextrin (MbetaCD) / simvastatin caused protein rearrangement; however, FRET demonstrated only minimal effect of these chemicals on the association between CD1d and GM1 ganglioside on cell-surface.Likewise, a modest effect was only observed in a co-culture assay between MbetaCD/simvastatin treated C1R-CD1d cells and invariant natural killer T cells on measuring secreted cytokines (IFNgamma and IL4).	Simvastatin	63-74	CD1d molecule	Homo sapiens	345-349
24482817-9	2014	Furthermore,CD1d rich regions were highly sensitive to low concentration of Triton X-100.	Octoxynol	76-88	CD1d molecule	Homo sapiens	12-16
24482817-10	2014	Physical proximity between CD1d, MHC and GM1 molecules was also detected in the plasma membrane.	G(M1) Ganglioside	41-44	CD1d molecule	Homo sapiens	27-31
23816303-2	2013	Previously, we showed that all-trans-retinoic acid (RA) increases the expression of CD1d and the magnitude of CD1d-mediated antibody production in vivo.	Tretinoin	27-50	CD1d molecule	Homo sapiens	84-88
24239091-3	2013	We crystallized a Vdelta1 TCR in complex with CD1d and the self-lipid sulfatide, revealing the unusual recognition of CD1d by germline Vdelta1 residues spanning all complementarity-determining region (CDR) loops, as well as sulfatide recognition separately encoded by nongermline CDR3delta residues.	lipid sulfatide	64-79	CD1d molecule	Homo sapiens	118-122
24239091-4	2013	Binding and functional analysis showed that CD1d presenting self-lipids, including sulfatide, was widely recognized by gut Vdelta1+ gammadelta T cells.	Sulfoglycosphingolipids	83-92	CD1d molecule	Homo sapiens	44-48
24248359-4	2013	To address these questions, we used a combination of cellular assays and demonstrated that saposins influence CD1d-restricted presentation to human iNKT cells not only of exogenous lipids but also of endogenous ligands, such as the self-glycosphingolipid beta-glucopyranosylceramide, up-regulated by antigen-presenting cells following bacterial infection.	Glycosphingolipids	237-254	CD1d molecule	Homo sapiens	110-114
24248359-4	2013	To address these questions, we used a combination of cellular assays and demonstrated that saposins influence CD1d-restricted presentation to human iNKT cells not only of exogenous lipids but also of endogenous ligands, such as the self-glycosphingolipid beta-glucopyranosylceramide, up-regulated by antigen-presenting cells following bacterial infection.	beta-glucopyranosylceramide	255-282	CD1d molecule	Homo sapiens	110-114
23239102-4	2014	Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs).	Glycolipids	21-31	CD1d molecule	Homo sapiens	73-77
23239102-4	2014	Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs).	Glycolipids	21-31	CD1d molecule	Homo sapiens	73-86
23239102-4	2014	Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs).	alpha-galactosylceramide	139-163	CD1d molecule	Homo sapiens	73-77
23239102-4	2014	Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs).	alpha-galactosylceramide	139-163	CD1d molecule	Homo sapiens	73-86
24619678-3	2014	Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist alpha-galactosylceramide (alpha-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies.	alpha-galactosylceramide	163-187	CD1d molecule	Homo sapiens	63-67
24619678-3	2014	Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist alpha-galactosylceramide (alpha-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies.	alpha-galactosylceramide	163-187	CD1d molecule	Homo sapiens	246-250
23816303-2	2013	Previously, we showed that all-trans-retinoic acid (RA) increases the expression of CD1d and the magnitude of CD1d-mediated antibody production in vivo.	Tretinoin	27-50	CD1d molecule	Homo sapiens	110-114
23816303-2	2013	Previously, we showed that all-trans-retinoic acid (RA) increases the expression of CD1d and the magnitude of CD1d-mediated antibody production in vivo.	Tretinoin	52-54	CD1d molecule	Homo sapiens	84-88
23816303-2	2013	Previously, we showed that all-trans-retinoic acid (RA) increases the expression of CD1d and the magnitude of CD1d-mediated antibody production in vivo.	Tretinoin	52-54	CD1d molecule	Homo sapiens	110-114
23891738-6	2013	CD1d-positive MB cells cross-presented glycolipid antigens to activate NKT-cell cytotoxicity.	Glycolipids	39-49	CD1d molecule	Homo sapiens	0-4
24213674-3	2013	In this study, we examined the effect of HCMV US2 on the expression and function of human CD1d (hCD1d), which presents glycolipid antigens to invariant NKT (iNKT) cells.	Glycolipids	119-129	CD1d molecule	Homo sapiens	90-94
24213674-3	2013	In this study, we examined the effect of HCMV US2 on the expression and function of human CD1d (hCD1d), which presents glycolipid antigens to invariant NKT (iNKT) cells.	Glycolipids	119-129	CD1d molecule	Homo sapiens	96-101
24076636-3	2013	We describe a population of human Vdelta1(+) gammadelta T cells that exhibit autoreactivity to CD1d and provide a molecular basis for how a gammadelta TCR binds CD1d-alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	166-190	CD1d molecule	Homo sapiens	95-99
24076636-3	2013	We describe a population of human Vdelta1(+) gammadelta T cells that exhibit autoreactivity to CD1d and provide a molecular basis for how a gammadelta TCR binds CD1d-alpha-galactosylceramide (alpha-GalCer).	alpha-galactosylceramide	166-190	CD1d molecule	Homo sapiens	161-165
23800654-3	2013	Most functional studies have focused on activation of T cell antigen receptors expressed by NKT cells and their responses to CD1d presentation of glycolipid and related antigens.	Glycolipids	146-156	CD1d molecule	Homo sapiens	125-129
24198748-1	2013	CD1d expressing dendritic cells (DCs) are good glyco-lipid antigen presenting cells for NKT cells.	Glycolipids	47-58	CD1d molecule	Homo sapiens	0-4
23710894-0	2013	A Thr/Ser dual residue motif in the cytoplasmic tail of human CD1d is important for the down-regulation of antigen presentation following a herpes simplex virus 1 infection.	Threonine	2-5	CD1d molecule	Homo sapiens	62-66
23710894-0	2013	A Thr/Ser dual residue motif in the cytoplasmic tail of human CD1d is important for the down-regulation of antigen presentation following a herpes simplex virus 1 infection.	Serine	6-9	CD1d molecule	Homo sapiens	62-66
23710894-4	2013	We proposed that the phosphorylation of T322 is a signal for CD1d lysosomal targeting and subsequent degradation.	Rosaniline Dyes	40-44	CD1d molecule	Homo sapiens	61-65
23610394-1	2013	Invariant natural killer T (iNKT) cells induce a protective immune response triggered by foreign glycolipid antigens bound to CD1d on antigen-presenting cells (APCs).	Glycolipids	97-107	CD1d molecule	Homo sapiens	126-130
23995283-2	2013	Although A. fumigatus is recognized by multiple microbial pattern-recognition receptors, we found that an A. fumigatus-derived glycosphingolipid, asperamide B, directly activates invariant natural killer T (iNKT) cells in vitro in a CD1d-restricted, MyD88-independent and dectin-1-independent fashion.	Glycosphingolipids	127-144	CD1d molecule	Homo sapiens	233-237
23995283-2	2013	Although A. fumigatus is recognized by multiple microbial pattern-recognition receptors, we found that an A. fumigatus-derived glycosphingolipid, asperamide B, directly activates invariant natural killer T (iNKT) cells in vitro in a CD1d-restricted, MyD88-independent and dectin-1-independent fashion.	1-O-beta-D-glucopyranosyl-(2S,2'R,3R,3'E,4E,8E)-N-(2'-hydroxy-3'-hexadecenoyl)-9-methyl-4,8-icosadien-1,3-diol	146-158	CD1d molecule	Homo sapiens	233-237
23995283-3	2013	Moreover, asperamide B, when loaded onto CD1d, directly stained, and was sufficient to activate, human and mouse iNKT cells.	1-O-beta-D-glucopyranosyl-(2S,2'R,3R,3'E,4E,8E)-N-(2'-hydroxy-3'-hexadecenoyl)-9-methyl-4,8-icosadien-1,3-diol	10-22	CD1d molecule	Homo sapiens	41-45
23836468-1	2013	CD1d molecule, a monomorphic major histocompatibility complex class I-like molecule, presents different types of glycolipids to invariant natural killer T (iNKT) cells that play an important role in immunity to infection and tumors, as well as in regulating autoimmunity.	Glycolipids	113-124	CD1d molecule	Homo sapiens	0-13
23836468-2	2013	Here, we present simultaneous topography and recognition imaging (TREC) analysis to detect density, distribution and localization of single CD1d molecules on THP1 cells that were loaded with different glycolipids.	Glycolipids	201-212	CD1d molecule	Homo sapiens	140-144
23836468-4	2013	The recognition map revealed binding sites visible as dark spots, resulting from oscillation amplitude reduction during specific binding between iNKT TCR and the CD1d-glycolipid complex.	Glycolipids	167-177	CD1d molecule	Homo sapiens	162-166
23898038-0	2013	Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells.	Glycolipids	26-37	CD1d molecule	Homo sapiens	10-14
23615906-5	2013	At least some of these CD1d-beta2m heterodimers are shorter-lived and can be rescued by provision of a defined exogenous antigen, alpha-galactosylceramide.	alpha-galactosylceramide	130-154	CD1d molecule	Homo sapiens	23-27
23885215-1	2013	Invariant natural killer T (iNKT) cells are innate T lymphocytes that specifically recognize alpha-linked glycosphingolipids (alpha-GSLs) as antigens presented by CD1d molecules.	alpha-linked glycosphingolipids	93-124	CD1d molecule	Homo sapiens	163-167
23885215-1	2013	Invariant natural killer T (iNKT) cells are innate T lymphocytes that specifically recognize alpha-linked glycosphingolipids (alpha-GSLs) as antigens presented by CD1d molecules.	alpha-gsls	126-136	CD1d molecule	Homo sapiens	163-167
23885215-4	2013	We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d.	alpha-galactosylceramide	137-161	CD1d molecule	Homo sapiens	58-62
23885215-4	2013	We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d.	alpha-galactosylceramide	137-161	CD1d molecule	Homo sapiens	321-325
23885215-7	2013	Thus, B cell neoplasias that co-express CD1c and CD1d may be particularly susceptible to alpha-GSL therapy, and cancer vaccines using alpha-GSLs as adjuvants may be most effective when presented by CD1c+ antigen-presenting cells.	alpha-gsl	89-98	CD1d molecule	Homo sapiens	49-53
23475484-2	2013	Most NKT cells express a semi-invariant T cell receptor that reacts with glycolipid antigens presented by the CD1d molecule on the surface of antigen-presenting cells.	Glycolipids	73-83	CD1d molecule	Homo sapiens	110-123
23280365-0	2013	CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells.	isoglobotrihexosylceramide	68-94	CD1d molecule	Homo sapiens	0-4
23280365-5	2013	The structural basis for this discrepancy was identified as a single amino acid variation between hCD1d and mCD1d, a glycine-to-tryptophan modification within the alpha2-helix that prevents flattening of the iGb3 headgroup upon TCR ligation.	Glycine	117-124	CD1d molecule	Homo sapiens	98-103
23280365-5	2013	The structural basis for this discrepancy was identified as a single amino acid variation between hCD1d and mCD1d, a glycine-to-tryptophan modification within the alpha2-helix that prevents flattening of the iGb3 headgroup upon TCR ligation.	Tryptophan	128-138	CD1d molecule	Homo sapiens	98-103
23518808-3	2013	Type I NKT cells have an invariant T-cell receptor alpha-chain and are readily detectable by alpha-galactosylceramide (alpha-GalCer)-loaded CD1d tetramers.	alpha-galactosylceramide	93-117	CD1d molecule	Homo sapiens	140-144
23518808-3	2013	Type I NKT cells have an invariant T-cell receptor alpha-chain and are readily detectable by alpha-galactosylceramide (alpha-GalCer)-loaded CD1d tetramers.	alpha-galactosylceramide	119-131	CD1d molecule	Homo sapiens	140-144
23458425-0	2013	Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.	Glycolipids	59-69	CD1d molecule	Homo sapiens	54-58
23458425-1	2013	Invariant natural killer T cells (iNKT cells) are restricted by CD1d molecules and activated upon CD1d-mediated presentation of glycolipids to T cell receptors (TCRs) located on the surface of the cell.	Glycolipids	128-139	CD1d molecule	Homo sapiens	98-102
23458425-3	2013	The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules.	alpha-galactosylceramide	31-56	CD1d molecule	Homo sapiens	17-21
23458425-3	2013	The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules.	alpha-galactosylceramide	31-56	CD1d molecule	Homo sapiens	203-207
23458425-3	2013	The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules.	alpha-galactosylceramide	58-70	CD1d molecule	Homo sapiens	17-21
23458425-3	2013	The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules.	alpha-galactosylceramide	58-70	CD1d molecule	Homo sapiens	203-207
23458425-4	2013	Analysis of crystal structures of the TCR-alpha-GalCer-CD1d ternary complex identified the alpha-methylene unit in the fatty acid side chain, and more specifically the pro-S hydrogen at this position, as a site for incorporating a label.	alpha-methylene	91-106	CD1d molecule	Homo sapiens	55-59
23458425-4	2013	Analysis of crystal structures of the TCR-alpha-GalCer-CD1d ternary complex identified the alpha-methylene unit in the fatty acid side chain, and more specifically the pro-S hydrogen at this position, as a site for incorporating a label.	Fatty Acids	119-129	CD1d molecule	Homo sapiens	55-59
23458425-4	2013	Analysis of crystal structures of the TCR-alpha-GalCer-CD1d ternary complex identified the alpha-methylene unit in the fatty acid side chain, and more specifically the pro-S hydrogen at this position, as a site for incorporating a label.	pro-s hydrogen	168-182	CD1d molecule	Homo sapiens	55-59
23458425-5	2013	We postulated that modifying the glycolipid in this way would exert a minimal impact on the TCR-glycolipid-CD1d ternary complex, allowing the labeled molecule to function as a good mimic for the CD1d agonist under investigation.	Glycolipids	33-43	CD1d molecule	Homo sapiens	195-199
23458425-6	2013	To test this hypothesis, the synthesis of a biotinylated version of the CD1d agonist threitol ceramide (ThrCer) was targeted.	threitol ceramide	85-102	CD1d molecule	Homo sapiens	72-76
23458425-6	2013	To test this hypothesis, the synthesis of a biotinylated version of the CD1d agonist threitol ceramide (ThrCer) was targeted.	thrcer	104-110	CD1d molecule	Homo sapiens	72-76
23065503-1	2013	Invariant natural killer T cells recognize glycolipid antigens such as alpha-galactosylceramide presented by CD1d.	Glycolipids	43-53	CD1d molecule	Homo sapiens	109-113
23065503-1	2013	Invariant natural killer T cells recognize glycolipid antigens such as alpha-galactosylceramide presented by CD1d.	alpha-galactosylceramide	71-95	CD1d molecule	Homo sapiens	109-113
23065503-12	2013	In conclusion, the invariant natural killer T-cell and CD1d axis is fundamentally intact in patients with early-stage chronic lymphocytic leukemia and, despite reduced circulating numbers, function is retained in fludarabine-treated patients.	fludarabine	213-224	CD1d molecule	Homo sapiens	55-59
22968995-2	2013	Upon stimulation with the CD1d-presented synthetic antigen alpha-galactosylceramide, human and rodent type I invariant NKT cells release large amounts of cytokines.	alpha-galactosylceramide	59-83	CD1d molecule	Homo sapiens	26-30
22829134-0	2012	The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR.	Sulfoglycosphingolipids	21-30	CD1d molecule	Homo sapiens	16-20
23307809-7	2013	Furthermore, microbial PG bound to CD1d molecules and plate-bound PG/CD1d complexes stimulated dNKT hybridomas, indicating direct recognition by the dNKT cell TCR.	Phosphatidylglycerols	23-25	CD1d molecule	Homo sapiens	35-39
23137012-10	2013	Human T-cell lines derived from nut-allergic patients produced IL-4 to Ber/lipid C in a CD1d- and dose-dependent manner.	lipid c	75-82	CD1d molecule	Homo sapiens	88-92
23064364-2	2012	The efficacy of glycolipids, such as the prototypic NKT cell antagonist alpha-galactosylceramide (alphaGalCer), is currently being evaluated in clinical trials, but little is known about factors that target lipid antigens for CD1d presentation and NKT cell activation in vivo.	Glycolipids	16-27	CD1d molecule	Homo sapiens	226-230
22829134-5	2012	Recombinant Vdelta1 TCRs from different individuals were shown to bind recombinant CD1d-sulfatide complexes in a sulfatide-specific manner.	Sulfoglycosphingolipids	88-97	CD1d molecule	Homo sapiens	83-87
22829134-5	2012	Recombinant Vdelta1 TCRs from different individuals were shown to bind recombinant CD1d-sulfatide complexes in a sulfatide-specific manner.	Sulfoglycosphingolipids	113-122	CD1d molecule	Homo sapiens	83-87
22445102-0	2012	Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric alpha-galactosyl ceramide analogues.	alpha-galactosylceramide	83-108	CD1d molecule	Homo sapiens	20-24
22820602-1	2012	Glycolipids presented by the major histocompatibility complex (MHC) class I homolog CD1d are recognized by natural killer T cells (NKT cells) characterized by either a semi-invariant T cell antigen receptor (TCR) repertoire (type I NKT cells or iNKT cells) or a relatively variable TCR repertoire (type II NKT cells).	Glycolipids	0-11	CD1d molecule	Homo sapiens	84-88
22820602-2	2012	Here we describe the structure of a type II NKT cell TCR in complex with CD1d-lysosulfatide.	psychosine-3'-sulfate ester	78-91	CD1d molecule	Homo sapiens	73-77
22820603-5	2012	At the XV19 TCR-CD1d-sulfatide interface, the TCRalpha and TCRbeta chains sat centrally on CD1d, where the malleable CDR3 loops dominated interactions with CD1d-sulfatide.	Sulfoglycosphingolipids	21-30	CD1d molecule	Homo sapiens	16-20
22820603-5	2012	At the XV19 TCR-CD1d-sulfatide interface, the TCRalpha and TCRbeta chains sat centrally on CD1d, where the malleable CDR3 loops dominated interactions with CD1d-sulfatide.	Sulfoglycosphingolipids	21-30	CD1d molecule	Homo sapiens	91-95
22820603-5	2012	At the XV19 TCR-CD1d-sulfatide interface, the TCRalpha and TCRbeta chains sat centrally on CD1d, where the malleable CDR3 loops dominated interactions with CD1d-sulfatide.	Sulfoglycosphingolipids	21-30	CD1d molecule	Homo sapiens	91-95
22683545-4	2012	Measuring ex vivo activation of NKT cells by the CD1d-restricted glycolipid ligand alpha-Galactosylceramide (alpha-GalCer) through cytokine expression profiles is a useful marker of NKT cell function, but for reasons that are unclear, this approach does not appear to work as well in humans and non-human primate macaque models in comparison to mice.	alpha-galactosylceramide	83-107	CD1d molecule	Homo sapiens	49-53
22445102-1	2012	A library of dimeric CD1d ligands, containing two alpha-galactosyl ceramide (alpha-GalCer) units linked by spacers of varying lengths has been synthesised.	alpha-galactosylceramide	50-75	CD1d molecule	Homo sapiens	21-25
22445102-1	2012	A library of dimeric CD1d ligands, containing two alpha-galactosyl ceramide (alpha-GalCer) units linked by spacers of varying lengths has been synthesised.	alpha-galactosylceramide	77-89	CD1d molecule	Homo sapiens	21-25
22652050-0	2012	New CD1d agonists: synthesis and biological activity of 6""-triazole-substituted alpha-galactosyl ceramides.	6""-triazole	56-68	CD1d molecule	Homo sapiens	4-8
22652050-0	2012	New CD1d agonists: synthesis and biological activity of 6""-triazole-substituted alpha-galactosyl ceramides.	alpha-galactosylceramide	81-107	CD1d molecule	Homo sapiens	4-8
22247226-4	2012	Even in the absence of non-iNKT cells, sulfatide inhibited alphaGC-mediated iNKT cell activation by reducing alphaGC/CD1d complex formations in a dose-dependent manner.	Sulfoglycosphingolipids	39-48	CD1d molecule	Homo sapiens	117-121
22585464-2	2012	Although RA promotes natural killer T (NKT) cell activation in vitro by increasing CD1d expression on antigen-presenting cells (APCs), the direct effects of RA on NKT-cell responses in vivo are not known.	Tretinoin	9-11	CD1d molecule	Homo sapiens	83-87
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	Glycolipids	21-31	CD1d molecule	Homo sapiens	81-85
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	Glycolipids	21-31	CD1d molecule	Homo sapiens	141-145
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	alpha-galactosylceramide	32-56	CD1d molecule	Homo sapiens	81-85
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	alpha-galactosylceramide	32-56	CD1d molecule	Homo sapiens	141-145
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	alpha-galactosylceramide	58-70	CD1d molecule	Homo sapiens	81-85
22639457-1	2012	The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells).	alpha-galactosylceramide	58-70	CD1d molecule	Homo sapiens	141-145
22324848-7	2012	All of the analogues were found to stimulate murine and human iNKT cells by CD1d-mediated presentation to varying degrees; however, the thioamide and carbamate analogues of ThrCer were of particular interest in that they elicited a strongly polarized cytokine response (more interferon-gamma (IFN-gamma), no interleukin-4 (IL-4)) in mice.	thrcer	173-179	CD1d molecule	Homo sapiens	76-80
22291186-1	2012	CD1d is an MHC class I-like molecule that presents glycolipid Ags to types I and II NKT cells.	Glycolipids	51-61	CD1d molecule	Homo sapiens	0-4
22291186-4	2012	The replacement of the arginines in this motif with alanines resulted in the extensive accumulation of CD1d in lysosomes but did not affect the cell surface expression.	Arginine	23-32	CD1d molecule	Homo sapiens	103-107
22291186-4	2012	The replacement of the arginines in this motif with alanines resulted in the extensive accumulation of CD1d in lysosomes but did not affect the cell surface expression.	Alanine	52-60	CD1d molecule	Homo sapiens	103-107
22407918-4	2012	Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion.	alpha-galactosylceramide	164-188	CD1d molecule	Homo sapiens	40-44
22407918-4	2012	Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion.	alpha-galactosylceramide	164-188	CD1d molecule	Homo sapiens	63-67
22407918-4	2012	Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion.	alpha-galactosylceramide	164-188	CD1d molecule	Homo sapiens	63-67
22407918-5	2012	Pulsed with melanoma Ag recognized by T cell 1 peptide, the CD1d-overexpressing hESC-DCs displayed enhanced capability to prime CD8(+) T cells without relying on alpha-galactosylceramide loading.	alpha-galactosylceramide	162-186	CD1d molecule	Homo sapiens	60-64
22395072-0	2012	Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptor.	Lysophospholipids	0-16	CD1d molecule	Homo sapiens	33-37
22395072-2	2012	Here, we describe our studies of lysophosphatidylcholine (LPC) presentation by human CD1d and its recognition by a native, LPC-specific iNKT TCR.	Lysophosphatidylcholines	33-56	CD1d molecule	Homo sapiens	85-89
22395072-2	2012	Here, we describe our studies of lysophosphatidylcholine (LPC) presentation by human CD1d and its recognition by a native, LPC-specific iNKT TCR.	Lysophosphatidylcholines	58-61	CD1d molecule	Homo sapiens	85-89
22395072-3	2012	Human CD1d presenting LPC adopts an altered conformation from that of CD1d presenting glycolipid antigens, with a shifted alpha1 helix resulting in an open A" pocket.	Glycolipids	86-96	CD1d molecule	Homo sapiens	6-10
22395072-3	2012	Human CD1d presenting LPC adopts an altered conformation from that of CD1d presenting glycolipid antigens, with a shifted alpha1 helix resulting in an open A" pocket.	Glycolipids	86-96	CD1d molecule	Homo sapiens	70-74
22395072-5	2012	The iNKT TCR CDR loop footprint on CD1d-LPC is anchored by the conserved positioning of the CDR3alpha loop, whereas the remaining CDR loops are shifted, due in part to amino-acid differences in the CDR3beta and Jbeta segment used by this iNKT TCR.	cdr3beta	198-206	CD1d molecule	Homo sapiens	35-39
22395072-6	2012	These findings provide insight into how lysophospholipids are presented by human CD1d molecules and how this complex is recognized by some, but not all, human iNKT cells.	Lysophospholipids	40-57	CD1d molecule	Homo sapiens	81-85
22419072-4	2012	We found that histone deacetylase inhibitors, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), induced CD1d gene expression in human (A549 and NCI-H292) and mouse (TC-1 and B16/F0) cancer cells.	trichostatin A	46-60	CD1d molecule	Homo sapiens	119-123
22419072-4	2012	We found that histone deacetylase inhibitors, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), induced CD1d gene expression in human (A549 and NCI-H292) and mouse (TC-1 and B16/F0) cancer cells.	trichostatin A	62-65	CD1d molecule	Homo sapiens	119-123
22419072-4	2012	We found that histone deacetylase inhibitors, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), induced CD1d gene expression in human (A549 and NCI-H292) and mouse (TC-1 and B16/F0) cancer cells.	Vorinostat	71-102	CD1d molecule	Homo sapiens	119-123
22419072-4	2012	We found that histone deacetylase inhibitors, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), induced CD1d gene expression in human (A549 and NCI-H292) and mouse (TC-1 and B16/F0) cancer cells.	Vorinostat	104-108	CD1d molecule	Homo sapiens	119-123
22247226-6	2012	Moreover, simultaneous injection of alphaGC with sulfatide decreased alphaGC/CD1d complex formations on DCs, accompanied by the reduced CD40L-up-regulation and IFN-gamma production by iNKT cells and IL-12p70 production by DCs.	Sulfoglycosphingolipids	49-58	CD1d molecule	Homo sapiens	77-81
22247226-8	2012	These results demonstrate that sulfatide competes with alphaGC to be loaded onto CD1d along the endocytic pathway in DCs, thereby inhibiting the iNKT cell response.	Sulfoglycosphingolipids	31-40	CD1d molecule	Homo sapiens	81-85
21956730-4	2012	By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTalpha, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants.	Serine	130-136	CD1d molecule	Homo sapiens	209-213
24900444-0	2012	Heteroaromatic Moieties in the Sphingosine Backbone of alpha-Galactosylceramides for Noncovalent Interactions with CD1d.	Sphingosine	31-42	CD1d molecule	Homo sapiens	115-119
24900444-0	2012	Heteroaromatic Moieties in the Sphingosine Backbone of alpha-Galactosylceramides for Noncovalent Interactions with CD1d.	alpha-galactosylceramide	55-80	CD1d molecule	Homo sapiens	115-119
24900444-1	2012	A series of alpha-GalCer analogues containing heterocyclic and aromatic moieties in the sphingosine backbone were synthesized to improve the selectivity in the Th1/Th2 cytokine profile via noncovalent interaction with three aromatic residues at the binding pocket of CD1d.	Sphingosine	88-99	CD1d molecule	Homo sapiens	267-271
21956730-4	2012	By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTalpha, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants.	Threonine	138-147	CD1d molecule	Homo sapiens	209-213
21956730-4	2012	By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTalpha, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants.	Asparagine	149-159	CD1d molecule	Homo sapiens	209-213
21956730-4	2012	By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTalpha, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants.	Isoleucine	163-173	CD1d molecule	Homo sapiens	209-213
21956730-5	2012	This effect was observed with CD1d loaded with either the artificial alpha-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid beta-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d.	Glycolipids	137-147	CD1d molecule	Homo sapiens	30-34
21956730-5	2012	This effect was observed with CD1d loaded with either the artificial alpha-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid beta-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d.	Glycolipids	137-147	CD1d molecule	Homo sapiens	335-339
21956730-5	2012	This effect was observed with CD1d loaded with either the artificial alpha-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid beta-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d.	beta-galactosyl ceramide	148-171	CD1d molecule	Homo sapiens	30-34
21956730-5	2012	This effect was observed with CD1d loaded with either the artificial alpha-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid beta-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d.	beta-galactosyl ceramide	148-171	CD1d molecule	Homo sapiens	335-339
21956730-6	2012	The serine-containing variant showed the strongest CD1d binding, offering an explanation for its predominance in vivo.	Serine	4-10	CD1d molecule	Homo sapiens	51-55
21493160-3	2011	alpha-S-GalCer stimulated cytokine release by iNKT cells in a CD1d-dependent manner and primed CD1d(+) target cells for lysis.	alpha-S-galactosylceramide	0-14	CD1d molecule	Homo sapiens	62-66
23550344-8	2012	We have shown that CD1d dependent stimulation by sulfatide may activate pDC antigen expressing cells that produce type I inteferons.	Sulfoglycosphingolipids	49-58	CD1d molecule	Homo sapiens	19-23
23109910-4	2012	Here we present crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a human CD1d-restricted TCR that utilizes a Valpha3.1-Jalpha18 rearrangement and displays a more restricted specificity for alpha-linked glycolipids than that of iNKT TCRs.	alpha-galactosylceramide	61-85	CD1d molecule	Homo sapiens	124-128
23109910-4	2012	Here we present crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a human CD1d-restricted TCR that utilizes a Valpha3.1-Jalpha18 rearrangement and displays a more restricted specificity for alpha-linked glycolipids than that of iNKT TCRs.	alpha-galactosylceramide	87-99	CD1d molecule	Homo sapiens	124-128
23109910-4	2012	Here we present crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a human CD1d-restricted TCR that utilizes a Valpha3.1-Jalpha18 rearrangement and displays a more restricted specificity for alpha-linked glycolipids than that of iNKT TCRs.	alpha-linked glycolipids	240-264	CD1d molecule	Homo sapiens	124-128
23110152-7	2012	Crystal structures of boCD1d bound to a short-chain C12-di-sulfatide antigen, as well as short-chain C16-alphaGalCer revealed that the A pocket of boCD1d is restricted in size compared to that of both mouse and human CD1d, explaining the inability of long chain GSL"s to bind to boCD1d.	c12-di-sulfatide	52-68	CD1d molecule	Homo sapiens	24-28
22065767-3	2011	With the exception of the Vbeta2 NKT TCR, NKT TCRs possess canonical tyrosine residues within complementarity determining region (CDR) 2beta that are critical for CD1d binding.	Tyrosine	69-77	CD1d molecule	Homo sapiens	163-167
22065767-7	2011	Nevertheless, clear fine specificity differences for the CD1d-Ag existed between the Vbeta2 NKT TCR and the Vbeta8.2 and Vbeta7 NKT TCRs, with the Vbeta2 NKT TCR exhibiting greater sensitivity to modifications to the glycolipid Ag.	Glycolipids	217-227	CD1d molecule	Homo sapiens	57-61
22065767-8	2011	Furthermore, within the Vbeta2 NKT TCR-CD1d-alphaGalCer complex, the CDR2beta loop mediated fewer contacts with CD1d, whereas the CDR1beta and CDR3beta loops contacted CD1d to a much greater extent compared with most Vbeta11, Vbeta8.2, and Vbeta7 NKT TCRs.	cdr2beta	69-77	CD1d molecule	Homo sapiens	39-43
22065767-8	2011	Furthermore, within the Vbeta2 NKT TCR-CD1d-alphaGalCer complex, the CDR2beta loop mediated fewer contacts with CD1d, whereas the CDR1beta and CDR3beta loops contacted CD1d to a much greater extent compared with most Vbeta11, Vbeta8.2, and Vbeta7 NKT TCRs.	cdr2beta	69-77	CD1d molecule	Homo sapiens	112-116
22065767-8	2011	Furthermore, within the Vbeta2 NKT TCR-CD1d-alphaGalCer complex, the CDR2beta loop mediated fewer contacts with CD1d, whereas the CDR1beta and CDR3beta loops contacted CD1d to a much greater extent compared with most Vbeta11, Vbeta8.2, and Vbeta7 NKT TCRs.	cdr2beta	69-77	CD1d molecule	Homo sapiens	112-116
22065767-8	2011	Furthermore, within the Vbeta2 NKT TCR-CD1d-alphaGalCer complex, the CDR2beta loop mediated fewer contacts with CD1d, whereas the CDR1beta and CDR3beta loops contacted CD1d to a much greater extent compared with most Vbeta11, Vbeta8.2, and Vbeta7 NKT TCRs.	cdr3beta	143-151	CD1d molecule	Homo sapiens	39-43
21964029-0	2011	NKT TCR recognition of CD1d-alpha-C-galactosylceramide.	C-galactosylceramide	33-54	CD1d molecule	Homo sapiens	23-27
21964029-1	2011	NKT cells respond to a variety of CD1d-restricted glycolipid Ags that are structurally related to the prototypic Ag alpha-galactosylceramide (alpha-GalCer).	Galactosylceramides	121-140	CD1d molecule	Homo sapiens	34-38
21964029-6	2011	Our findings support the concept that for CD1d-restricted NKT cells, altered glycolipid ligands can promote markedly different responses while adopting similar TCR-docking topologies.	Glycolipids	77-87	CD1d molecule	Homo sapiens	42-46
21169066-5	2011	iNKT specifically recognize the glycolipid alpha-galactosylceramide in the context of CD1d resulting in their activation.	Glycolipids	32-42	CD1d molecule	Homo sapiens	86-90
21169066-5	2011	iNKT specifically recognize the glycolipid alpha-galactosylceramide in the context of CD1d resulting in their activation.	alpha-galactosylceramide	43-67	CD1d molecule	Homo sapiens	86-90
22087000-1	2011	Unlike the dominant role of one class II invariant chain peptide (CLIP) in blocking MHC class II, comparative lipidomics analysis shows that human cluster of differentiation (CD) proteins CD1a, CD1b, CD1c, and CD1d bind lipids corresponding to hundreds of diverse accurate mass retention time values.	lipidomics	110-120	CD1d molecule	Homo sapiens	210-214
21764041-1	2011	The title compound containing dihydroceramide as a ligand for CD1d was accomplished using the mannosyl, glucosaminyl, and fucosyl donors, and a sphinganine analogue, as suitable building blocks.	dihydroceramide	30-45	CD1d molecule	Homo sapiens	62-66
21764041-1	2011	The title compound containing dihydroceramide as a ligand for CD1d was accomplished using the mannosyl, glucosaminyl, and fucosyl donors, and a sphinganine analogue, as suitable building blocks.	safingol	144-155	CD1d molecule	Homo sapiens	62-66
21846915-3	2011	CD1d is an HLA class I-like molecule that presents glycolipids to invariant natural killer T cells.	Glycolipids	51-62	CD1d molecule	Homo sapiens	0-4
21493160-3	2011	alpha-S-GalCer stimulated cytokine release by iNKT cells in a CD1d-dependent manner and primed CD1d(+) target cells for lysis.	alpha-S-galactosylceramide	0-14	CD1d molecule	Homo sapiens	95-99
21458849-2	2011	Ligation of the invariant natural killer T cell (iNKT) T-cell receptor (TCR) by sphingolipids presented via the CD1d molecule leads to copious secretion of T(h)2-type cytokines.	Sphingolipids	80-93	CD1d molecule	Homo sapiens	112-125
21653690-2	2011	Activation of NKT cells is crucial for their antitumor activity and is induced by alpha-galactosylceramide (alpha-GalCer, KRN7000) presented by CD1d on dendritic cells (DC).	alpha-galactosylceramide	82-106	CD1d molecule	Homo sapiens	144-148
21653669-6	2011	gB initiates the interaction with CD1d in the endoplasmic reticulum and stably associates with it throughout CD1d trafficking.	gb	0-2	CD1d molecule	Homo sapiens	34-38
21653669-6	2011	gB initiates the interaction with CD1d in the endoplasmic reticulum and stably associates with it throughout CD1d trafficking.	gb	0-2	CD1d molecule	Homo sapiens	109-113